NZ543229A - Ester compound and medicinal use thereof - Google Patents

Abstract

Disclosed is a biphenyl compound represented by the formula (100) wherein: R1' is H, alkyl, halogen, haloalkyl or alkoxy; R2''' is H alkyl, halogen, haloalkyl or alkenyl; R3'' is -CON(R11a)(R12a) wherein R11a and R12a are as defined in the specification; R4' is H, halogen, alkyl or haloalkyl; R50 is H, methyl or optionally substituted aryl; and 1a is an integer of 1 to 3. Compounds of the type disclosed are useful in the treatment or prophylaxis of hyperlipidemia, arteriosclerosis, coronary artery diseases, obesity, diabetes or hypertension.

Description

New Zealand Paient Spedficaiion for Paient Number 543229 Patents Form No. 5 Our Ref: MK505603 NEW ZEALAND PATENTS ACT 1953 Divisional of NZ 531890 Filed: 28 February 2003 COMPLETE SPECIFICATION ESTER COMPOUND AND MEDICINAL USE THEREOF We, JAPAN TOBACCO INC, a body corporate organised under the laws of Japan of JT BIdg, 2-1, Toranomon 2-chome, Minato-ku, Tokyo 105-8422, Japan hereby declare the invention, for which We pray that a patent may be granted to us and the method by which it is to be performed, to be particularly described in and by the following statement: PT054474481 intefisetusl ^rep«rty Offle® of N.Z- 2 5 OCT 2005 RECEIVED 300460909_1 1 DESCRIPTION ESTER COMPOUND AND MEDICINAL USE THEREOF Technical Field The present invention relates to a novel ester compound, and also relates to a pharmaceutical composition comprising a novel ester compound which selectively inhibits microsomal triglyceride transfer protein (MTP) in the small intestine or a prodrug thereof, or a pharmaceutically acceptable salt of either. Further, the present invention relates to an agent for the treatment or prophylaxis of hyperlipidemia, arteriosclerosis, coronary artery diseases, obesity, diabetes or hypertension comprising a novel ester compound which selectively inhibits MTP in the small intestine or a prodrug thereof, or a pharmaceutically acceptable salt of either as an active ingredient. In addition, the present invention relates to an agent for the treatment or prophylaxis of hyperlipidemia, arteriosclerosis, coronary artery diseases, obesity, diabetes or hypertension, which has a novel function that has never been known before.

Background Art Unless the context clearly requires otherwise, throughout the description and the claims, the words "comprise", "comprising", and the like, are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense, that is to say, in the sense of "including, but not limited to".

The reference to any prior art in the specification is not, and should not be taken as, an acknowledgement, or any form of suggestion, that the prior art forms part of the common general knowledge in New Zealand. 300467125_1.DOC Intellectual Property Office of N.Z. - 3 OCT 2006 RECEIVED 1A It has been said that hyperlipidemia, diabetes, hypertension or the like is one of the risk factors for arteriosclerosis. Hyperlipidemia is a condition where the concentration of lipid such as cholesterol is abnormally elevated in the blood. Types of hyperlipidemia, depending on the cause, include primary hyperlipidemia caused by genetic 3Q0467125_1.DOC Intellectual Property Office of N.2. - 3 OCT 2006 RECEIVED 2 abnormality in enzyme, protein, lipoprotein and the like which participate in the metabolism of low-density lipoprotein (LDL), secondary hyperlipidemia due to various disease or drug administration, and acquired hyperlipidemia basically 5 resulting from overnutrition.

Meanwhile, lipid taken in from food is absorbed in the small intestine by the action of bile acid, and secreted as chylomicron in the blood via lymphatic vessels. The triglyceride moiety of the secreted chylomicrons is hydrolyzed 10 to free fatty acids by the action of lipoprotein lipase (LPL) existing in capillary vessels to become chylomicron remnants having a high content of cholesteryl ester (CE) , which is then absorbed in the liver by the mediation of chylomicron remnant receptor in the liver. Further, in the liver, the absorbed 15 chylomicron remnant and free fatty acid are converted to CE and TG, respectively, which are then associated with apolipoprotein B synthesized on rough surfaced endoplasmic reticulum to form very low density lipoprotein (VLDL). The VLDL is transferred to the Golgi apparatus, modified and secreted outside cells, 20 and it becomes intermediate density lipoprotein (IDL) by the action of LPL. The IDL is converted to LDL by the action of hepatic triglyceride lipase (HTGL), and lipids are distributed to peripheral tissues.

It has long been indicated that, during the 25 above-mentioned formation of chylomicron in the small intestine or VLDL in the liver, a protein having TG- or CE-transfer activity is existing in microsomal fractions of the small Intestine or liver. Meanwhile, the protein, i.e. MTP (microsomal triglyceride transfer protein) was purified and 3 separated from microsomal fractions of bovine liver by Wetterau et al. in 1985 (Wetterau J.R. et al: Chem.Phys.Lipids 38, 205-222(1985)). MTP, however, began attracting a lot of attention in the field of clinical medicine only after it was 5 reported in 1993 that the cause of abetalipoproteinemia lay in the deficit of MTP. In other word, the disease is characterized in that, while the genes related to apolipoprotein B are normal, apolipoprotein B is hardly detected in the serum, the level of serum cholesterol is 50mg/dL or lower, the level of serum 10 triglyceride is extremely low and, moreover, lipoproteins including apolipoprotein B such as chylomicron, VLDL, LDL, etc. do not at all exist in the blood. By this finding, it has been shown that MTP is an integral protein involved in the association between apolipoprotein B and TG or CE, i.e. the 15 formation of VLDL or chylomicron, and plays an essential role in secretion thereof.

Since lipid is by nature insoluble in water, lipid in the blood is combined with a hydrophilic protein known as apolipoprotein and exists as so-called lipoprotein. All the 20 VLDL, IDL, LDL or chylomicron, etc. related to hyperlipidemia are a lipoprotein.

MTP exists in the microsome fractions of hepatocytes and intestinal epithelial cells, and catalyses the transfer of TG or CE in cells. In the liver and small intestine, along with 25 the synthesis of apolipoprotein (apolipoprotein B100 in the liver and apolipoprotein B48 in the small intestine), TG and CE are combined with respective apolipoprotein B by the transfer activity of MTP, and thus VLDL or chylomicron is formed. As a result, those lipoproteins are secreted outside the cells as 4 VLDL in the liver or as chylomicron in the small intestine. It should be said that MTP is indispensable for the construction of those lipoproteins. Namely, if the activity of MTP is blocked, the transfer of lipid such as TG and CE, etc. to 5 apolipoprotein is inhibited, whereby formation of a lipoprotein can be inhibited.

On the other hand, it has been elucidated that LDL in general is closely related to the progression of arteriosclerosis. That is, LDL permeating endothelium of 10 blood vessels is deposited in intercellular matrix of vessel wall, where oxidative denaturation takes place and lipid peroxides or denaturated proteins induce a series of inflammation reactions. Consequently, macrophage invasion, leading to lipid deposit or foaming cells, migration or 15 proliferation of smooth muscle cells and increase in intercellular matrix, etc. take place, which leads to the development of arteriosclerosis plaque. On the basis of the above, it is supposed to be possible to prevent or treat arteriosclerosis, coronary artery diseases or hypertension by 20 reducing the level of LDL.

As already mentioned, it is possible to inhibit the formation of lipoprotein such as chylomicron, VLDL, LDL, etc. by inhibiting the action of MTP. Accordingly, it has been expected that it should become possible to control lipoprotein 25 such as TG, cholesterol and LDL, etc. in blood and to control lipid in cells by adjusting the activity of MTP, and therefore, a novel agent for the treatment or prophylaxis of hyperlipidemia, arteriosclerosis, coronary artery diseases, diabetes, obesity, or hypertension, and further, an agent for the treatment or prophylaxis of pancreatitis, hypercholesterolemia, hyperglyceridemia, etc. has been expected to be provided.

However, with the development of MTP inhibitors, some cases of fatty liver were reported and concern over 5 hepatotoxicity has been raised.

For these reasons, a novel MTP inhibitor causing no side effect such as a fatty liver, etc. has been strongly desired.

In the conventional manners, combined therapies of various combinations of different antihyperlipidemic drugs 10 have been tried. However, when, for example, a statin-type drug and a resin-type drug are given together, undesirable side effects such as increased GTO and GPT, constipation, blocking of absorption of vitamin A, D, E and K and the like are observed. On the other hand, when a statin-type drug and a fibrate drug 15 are given together, side effects such as rhabdomyolysis or increased CPK (creative phosphokinase) are observed. Thus, with regard to a combined therapy for hyperlipidemia, a medicament for a combined administration which can be administered in combination with a conventional 20 antihyperlipidemic drug without causing any above-mentioned side effect has been desired.

Meanwhile, examples of the known compound having MTP inhibitory activity with a similar structure of the compounds 25 of the present invention are described below.

The following compound is disclosed in W097/26240. 7 The following compound Is disclosed in W02000/5201 The following compound is disclosed in J. Chem.(2001), 44(6) p.851-856.

CF; Med.

The following compound is disclosed in EP 1099701. 8 The following compound is disclosed in W02001/77077 CF, The following compound is disclosed in J. Med. Chem.(2001), 44(6) p.4677-4687.

CF, NHC02Me The following compound is disclosed in W02002/4403. 9 U J R7 _ o R5 R6 R2— k V R4 0 DO I R3 In the above literatures, however, there is no disclosure of a compound comprising ester as the essential structure as 5 that disclosed in the present invention, much less the disclosure of the data indicating that when a compound has the structure disclosed in the present invention, the compound selectively inhibits MTP in the small intestine while rarely affects MTP in the liver.

Disclosure of the Invention Although the development of new antihyperlipidemic drugs working due to its MTP inhibitory activity has been advanced nowadays, those drugs are not satisfactory in terms of the level 15 of action and the accompanying side effect such as a fatty liver, etc. Thus, the development of an antihyperlipidemic drug causing no side effect against the liver that is seen in the case of conventional MTP inhibitors and also having excellent MTP inhibitory activity has been strongly desired. 20 The inventors and those involved in the present invention have carried out intensive studies to provide a novel MTP inhibitor causing no above-mentioned side effect such as a fatty liver. As a result, they have found that an MTP inhibitor, which selectively inhibits MTP in the small intestine but substantially does not inhibit MTP in the liver, significantly lowers the level of unnecessary TG or cholesterol without causing a side effect such as a fatty liver, etc. Surprisingly, 5 they have also found that the compound having ester structure represented by the below-mentioned formula (1) is immediately metabolized in the small intestine, blood or liver, which makes it possible for the compound to selectively affect MTP in the small intestine without substantially inhibiting MTP in the 10 liver.

To be more specific, according to the conventional drug design concept for the preparation of a prodrug, the carboxylic acid which is the active principle is esterified to improve the absorption rate in the small intestine and is immediately 15 metabolized in blood to reproduce carboxylic acid which is the active principle. On the other hand, a drug design concept that is different from the above concept for the preparation of a prodrug is used in the present invention. Namely, by introducing at least one ester in a molecular body of a compound 20 having MTP inhibitory activity, the compound is, after it exerts MTP inhibitory activity on mucous membranes of the small intestine, immediately metabolized by an esterase or a metabolic enzyme, etc. in the small intestine, portal (blood) and liver to be transformed to corresponding carboxylic acid 25 and alcohol which do not have MTP inhibitory activity. This is completely a new concept, by means of which MTP in the liver is not substantially affected and MTP in the small intestine is selectively inhibited. Further, the compounds of the present invention show strong MTP inhibitory activity in vitro, 11 thus potently inhibit MTP in the small intestine and significantly lower triglyceride and cholesterol in blood. In addition, the compounds of the present invention significantly lower non-HDL cholesterol and, surprisingly, increase plasma 5 HDL cholesterol.

Accordingly, the inventors of the present invention have found that when a compound comprises the ester structure represented by the below-mentioned formula (1), the compound is immediately metabolized in the small intestine, blood or 10 liver after it strongly inhibits MTP in the small intestine and hence MTP in the liver is not substantially inhibited, whereby they have completed the present invention.

R1 and R2 are each hydrogen, Ci-C6 alkyl, C3-C7 cycloalkyl, Ci-C6 alkoxy, halo Ci-C6 alkyl, halo Ci-C6 alkyloxy, optionally 20 substituted C6-C14 aryl, optionally substituted C7-Cx6 aralkyl, optionally substituted C6-Ci4 aryloxy, optionally substituted C7-C16 aralkyloxy, optionally substituted C7-C15 arylcarbonyl, optionally substituted heterocycle, C2-C7 alkoxycarbonyl, halogen, C2-C6 alkenyl, -N(R40)(R41) wherein R40 and R41 are each 25 independently hydrogen or optionally substituted C6-Ci4 aryl; Thus, the present invention relates to 15 (1) An ester compound represented by the formula (1) (1 ) wherein ring A is C6-Cx4 aryl, heterocycle, or 12 or § X is -COO-(CH2)„-, -CON(R10)-(CH2)n- or -N(R10) -CO- (CH2)n-wherein R10 is hydrogen, Ci-C6 alkyl or C3-C7 cycloalkyl and n is an integer of 0 to 3; R3 and R4 are each independently hydrogen, hydroxy, halogen, optionally substituted Ci-C6 alkyl, Ci-C6 alkoxy, halo Ci-C6 alkyl, C7-Ci6 aralkyloxy, Ci-C6 acyl, optionally substituted heterocycle, - CON (R11) (R12) (wherein R11 and R12 are each independently hydrogen, C1-C6 alkyl, optionally substituted C6-Ci4 aryl, optionally substituted C7-Ci6 aralkyl, Ci-C6 alkoxy, or R11 and RX2 may be taken together with the nitrogen to which they are attached to form / -N V ()) P —N 0 J \ / or , wherein p is an integer of 0 to 2), -(CH2)q-N(R13) (RX4) (wherein ,14 ■ R13 and R" are each independently hydrogen, Cj.-C6 alkyl, C2-C7 alkoxycarbonyl, Ci-C6 acyl, or R13 and R14 may be taken together with the nitrogen to which they are attached to form >14 —N )p / \ -N 0 \ / or , wherein p has the same meaning as defined above and g is an integer of 0 to 3), or -CO(R15) (wherein R15 is hydroxy, Ci-C6 13 alkoxy, optionally substituted C6-Ci4 aryloxy, optionally substituted C7-C16 aralkyloxy or C1-C6 alkyl); ring B is o N N r XN r~ or , wherein K is an integer of 0 to 2, or ring B may be taken together with R3, R10 and the nitrogen bound to R10 to form —N —N Alkl1 is alkanediyl or alkenediyl; Alkl is alkanediyl or alkenediyl; 14 1 is an integer of 0 to 3; m is an integer of 0 to 3; D is Ci-C6 alkyl> C2-C6 alkenyl, C2-C7 alkoxycarbonyl, -N(R42) -CO(R43) (wherein R42 is hydrogen or Ci-C6 alkyl and R43 is C6-C14 aryl or C7-C16 aralkyl), or the group represented by the following formula (wherein R5, R6 and R7 are each independently hydrogen, Ci-C6 alkyl, Ci-C6 alkoxy, C2-C7 alkoxycarbonyl, carboxyl, halogen, cyano, nitro, halo Ci-C6 alkyl, Ci-C6 acyl, hydroxy, amino, optionally substituted C6-C14 aryl, or - (CH2)r-CON(R16) (R17) (wherein R16 and R17 are each independently hydrogen, Ci-C6 alkyl or halo C1-C6 alkyl and r is an integer of 0 to 3); ring C is C6-Ci4 aryl, C7-C15 arylcarbonylamino, C8-Ci7 aralkylcarbonylamino, heterocycle residue, C3-C7 cycloalkyl or C7-C16 aralkyl, or ring C may be taken together with R7 and R8 to form R8 and R9 are each independently hydrogen, Ci-C6 alkyl, optionally substituted C6-Ci4 aryl, hydroxy C1-C6 alkyl.

- CON (R18) (R19) (wherein R18 and R19 are each independently hydrogen, Ci-C6 alkyl, C3-C7 cycloalkyl, halo Ci-C6 alkyl, C2-Ci2 alkoxyalkyl or optionally substituted C6-Ci4 aryl) , -COO(R20) or - (CH2)s-OCO(R20) (wherein R20 is hydrogen, Ci-C6 alkyl or C3-C7 cycloalkyl; s is an integer of 0 to 3), -N(R21) (R22) (wherein R21 and R22 are each independently hydrogen, C1-C6 alkyl, C1-C6 acyl, Ci-C6 alkylsulfonyl, or R21 and R22 may be taken together with the nitrogen to which they are attached to form 0 V~| —N y- ), or R8 and R9 may be taken together to form C3-C7 cycloalkyl, or a prodrug thereof, or a pharmaceutically acceptable salt of either; (2) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (1), wherein D is Ci-C6 alkyl, C2-C6 alkenyl, C2-C7 alkoxycarbonyl or -N(R42) -CO(R43) in which R42 and R43 each has the same meaning as defined above; (3) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (1), wherein D is the group represented by the formula 16 in which R5, R6 and R7 each has the same meaning as defined above; (4) The ester compound or a prodrug thereof, or a 5 pharmaceutically acceptable salt of either according to the above (3), wherein the ring C is or ,in which q is an integer of 0 to 3; (5) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (2) or (4), wherein ring B is rr^ -N — or (6) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (5), wherein ring A is 17 N or (7) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (6), wherein X is -CON(R10) -(CH2)n- in which R10 and n each has the same meaning as defined above; (8) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (6), wherein X is -COO-(CH2)n- in which n has the same meaning as defined above; (9) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (7) or (8), wherein n is 0; (10) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (10), which is represented by the formula (1') R2' R2" R4 0 h A fr li \ ^ jt—(CH2)| 0 (CH2)b ■ ,R8 (1 ' ) wherein 18 R2 and R2 are each independently hydrogen, Ci-C6 alkyl.

C3-C7 cycloalkyl, Ci-C6 alkoxy, halogen, halo Ci-C6 alkyl, Ci-C6 acyl, C2-C6 alkenyl or cyano; Xi is -O- or -NR10- wherein R10 is hydrogen, C1-C6 alkyl or C3-C7 cycloalkyl; and R1, R3, R4, R5, R6, R7, R8, R9, ring C, 1 and m each has the same meaning as defined above, or a prodrug thereof, or a pharmaceutically acceptable salt of either; (11) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (10), wherein the ring C is or , in which q is an integer of 0 to 3; (12) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (11), wherein Xx is -NR10- in which R10 has the same meaning as defined above; (13) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the 19 above (11), wherein Xi is -0-; (14) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (10) to (13), wherein the group -(CH2)i- is located at the h-position of the benzene ring in the formula (1'); (15) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (10) to (13), wherein the group -(CH2)i- is located at the i-position of the benzene ring in the formula (1'); (16) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (10) to (15), wherein R8 and R9 are each independently -CON(R18) (R19) - in which R18 and R19 each has the same meaning as defined above; (17) The ester compound or a prodrug thereof, or a 20 pharmaceutically acceptable salt of either according to the above (10) to (15), wherein R8 and R9 are each independently -COO(R20)- in which R20 has the same meaning as defined above; (18) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (12) to (17), wherein the ring C is C6-C14 aryl; (19) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (18), wherein C6-Ci4 aryl is phenyl; (20) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (12) to (17), wherein the ring C is C3-C7 cycloalkyl; (21) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (12) to (17), wherein the ring C is (22) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (1), which is selected from the group consisting of {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, 2-phenyl-2-{2-[4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-malonic acid diethyl ester, 2-(2-{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[methyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)- or 21 amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, {4-[(4'-trifluoromethy1-bipheny1-2-carbonyl)-amino]-phenyl}-acetic acid 9-(2,2,2-trifluoro-ethylcarbamoyl)-9h-5 fluoren-9-ylmethyl ester, 2-{4-[(4'-trifluoromethy1-biphenyl-2-carbonyl)-amino]-phenyl}-propionic acid 9-(2,2,2-trifluoro-ethylcarbamoyl ) -9h-fluoren-9-ylmethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-10 phenyl}-acetic acid 2-phenyl-2-(2,2,2-trifluoro-ethylcarbamoyl) -ethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino] -phenyl}-acetoxymethyl) -malonic acid diethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- phenyl}-acetic acid 1-(2,2,2-trifluoro-ethylcarbamoyl)-cyclopentylmethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diisopropyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl) -ethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-25 carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dimethyl ester, 2-cyclopentyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester. 22 {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 1-(2,2,2-trifluoro-ethylcarbamoyl)-cyclohexylmethyl ester, 2-phenyl-2-{2-[4-(2-trifluoromethyl-benzoylamino)-phenyl]-acetoxymethyl}-malonic acid diethyl ester, 2-{2-[4-(2-phenoxy-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-{2-[4-(2-butoxy-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-{2-[4-(2-trifluoromethyl-benzoyloxy)-phenyl]-acetoxymethyl}-malonic acid diethyl ester, 2-{2-[4-(2-benzoyl-benzoyloxy)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-{2-[4-(2-benzoyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethy1-biphenyl- 2 -carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dicyclohexyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-cyclohexylcarbamoyl-2-phenyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-phenylcarbamoyl-ethyl ester, {4—[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-isopropylcarbamoyl-2-phenyl-ethyl ester, 2-benzyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl 23 ester, 2-(2-{2-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 5 41-trifluoromethyl-biphenyl-2-carboxylic acid 4-[2- phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester, biphenyl-2-carboxylic acid 4-[2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl 10 ester, 2-butoxy-benzoic acid 4-[2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester, 2-cyclohexyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-15 carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, {4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl ester, [4-(2-phenoxy-benzoylamino)-phenyl]-acetic acid 2- phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl ester, 2-phenyl-2-(2-{2-trifluoromethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-25 acetoxymethyl)-malonic acid diethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- 24 phenyl}-acetic acid 2,2-bis-methylcarbamoyl-2-phenyl-ethyl ester, 2-pyridin-2-yl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-pyridin-3-yl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl)-phenyl ester, 2-phenyl-2-(2-{3-trifluoromethyl-4-[(4'— trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 14-(2-butoxy-benzoylamino)-phenyl]-acetic acid 2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl ester, {4-[(41-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-butylcarbamoyl-2-phenyl-ethyl ester, 2—(2—{4—[(9-oxo-9h-fluorene-1-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(9h-fluorene-1-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-methyl-4-[(41-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, 2-(2-{4-[(4'-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(4'-methoxy-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, {4-[(4*-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoyl-propyl ester, {4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, [4-(2-phenoxy-benzoylamino)-phenyl]-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, [4-(2-butoxy-benzoylamino)-phenyl]-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, 2-phenyl-2-(2-{4-[(3'-trifluoromethyl-biphenyl-2-carbonyl) - amino ] -phenyl} - acetoxymethyl) -malonic acid diethyl I ester, 2-(2-{4-[2-(4-fluoro-benzoyl)-benzoylamino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl)-2-chloro-phenyl ester, 2-phenyl-2-{2-[4-(2-thiophen-3-yl-benzoylamino)-phenyl]-acetoxymethyl}-malonic acid diethyl ester, 2-(2-{4-[(biphenyl-3-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[isopropyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester. 26 2-(2-{4-[cyclohexyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-{2-[4-(2-isopropyl-benzoylamino)-phenyl]-5 acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-{2-[4-(2-benzyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dipropyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diisobutyl ester, 2-phenyl-2-{2-[4-(2-trifluoromethoxy-benzoylamino)-15 phenyl]-acetoxymethyl}-malonic acid diethyl ester, 2-{2-[4-(2-butoxycarbonyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-isobutylcarbamoyl-2-phenyl-ethyl 20 ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-(3-methyl-butylcarbamoyl)-2-phenyl-ethyl ester, 2-(2-{4-[ethyl-(4■-trifluoromethyl-biphenyl-2-25 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, [ 4 - (2-cyclohexyl-benzoylaxnino) -phenyl] - acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, {4-[(4'-chloro-biphenyl-2-carbonyl)-amino]-phenyl}- 27 acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, {4-[(3',4'-dichloro-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, {3-methyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-(2-methoxy-ethylcarbamoyl)-2-phenyl-ethyl ester, 2-[2 — {4 — {[2-methyl-4-(4-trifluoromethyl-phenyl)-thiazole-5-carbonyl]-amino}-phenyl)-acetoxymethyl]-2-phenyl-malonic acid diethyl ester, (4-{[2-methyl-4-(4-trifluoromethyl-phenyl)-thiazole-5-carbonyl]-amino}-phenyl)-acetic acid 2,2-bis-ethylcarbamoyl- 2 -phenyl -ethyl ester, (4-{[2-(4-trifluoromethyl-phenyl)-pyridine-3-carbonyl]-amino}-phenyl)-acetic acid 2,2-bis-ethylcarbamoyl- 2-phenyl-ethyl ester, (3-methyl-4-{[2-(4-trifluoromethyl-phenyl)-pyridine- 3-carbonyl]-amino}-phenyl)-acetic acid 2,2-bis-ethylcarbamoyl- 2 -phenyl- ethyl ester, 2-(2-{3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-isopropyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino] -phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, 2-(2-{3-isopropyl-4-[(4'-trifluoromethyl-biphenyl-2- 28 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-5 3-phenyl-propyl ester, {3-isobutyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl 2-phenyl-ethyl ester, 2-(2-{3-isobutyl-4-[(4'-trifluoromethyl-biphenyl-2-10 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-chloro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 15 2-(2-{3-bromo-4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl 2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-20 ethylcarbamoyl-2-phenyl-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl 2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester, {3-methylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2 25 carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl 2-phenyl-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl 2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, 29 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-benzylcarbamoyl-4-[(41-trifluoromethyl-biphenyl-2-5 carbonyl) - amino ] -phenyl}-acetic acid 2, 2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 4,4-bis-ethylcarbamoyl-4-phenyl-butyl ester, 10 {3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl ester, {3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-15 ethylcarbamoyl-2-phenyl-ethyl ester, 2-(2-{3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl-20 biphenyl-2-carbonyl) -amino] -phenyl}-acetoxymethyl) -2-phenyl-malonic acid diethyl ester, {3-(isopropyl-methyl-carbamoyl)-4-[(4"-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-25 ethylcarbamoyl-2-phenyl-ethyl ester, 2-(2-{3-(ethyl-methyl-carbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl) -amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-(ethyl-methyl-carbamoyl)-4-[(4'-trifluoromethyl- biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2 -phenyl- ethyl ester, {3-(ethyl-methyl-carbamoyl)-4-[(41-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-5 ethylcarbamoyl-3-phenyl-propyl ester, {3-(piperidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl ester, {3-(pyrrolidine-1-carbonyl)-4-[(4'-trifluoromethyl-10 biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl- 2 -phenyl- ethyl ester, {3-(pyrrolidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -ace tic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl ester, 15 {3-(methyl-propyl-carbamoyl)-4-[(4'-trifluoromethyl- biphenyl- 2 -carbonyl) -amino] -phenyl} -ace tic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl ester, {3-(methyl-propyl-carbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-20 ethylcarbamoyl-3-phenyl-propyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-ethylcarbamoyl-2-phenyl-ethyl ester, 2-phenyl-2-(2-{3-(pyrrolidine-1-carbonyl)-4-[(4'-25 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-phenyl-2-(2-{3-(plperidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 31 {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl)-acetic acid 2-phenyl-2-propionylamino-ethyl ester, {3-dimethylcarbamoyl-4-[(41-trifluoromethyl-biphenyl-5 2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2-propionylamino-ethyl ester, {3-dimethylcarbamoyl-4-[(41-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-(2,5-dioxo-pyrrolidin-l-yl)-2-phenyl-ethyl ester, 10 {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2-carbonyl)-amino]-phenyl}-acetic acid 2-ethylcarbamoyl-benzyl ester, {3-dimethylcarbamoyl-4-[(41-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-15 ethylcarbamoylmethyl-benzyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-isopropylamino-2-phenyl-ethyl ester hydrochloride, [3-dimethylcarbamoyl-4-(2-trifluoromethyl-20 benzoylamino)-phenyl]-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, 2-{2-[3-dimethylcarbamoyl-4-(2-trifluoromethyl-benzoylamino) -phenyl] -acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-fluoro-biphenyl-2-carbonyl) - amino ] -phenyl}-acetoxymethyl) - 2-phenyl-malonic 32 acid diethyl ester, 2-(2-{4-[(4'-bromo-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoy1-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 5 {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2-carbonyl)-amino]-phenyl}-acetic acid 2-acetylamino-2-phenyl-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-butyrylamino-2-10 phenyl-ethyl ester, [4-(2-benzoyl-benzoylamino)-3-dimethylcarbamoyl-phenyl]-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, 2-{2-[4-(2-benzoyl-benzoylamino)-3-dimethylcarbamoyl-15 phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid dimethyl ester, 2-cyclopentyl-2-(2-{3-dimethylcarbamoyl-4-[(41 -20 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy methyl)-malonic acid diethyl ester, 2-cyclohexyl-2-(2-{3-dimethylcarbamoyl-4 -[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy methyl)-malonic acid diethyl ester, 25 2-(2-{4-t(4'-chloro-biphenyl-2-carbonyl)-amino]-3- dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(4'-acetyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic 33 acid diethyl ester, t3-dimethylcarbamoyl-4-(2-phenoxy-benzoylamino)-phenyl]-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, 2-{2 -[3-dimethylcarbamoyl-4-(2-phenoxy-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(4'-cyano-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4-methyl-4'-trif luorome thyl-biphenyl-2-carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2 -{3-dimethylcarbamoyl-4-[(5-methyl-41 -trifluoromethyl-biphenyl-2-carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-methanesulfonylamino-2-phenyl-ethyl ester, 3-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-2-phenyl-propionic acid ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-(methyl-propionyl-amino)-2-phenyl-ethyl ester, 2—[3—(2 — {3-dimethylcarbamoyl-4-[(41 -trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-propyl]-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(5-methoxy-4'-trif luoromethyl-biphenyl-2-carbonyl) -amino] -phenyl}- 34 acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(5-chloro-4'-trifluoromethyl-biphenyl-2 carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 5 2-(2-{3-dimethylcarbamoyl-4-[(6-methyl-4'- trif luorome thyl-biphenyl-2-carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester) , 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-10 phenyl-malonic acid di-2,2,2-trifluoroethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(2'-fluoro-4*-trifluoromethyl-biphenyl-2-carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{5-dimethylcarbamoyl-2-fluoro-4-[(4 1 -15 trif luoromethyl - biphenyl - 2 - carbonyl) - amino ] - phenyl} -acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-bromo-5-dimethylcarbamoyl-4-[(4'-trif luoromethyl - biphenyl - 2 - carbonyl) - amino ] - phenyl} -acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 20 2-(2-{3-chloro-5-dimethylcarbamoyl-4-[(41 - trif luoromethyl-biphenyl-2-carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(31-fluoro-41 -trif luoromethyl - biphenyl - 2 - carbonyl) - amino ] - phenyl} -25 acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(3'-chloro-4'-trifluoromethyl-biphenyl-2 carbonyl) - amino ] - 3 - dimethylcarbamoyl - phenyl} -acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(5-nitro-pyridin-2-yl)-malonic acid diethyl ester, 2-(5-amino-pyridin-2-yl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl} 5 acetoxymethyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-pyridin-2-yl-malonic acid diethyl ester, 2-(2-{3-chloro-5-dimethylcarbamoyl-2-fluoro-4-[(41 -10 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-bromo-5-dimethylcarbamoyl-2-fluoro-4-[(4'— trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 15 2-(2-{3-dimethylcarbamoyl-4-[(41 -trifluoromethyl- biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-o-tolyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-m-20 tolyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-p-tolyl-malonic acid diethyl ester, 2-(2-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4' 25 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-(3-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4' trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester. 36 2-(4-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4' trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-5 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-succinic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-(2-methoxy-phenyl)-malonic acid diethyl ester, 10 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-2-(3-methoxy-phenyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(4-15 methoxy-phenyl)-malonic acid diethyl ester, 2-(2-{4-[(5,4'-bis^trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(6-chloro-4'-trifluoromethyl-biphenyl-2-20 carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}- acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(6-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 25 2-[2-(2-{3-dlmethylcarbamoyl-4-[(5-methyl-4'- trif luoromethyl-biphenyl - 2 - carbonyl) - amino ] -phenyl} -acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(5-ethoxy-4'-trif luoromethyl-biphenyl-2-carbonyl) -amino] -phenyl}- 37 acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(5-isopropoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{4-[(5,4*-bis-trifluoromethyl-biphenyl-2-carbonyl) - amino ] - 3 - dimethylcarbamoyl - phenyl} - acetoxy) -ethyl]-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(6-methoxy-4'-trif luoromethyl-biphenyl-2-carbonyl) -amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(3-methyl-4'-trif luoromethyl-biphenyl-2-carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-{2-[4-{2,4-bis-trifluoromethyl-benzoylamino)-3-dimethylcarbamoyl-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-ethyl-4-trifluoromethyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-ethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropenyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic 38 acid diethyl ester, 2-{2-[3-dimethylcarbamoyl-4-(2-isopropenyl-4-trif luorome thyl-benzoylamino) -phenyl] -acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 5 2 — {2 —[3-dimethylcarbamoyl-4-(2-isopropyl-4- trifluoromethyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[2-(3-trifluoromethyl-phenylamino)-benzoylamino]-phenyl}-acetoxymethyl)-2-phenyl-10 malonic acid diethyl ester, 2-{2-[3-dimethylcarbamoyl-4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-(2 -{3-dimethylcarbamoyl-4-[2-(3-trifluoromethyl-15 phenoxy)-benzoylamino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-ethyl-2-phenyl-butyl ester, 2-(2-{3-dimethylcarbamoyl-4-[2-(4-trifluoromethyl- phenoxy)-benzoylamino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 1-phenyl-25 cyclopropylmethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-diphenyl-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 39 2-carbonyl)-amino]-phenyl}-acetic acid 1-phenyl-cyclopentylmethyl ester, {3-dimethylcarbamoyl-4-[(41-trifluoromethyl-biphenyl 2-carbonyl)-amino]-phenyl}-acetic acid 3-hydroxy-2-5 hydroxymethyl-2-phenyl-propyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl 2-carbonyl)-amino]-phenyl}-acetic acid 3-acetoxy-2-acetoxymethyl-2-phenyl-propyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-10 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-thiophen-2-yl-malonic acid diethyl ester, 2-(2-{3-dime thylcarbamoyl-4-[(41-trifluoromethyl-biphenyl-2-carbonyl) -amino] -phenyl}-acetoxymethyl)-2-thiophen-3-yl-malonic acid diethyl ester, 15 2-(2-{4-dimethylcarbamoyl-5-[(41 -trifluoromethyl- biphenyl-2-carbonyl)-amino]-pyridin-2-yl}-acetoxymethyl)-2 phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(3-20 methyl-thiophen-2-yl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(5-methyl-thiophen-2-yl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-25 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-thiazol-2-yl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethy1-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-isopropyl-malonic acid diethyl ester. 40 2-sec-butyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl) -amino] -phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-t(4'-trifluoromethyl-5 biphenyl - 2 - carbonyl) - amino ] -phenyl} - acetoxymethyl) - 2 -isobutyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-propyl-malonic acid diethyl ester, 10 2-(2-{3-dimethylcarbamoyl-4-[(41-trifluoromethyl- biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-ethyl malonic acid diethyl ester, 2-butyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-15 acetoxymethyl)-malonic acid diethyl ester, 2-allyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 3-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-20 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-2,2-bis- ethoxycarbonyl-propionic acid ethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl) -amino] -phenyl}-acetoxymethyl) -2- (lime thyl-butyl)-malonic acid diethyl ester, 25 2-(2-{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl 41 2-phenyl-ethyl ester, {3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl 2-phenyl-ethyl ester, 2-(2-{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester, {3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl 3-phenyl-propyl ester, {3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl 2-phenyl-ethyl ester, {3-ethoxy-4-[(41-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl 3-phenyl-propyl ester, 2-(2-{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl 2-phenyl-ethyl ester, {3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl 3-phenyl-propyl ester, {3-propoxy-4-[(4'-trifluoromethyl-biphenyl-2- 42 carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, {3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-5 2-phenyl-ethyl ester, 2-(2-{3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-10 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-{2-[3-methoxy-4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, {3-dimethylamino-4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, {3-piperidin-l-yl-4-[(41-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-20 2-phenyl-ethyl ester, {3-pyrrolidin-l-yl-4-[(4*-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, 2-phenyl-2-(2-{3-piperidin-l-yl-4-[(4'-25 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-phenyl-2-(2-{3-pyrrolidin-l-yl-4-[(4'— trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester. 43 2-(2-{3-dimethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-morpholin-4-yl-4-[(4'-trifluoromethyl-bipheny 5 1-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-diethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 10 2-[2-(2-{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-(2-{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl) - amino] -phenyl}-acetoxymethyl) -malonic acid diethyl 15 ester, 2-phenyl-2-[2-(2-{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-malonic acid diethyl ester, {3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-20 phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, {3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoyl-propyl ester, 2-[2-(2-{4-methyl-3-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{2-methyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic 44 acid diethyl ester, {3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-isopropylcarbamoyl-3-phenyl-propyl ester, {2-methyl-3-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl 3-phenyl-propyl ester, {2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 4,4-bis-ethylcarbamoyl 10 4-phenyl-butyl ester, {2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoy1-propyl ester, {2-methoxy-3-[(4'-trifluoromethyl-biphenyl-2-15 carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl 3-phenyl-propyl ester, 2-12-(2-{2-methoxy-3-[(4'-trifluoromethyl-biphenyl-2 carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 20 {2-ethoxy-3-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl 3-phenyl-propyl ester, 2-[2-(2-{2-ethoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic 25 acid diethyl ester, 2-[2-(2-{2-isopropoxy-3-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -acetoxy) -ethyl]-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{2-methoxycarbonyl-3-[(4'-trifluoromethyl- 45 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{2-ethoxy-5-methyl-3-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-[9-(2,2,2-trifluoro-ethylcarbamoyl)-9h-fluoren-9-yl]-ethyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-(9h-fluoren-9-yl)-ethyl ester, n-biphenyl-2-yl-terephthalamic acid 2-[9-(2,2,2-trifluoro-ethylcarbamoyl)-9h-fluoren-9-yl]-ethyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-[(biphenyl-2-carbonyl)-amino]-ethyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-(2-biphenyl-2-yl-acetylamino)-ethyl ester, 4-[(41 -trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-naphthalen-l-yl-3-(2,2,2-trifluoro-ethylcarbamoyl )-propyl es t er, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-[2-(2,2,2-trifluoro-ethylcarbamoyl)-naphthalen-l-yl]-propyl ester, 4-t(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3,3-diphenyl-3-(2,2,2-trifluoro-ethylcarbamoyl )-propyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-biphenyl-2-yl-3-(2,2,2-trifluoro-ethylcarbamoyl )-propyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- 46 benzoic acid 3-phenyl-3-(2,2,2-trifluoro-ethylcarbamoyl)-propyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-[8-(2,2,2-trifluoro-ethylcarbamoyl)-5 naphthalen-l-yl]-ethyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-(2,6-dichloro-phenyl)-3-(2,2,2-trifluoro-ethylcarbamoyl )-propyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-10 benzoic acid 3-(2-chloro-phenyl)-3-(2,2,2-trifluoro-ethylcarbamoyl )-propyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-malonic acid diethyl ester, 2-(2-{3-methyl-4-[(41-trifluoromethyl-biphenyl-2- carbonyl)-amino]-benzoyloxy}-ethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{2-chloro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-2-phenyl-malonic acid 20 diethyl ester, 2-phenyl-2-{2-[4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-benzoyloxy]-ethyl}-malonic acid diethyl ester, 2-{2-[4-(2-benzoyl-benzoyloxy)-benzoyloxy]-ethyl}-2-phenyl-malonic acid diethyl ester, 25 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- benzoic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3-bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-2-chloro-phenyl ester. 47 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3-bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-phenyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3-bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-2,6-dichloro-phenyl ester, 4-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-cyclohexanecarboxylic acid 2-[9-(2,2,2-trifluoro-ethylcarbamoyl)-9h-fluoren-9-yl]-ethyl ester, 10 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- cyclohexanecarboxylic acid 2-[9-(2,2,2-trifluoro-ethylcarbamoyl)-9h-fluoren-9-yl]-ethyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-cyclohexanecarboxylic acid 3-phenyl-3-(2,2,2-trifluoro-15 ethylcarbamoyl)-propyl ester, 2-phenyl-2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-cyclohexanecarbonyloxymethyl}-malonic acid diethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-20 carbonyl)-amino]-cyclohexanecarbonyloxy}-ethyl)-malonic acid diethyl ester, 2-phenyl-2-(2-{4-[(41-trifluoromethyl-biphenyl-2-carbonyl)-amino]-piperidin-l-yl}-acetoxymethyl)-malonic acid diethyl ester, 25 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-indol-1-yl}-acetoxymethyl) -malonic acid diethyl ester, 2-(2-{2-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoimidazol-l-yl}-acetoxymethyl)-2- 48 phenyl-malonic acid diethyl ester, [2-OXO-3-(4'-trifluoromethyl-biphenyl-2-carbonyl)-2,3-dihydro-benzooxazol-6-yl]-acetic acid 2,2-bis-ethylcarbamoyl- 2 -phenyl-ethyl ester, 5 2-(2-{3-ethoxycarbonyl-4-[(4'-trifluoromethyl- biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(3-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-propionyloxymethyl)-2- phenyl-malonic acid diethyl ester, 4-{[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-methyl}-benzoic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, 3-{4-[(4*-trifluoromethyl-biphenyl-2-carbonyl)- amino]-phenyl}-propionic acid ethylcarbamoyl-phenyl-methyl ester, -(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl) -2- [(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid benzyl ester, 5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl- methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid, -(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- benzoic acid ethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzolmidazol-l-yl}-acetoxymethyl)-malonic acid diethyl ester, 3-{[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- 49 methyl}-benzoic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, -(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-5 benzoic acid methyl ester, 2-(2-{3-benzyloxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-carboxy-4-[(4'-trifluoromethyl-biphenyl-2-10 carbonyl) -amino] -phenyl}-acetoxymethyl) -2-phenyl-malonic acid diethyl ester, 2-{2-[2-OXO-3-(4'-trifluoromethyl-biphenyl-2-carbonyl)-2,3-dihydro-benzooxazol-6-yl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 15 2-{2-[8-oxo-7-(4'-trifluoromethyl-biphenyl-2- carbonyl)-7-aza-bicyclo[4.2.0]octa-1(6),2,4-trien-3-yl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-(2-{3-isopropoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-20 phenyl-malonic acid diethyl ester, 2-(2-{3-methoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl -2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-[2-(3-dimethylcarbamoyl-4-{[1-(2-nitrol-4-trifluoro-25 methyl-phenyl)-pyrrolidine-2-carbonyl]-amino}-phenyl)-acetoxymethyl]-2-phenyl-malonic acid diethyl ester, 2-(2-{3-acetylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester. 50 2-(2-{3-methoxycarbonylamino- 4 -[(41 -trifluoromethy1-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-(4-methyl-thiazol-2-yl)- 4 - [ (4 ' -5 trif luoromethyl-biphenyl-2-carbonyl) -amino] - phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-(2-{6-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-biphenyl-3-yl}-acetoxymethyl)-malonic acid diethyl ester, 2-(2-{3-formyl-4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethy laminomethyl-4-[(41-trifluoromethyl-biphenyl-2-carbonyl) -amino]-phenyl}-acetoxymethyl)-2-15 phenyl-malonic acid diethyl ester, 2-(2-{3-(methoxy-methyl-carbamoyl)-4-[(4'-t rif luoromethyl - biphenyl - 2 - carbonyl) - amino ] - phenyl} -acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-isobutyryl-4-[(4'-trifluoromethyl-biphenyl-2-20 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, and 2-(2-{3-(l-hydroxy-2-methyl-propyl)-4- [ (4'-trifluoromethyl-biphenyl-2-carbonyl) -amino] -phenyl}-ace toxym ethyl)-2-phenyl-malonic acid diethyl ester; (23) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (1), which is selected from the group consisting of 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- 51 phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, 2-phenyl-2-{2-[4-[(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-malonic acid diethyl ester, 2-(2-{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[methyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl-2-phenyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 9-(2,2,2-trifluoro- ethylcarbamoyl) -9h-fluoren- 9 -ylmethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-propionic acid 9-(2,2,2-trifluoro- ethylcarbamoyl)-9h-fluoren-9-ylmethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl ester, 2-phenyl-2-(2-{4-[4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diisopropyl ester. 52 {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl) -ethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dimethyl ester, 2-cyclopentyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dicyclohexyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-cyclohexylcarbamoyl-2-phenyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-phenylcarbamoyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-isopropylcarbamoyl-2-phenyl-ethyl ester, 2-benzyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl-malonic acid diethyl ester, 2-(2-{2-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl-2-phenyl-malonic acid diethyl ester, 4' -trifluoromethyl-biphenyl-2-carboxylic acid 4-[2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)- 53 ethoxycarbonylmethyl]-phenyl ester, biphenyl-2-carboxylic acid 4-[2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester, 2-cyclohexyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl- 2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, {4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl 10 ester, 2-phenyl-2-(2-{2-trifluoromethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-15 phenyl}-acetic acid 2,2-bis-methylcarbamoyl-2-phenyl-ethyl ester, 2-pyridin-2-yl-2-(2-{4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl-malonic acid diethyl ester, 20 2-pyridin-3-yl-2-(2-{4-[(4'-trifluoromethyl- biphenyl- 2 -carbonyl) -amino] -phenyl} -acetoxymethyl) -malonic acid diethyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl)-phenyl 25 ester, 2-phenyl-2-(2-{3-trifluoromethyl-4-[(4'-trifluorome thyl- biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-malonic acid diethyl ester, {4-t(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- 54 phenyl}- acetic acid 2,2-bis-butylcarbamoyl-2-phenyl-ethyl ester, {3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-5 2-phenyl-ethyl ester, 2-(2-{4-[(4'-methyl-biphenyl-2-carbonyl}-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(4'-methoxy-biphenyl-2-carbonyl}-amino]-phenyl}- acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 10 {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl}-amino]- phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl}-amino]-phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoyl-propyl 15 ester, {4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, 2-phenyl-2-(2-{4-[(3'-trifluoromethyl-biphenyl-2-carbonyl)-amino] -phenyl}-acetoxymethyl) -malonic acid diethyl 20 ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl)-2-chloro-phenyl ester, 2-(2-{4-[isopropyl-(4'-trifluoromethyl-25 biphenyl-2-carbonyl}-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[cyclohexyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 55 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dipropyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-5 carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diisobutyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl}-amino]-phenyl}-acetic acid 2,2-bis-isobutylcarbamoyl-2-phenyl-ethyl ester, {4-[(4'-trifluoromethy1-biphenyl-2-carbonyl}-amino]- phenyl}-acetic acid 2,2-bis-(3-methyl-butylcarbamoyl-2-phenyl-ethyl ester, 2-(2-{4-[ethyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic 15 acid diethyl ester, {4-[(4'-chloro-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-(ethylcarbamoyl-2-phenyl-ethyl ester, {4-[(3',4'-dichloro-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-(ethylcarbamoyl-2-phenyl-ethyl 20 ester, {3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl}-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl}-25 amino]-phenyl}-acetic acid 2,2-bis-(2-methoxy- ethylcarbamoyl)-2-phenyl-ethyl ester, 2-(2-{3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl}-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester. 56 {3-isopropyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl}-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl ester, 2-(2-{3-isopropy1-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, {3-isobutyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl ester, 2-(2-{3-isobutyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-chloro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-bromo-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl -2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl 2,2-bis-propylcarbamoyl-ethyl ester, {3-methylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- 57 ethylcarbamoyl- 2 -phenyl-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl- 3 -phenyl- ethyl ester, 5 2-(2-{3-diethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-benzylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl-2-phenyl-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 4,4*-bis- ethylcarbamoyl-4-phenyl-butyl ester, {3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2 15 -carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl -2 -phenyl -ethyl ester, {3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -acetic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl ester, 20 2-(2-{3-diethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-25 phenyl-malonic acid diethyl ester, {3-(isopropyl-methylcarbamoyl)-4-[(4'-trifluoromethyl -biphenyl -2 -carbonyl) -amino] -phenyl} -acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, 2-(2-{3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoro- 58 me thyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis 5 ethylcarbamoyl-2-phenyl-ethyl ester, {3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -ace tic acid 3,3-bis ethylcarbamoyl-3-phenyl-propyl ester, {3-(piperidine-1-carbonyl)-4-[(4'-trifluoromethyl-10 biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl ester, {3-(pyrrolidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl ester, 15 {3-(methyl-propylcarbamoyl)-4-[(4'-trifluoromethyl- biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl ester, {3-(methyl-propylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -ace tic acid 3,3-bis 20 ethylcarbamoyl-3-phenyl-ethyl ester, {3-(dimethylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-ethyl carbamoyl-2-phenyl-ethyl ester, 2-phenyl-2-(2-{3-(pyrrolidine-1-carbonyl)-4-[(4'-25 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-phenyl-2-(2-{3-(piperidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester. 59 {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2-propionylamino-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-5 biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2-propionylamino-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-(2,5-dioxo-pyrrolidin-l-yl)-2-phenyl-ethyl ester, 10 {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2- ethylcarbamoyl-benzyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl -2 -carbonyl} -amino] -phenyl} -acetic acid 2- ethylcarbamoylmethyl-benzyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -acetic acid 2-isopropylamino-2-phenyl-ethyl ester hydrochloride, 2-[2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-20 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-fluoro-biphenyl-2-carbonyl}-amino]-phenyl}-acetoxymethyl)-2-phenyl- malonic acid diethyl ester, 25 2-(2-{4-[(4*-bromo-biphenyl-2-carbonyl)-amino]-3- dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl -2-carbonyl)-amino]-phenyl}-acet ic acid 2- 60 acetylamino-2-phenyl-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2- butyrylamino-2-phenyl-ethyl ester, 5 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid dimethyl ester, 2-cyclopentyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-10 acetoxymethyl)-malonic acid diethyl ester, 2-cyclohexyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-(2-{4-[(4'-chloro-biphenyl-2-carbonyl)-amino]-3-15 dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(4'-acetyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 20 2-(2-{4-[(4'-cyano-biphenyl-2-carbonyl)-amino]-3- dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-25 acetoxymethyl)- 2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(5-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- 61 biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2 methanesulfonylamino-2-phenyl-ethyl ester, 3-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-2-phenyl-5 propionic acid ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-(methyl propionyl-amino)-2-phenyl-ethyl ester, 2-[3-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-10 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-propyl]-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(5-methoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl]-2-phenyl-malonic acid diethyl ester, 15 2-(2-{4-[5-chloro-4'-trifluoromethyl-biphenyl-2- carbony1)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(6-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-20 acetoxymethyl)- 2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-aminoJ-phenyl}-acetoxymethyl)-2-phenyl-malonic acid di-2,2,2-trifluoroethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(2'-fluoro-4'-25 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester. 62 2-(2-{3-bromo-5-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-chloro-5-dimethylcarbamoyl-4-[(4'-5 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(3*-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 10 2-(2-{4-(3'-chloro-4'-trifluoromethyl- biphenyl -2 -carbonyl) -amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2 — {3 — dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-15 (5-nitro-pyridin-2-yl)-malonic acid diethyl ester, 2-(5-amino-pyridin-2-yl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-20 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-pyridin-2-yl-malonic acid diethyl ester, 2-(2-{3-chloro-5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 25 2-(2-{3-bromo-5-dimethylcarbamoyl-2-fluoro-4-[(4'- trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-o- 63 tolyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl -2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-m-tolyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-2-p-tolyl-malonic acid diethyl ester, 2-(2-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl} acetoxymethyl)-malonic acid diethyl ester, 2-(3-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl} acetoxymethyl)-malonic acid diethyl ester, 2-(4-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl} acetoxymethyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-succinic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(2-methoxy-phenyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl -2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-(3-methoxy-phenyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(4-methoxy-phenyl)-malonic acid diethyl ester, 2-(2-{4-(5,4'-bis-trifluoromethyl-biphenyl-2- 64 carbonyl)- amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl}-malonic acid diethyl ester, 2-(2-{4-(6-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-5 acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(6-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{3-dimethylcarbamoyl-4-[(5-methyl-4'-10 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(5-ethoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 15 2-(2-{3-dimethylcarbamoyl-4-[(5-isopropoxy-4'- trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{4-[(5,4'-bis-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxy)-20 ethyl]-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(6-methoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(3-methyl-4' -25 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-{2-[4-(2,4-bis-trifluoromethyl-benzoylamino)-3-dimethylcarbamoyl-phenyl]-acetoxymethyl)-2-phenyl-malonic acid diethyl ester. 65 2-(2-{3-dimethylcarbamoyl-4-[(4'-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-{2-[3-dimethylcarbamoyl-4-(2-ethyl-4-trifluoromethyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-ethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropenyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-{2-[3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-ethyl-2 phenyl-butyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 1-phenyl cyclopropylmethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2 diphenyl-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl -2-carbonyl)-amino]-phenyl}-acet ic acid 1-phenyl 66 cyclopentylmethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-hydroxy 2-hydroxymethyl-2-phenyl-propyl ester, 5 {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl- 2 -carbonyl) -amino] -phenyl} -acetic acid 3-acetoxy 2-acetoxymethyl-2-phenyl-propyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-10 thiophen-2-yl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl -2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-2-thiophen-3-yl-malonic acid diethyl ester, 2-(2-{4-dimethylcarbamoyl-5-[(4'-trifluoromethyl-15 biphenyl-2-carbonyl)-amino]-pyrldin-2-yl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(3-methyl-thiophen-2-yl)-malonic acid diethyl ester, 20 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-(5-methyl-thiophen-2-yl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-2-25 thiazol-2-yl-malonic acid diethyl ester, 2-(2-£ 3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2- 67 carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl- 2-phenyl-ethyl ester, {3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl- 2-phenyl-ethyl ester, 2-(2-{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-10 carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester, {3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, 15 {3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl- 2 -phenyl-ethyl ester, {3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis- ethylcarbamoyl-3-phenyl-propyl ester, 2-(2-{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-25 carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl -2 -phenyl- ethyl ester, {3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis- ethylcarbamoyl- 3 -phenyl-propyl ester, 68 {3-propoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl- 2-phenyl-ethyl ester, {3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl -2-phenyl-ethyl ester, 2-(2-{3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-{2-[3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, {3-dimethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl- 2-phenyl-ethyl ester, {3-piperidin-l-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl -2 -phenyl- ethyl ester, {3-pyrrolidin-l-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl -2 -phenyl- ethyl ester, 2-phenyl-2-(2-{3-piperidin-l-yl-4-[(4'-trifluoromethyl- biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-phenyl-2-(2-{3-pyrrolidin-l-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}- 69 acetoxymethyl)-malonic acid diethyl ester, 2-(2-{3-dimethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, (2-{3-morpholin-4-yl-4-[(4'-trifluoromethyl-biphenyl- 2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-diethylamino-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-(2-{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-phenyl-2-[2-(2-{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-malonic acid diethyl ester, {3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, {3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, {3 —[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-phenyl-3,3-bis- propylcarbamoyl-propyl ester, 2-[2-(2-{4-methyl-3-[(4'-trifluoromethyl-biphenyl-2- 70 carbonyl)-amino]-phenyl}-acetoxy-ethyl)-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{2-methyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic 5 acid diethyl ester, •C3 — [ (4 ' - trif luoromethyl-biphenyl-2-carbonyl) -amino] -phenyl}-acetic acid 3,3-bis-isopropylcarbamoyl-3 phenyl-propyl ester, {2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-10 carbonyl)-amino]-phenyl}-acetic acid 3,3-bis ethylcarbamoyl-3-phenyl-propyl ester, {2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 4,4-bis ethylcarbamoyl-4-phenyl-butyl ester, 15 {2-methyl-3-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetic acid 3-phenyl-3,3-bis propylcarbamoyl-propyl ester, {2-methoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis ethylcarbamoyl-3-phenyl-propyl ester, 2-[2-(2-{2-methoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, {2-ethoxy-3-[(4'-trifluoromethyl-biphenyl-2-25 carbonyl)-amino]-phenyl}-acetic acid 3,3-bis ethylcarbamoyl-3-phenyl-propyl ester, 2-[2-(2-{2-ethoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester. 71 2-[2-(2-{2-isopropoxy-3-[(4'-trifluoromethyl-biphenyl -2 -carbonyl) -amino] -phenyl} -acetoxy) -ethyl]-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{2-methoxycarbonyl-3-[(4'-trifluoromethyl-5 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{2-ethoxy-5-methyl-3-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 10 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- benzoic acid 2-[9-(2,2,2-trifluoro-ethylcarbamoyl)-9h fluoren-9-yl]-ethyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-[9h-fluoren-9-yl]-ethyl ester, 15 n-biphenyl-2-yl-terephthalamic acid 2-[9-(2,2,2 trifluoro-ethylcarbamoyl)-9h-fluoren-9-yl]-ethyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-[(biphenyl-2-carbonyl)-amino]-ethyl ester, 4-t(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-20 benzoic acid 2-(2-biphenyl-2-yl-acetylamino)-ethyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-naphthalen-l-yl-3-(2,2,2-trifluoro ethylcarbamoyl)-propyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-25 benzoic acid 3-[2-(2,2,2-trifluoro-ethylcarbamoyl) naphthalen-1-yl]-propyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3,3-diphenyl-3-(2,2,2-trifluoro-ethylcarbamoyl )-propyl ester, 72 4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl)-amino]-benzoic acid 3-biphenyl-2-yl-3-(2,2,2-trifluoro- ethylcarbamoyl)-propyl ester, 4-t(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-5 benzoic acid 3-phenyl-3-(2,2,2-trifluoro- ethylcarbamoyl)-propyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-[8-(2,2,2-trifluoro- ethylcarbamoyl) -naphthalen-l-yl] -ethyl ester, 10 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- benzoic acid 3-[(2,6-dichloro-phenyl)-3- (2,2,2-trifluoro-ethylcarbamoyl)-propyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-(2-chloro-phenyl)-3-(2,2,2-trifluoro-15 ethylcarbamoyl)-propyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-malonic acid diethyl ester, 2-(2-{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-20 carbonyl)-amino]-benzoyloxy}-ethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{2-chloro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-{2-[4-[(4'-trifluoromethyl-biphenyl-2- carbonyloxy)-benzoyloxy]-ethyl}-malonic acid diethyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3- 73 bis-ethylcarbamoyl-3-phenyl-propoxycarbony) - 2 -chloro-phenyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3 bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-phenyl ester, 5 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3 bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-2,6-dichloro-phenyl ester, 2-(2-{3-ethoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl-acetoxymethyl)-2-10 phenyl-malonic acid diethyl ester, 2-(3-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-propionyloxymethyl)-2-phenyl-malonic acid diethyl ester, 2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-15 amino]-phenyl}-propionic acid ethylcarbamoyl-phenyl-methyl ester, -(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl) -2-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid benzyl ester, 20 5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl methyl) -2- [(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid, -(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl) -2- [(4'-trifluoromethyl-biphenyl-2-carbonyl)-25 amino]-benzoic acid ethyl ester, -(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl) -2- [ (4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid methyl ester, 2-(2-{3-benzyloxycarbonyl-4-[(4'-trifluoromethyl- 74 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-(2-{3-carboxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic 5 acid diethyl ester, 2-(2-{3-isopropoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-methoxycarbonyl-4-[(4'-trifluoromethyl-10 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-acetylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 15 2-(2-{3-methoxycarbonylamino-4-[(4'-trifluoromethyl- biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-(4-methyl-thiazol-2-yl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-20 acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-(2-{6-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-biphenyl-3-yl}-acetoxymethyl)-malonic acid diethyl ester, 2-(2-{3-formyl-4-[(4'-trifluoromethyl-biphenyl-2-25 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylaminomethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-3-acetoxymethyl)-2-phenyl-malonic acid diethyl ester. 75 2-(2-{3-methoxy-methylcarbamoyl) - 4 - [ (4 ' -trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-3-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-isobutyryl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-3-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, and 2—(2—{3—{1-hydroxy-2-methyl-propyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester; (24) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (1), which is selected from the group consisting of {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-15 phenyl}-acetic acid 2,2-bis-ethylcarbamoyl)-2-phenyl-ethyl ester, 2-phenyl-2-{2-[4-[(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-malonic acid diethyl ester, 2-(2-{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[methyl-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic 25 acid diethyl ester, {3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-2-phenyl]-acetic acid 2,2-bis- ethylcarbamoyl -phenyl -ethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2- 76 carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- malonic acid 5 diisopropyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-(2,2,2- trifluoro-ethylcarbamoyl)-ethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-10 carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dimethyl ester, 2-cyclopentyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 15 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dicyclohexyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-cyclohexylcarbamoyl-2-20 phenyl ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-phenylcarbamoyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-25 phenyl}-acetic acid 2,2-bis-isopropylcarbamoyl-2-phenyl-ethyl ester, 2-benzyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester. 77 2-(2-{2-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-[2-5 phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester, biphenyl-2-carboxylic acid 4-[2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester, 2-cyclohexyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl- 2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, {4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl 15 ester, 2-phenyl-2-(2-{2-trifluoromethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-20 phenyl}-acetic acid 2,2-bis-methylcarbamoyl-2-phenyl-ethyl ester, 2-pyridin-2-yl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 25 2-pyridin-3-yl-2-(2-{4-[(4'-trifluoromethyl- biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-malonic acid diethyl ester, 4'-trifluoromethyl-biphenyl-2-carbxylic acid 4-(2,2-bis-ethylcarbamoyl)-2-phenyl-ethoxycarbonylmethyl)- 78 phenyl ester, 2-phenyl-2-(2-{3-trifluoromethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 5 {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- phenyl}-acetic acid 2,2-bis-butylcarbamoyl-2-phenyl-ethyl ester, {3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-10 2-phenyl-ethyl ester, 2-(2-{4-[(4'-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(4'-methoxy-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 15 {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoyl-propyl 20 ester, {4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, 2-phenyl-2-(2-{4-[(3'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl 25 ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(2,2-bis-ethylcarbamoyl)-2-phenyl-ethoxycarbonylmethyl)-2-chloro-phenyl ester, 2-(2-{4-[isopropyl-(4'-trifluoromethyl-biphenyl-2- 79 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[cyclohexyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dipropyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diisobutyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-isobutylcarbamoyl-2 phenyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-(3-methyl butylcarbamoyl)-2-phenyl-ethyl ester, 2-(2-{4-[ethyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {4-[(4'-chloro-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl ethyl ester, {4-[(3'4'-dichloro-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl ethyl ester, {3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis propylcarbamoyl-ethyl ester. 80 {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-(2-methoxy-ethylcarbamoyl)-2 phenyl-ethyl ester, 2-(2-{3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-isopropyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethy1 es ter, 2-(2-{3-isopropyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-ethyl-4-f(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis ethylcarbamoyl-3-phenyl-propyl ester, {3-isobutyl-4-t(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl ester, 2-(2-{3-isobutyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-chloro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-bromo-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2- 81 phenyl-malonic acid diethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester, 5 {3-methylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl -2-phenyl-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-10 ethylcarbamoyl-3-phenyl-propyl ester, 2-(2-{3-diethylcarbamoy1-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-benzylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-15 2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl -2 -phenyl -ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 4,4-bis-ethylcarbamoy1-4-phenyl-butyl ester, 20 {3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2-carbonyl)-amino]-phenyl}7acetic acid 2,2-bis- ethylcarbamoyl -2-phenyl-ethyl ester, {3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl-biphen yl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl-2-phenyl-ethyl ester, 2-(2-{3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl- 82 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-(isopropyl-methylcarbamoyl)-4-[(4'-trifluoromethyl -biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-5 ethylcarbamoyl-2-phenyl-ethyl ester, 2-(2-{3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-10 biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl- 2 -phenyl- ethyl ester, {3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, 15 {3-(piperidin-1-carbonyl)-4-[(4'-trifluoromethyl- biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2 -phenyl- ethyl ester, {3-(pyrrolidin-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -ace tic acid 2,2-bis-20 ethylcarbamoyl-2-phenyl-ethyl ester, {3-(methyl-propylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl ester, {3-(methyl-propylcarbamoyl)-4-[(4'-trifluoromethyl-25 biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl- 3 -phenyl-propyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl -2 -carbonyl) -amino] -phenyl} -ace tic acid 2-ethylcarbamoyl-2-phenyl-ethyl ester, 83 2-phenyl-2-(2-{3-pyrrolidin-l-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-phenyl-2-(2-{3-piperidin-l-carbonyl)-4-[(4'-5 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -ace tic acid 2-phenyl-2-propionylamino-ethyl ester, 10 {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-(2,5-dioxo-pyrrolidin-l-yl)-2-phenyl-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetic acid 2-ethylcarbamoyl-benzyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-ethylcarbamoylmethyl-benzyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-20 biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-isopropylamino-2-phenyl-ethyl ester hydrochloride, 2-[2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 25 2-(2-{3-dimethylcarbamoyl-4-[(4'-fluoro-biphenyl-2- carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(4'-bromo-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic 84 acid diethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetic acid 2-acethylamino-2-phenyl-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetic acid 2-butyrylamino-2-phenyl-ethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid dimethyl ester, 2-cyclopentyl-2-(2-{3-dimethylcarbamoyl- 4 - [ (4 ' -trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-cyclohexyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-(2-{4-[(4'-chloro-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(4'-acetyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(4'-cyano-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4-methyl-4'-trifluromethy1-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(5-methyl-4'- 85 trifluromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-methanesulfonylamino-2-phenyl-ethyl ester, 3-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-2-phenyl-propionic acid ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-10 biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-(methyl-propionyl-amino)-2-phenyl-ethyl ester, 2-[3-(2-{3-dimethylcarbamoyl-4-[(4'-trifluromethy1--biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-propyl]-2-phenyl-malonic acid diethyl ester, 15 2-(2-{3-dimethylcarbamoyl-4-[(5-methoxy-4'- trifluromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(5-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-20 acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(6-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-25 -biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid di-2,2,2-trifluoroethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(2'-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester. 86 2- (2-{5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-bromo-5-dimethylcarbamoyl-4-[(4'-5 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-chloro-5-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 10 2-(2-{3-dimethylcarbamoyl-4-[(3'-fluoro-4'- trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(3'-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-15 acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(5-nitro-pyridin-2-yl)- malonic acid diethyl ester, 2-(5-amino-pyridin-2-yl)-2-(2-{3-dimethylcarbamoyl 20 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-pyridin-2-yl-malonic acid diethyl ester, 25 2-(2-{3-chloro-5-dimethylcarbamoyl-2-fluoro-4-[(4' trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-bromo-5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}- 87 acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-o-tolyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-2-m-tolyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-p-tolyl-malonic acid diethyl ester, 2-(2-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl} acetoxymethyl)-malonic acid diethyl ester, 2-(3-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl} acetoxymethyl)-malonic acid diethyl ester, 2-(4-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl} acetoxymethyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-succinic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(2-methoxy-phenyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(3-methoxy-phenyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- 88 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(4-methoxy-phenyl)-malonic acid diethyl ester, 2-(2-{4-[(5,4'-bis-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-5 acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(6-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(6-fluoro-4F-10 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{3-dimethylcarbamoyl-4-[(5-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 15 2-(2-{3-dimethylcarbamoyl-4-[(5-ethoxy-4'- trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(5-isopropoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-20 acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{4-(5,4'-bis-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-(6-methoxy-4'-25 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(3-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester. 89 2-{2-[4-(2,4-bis-trifluoromethyl-benzoylamino)-3-dimethylcarbamoy1-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-methyl-biphenyl-2-5 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-{2-[3-dimethylcarbamoyl-4-[(2-ethyl-4-trifluoromethyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 10 2-(2-{3-dimethylcarbamoyl-4-[(4'-ethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropenyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-15 phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-{2-[3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-20 biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-ethyl 2-phenyl-butyl ester, 25 {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 1-phenyl cyclopropylmethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2 90 diphenyl-ethyl ester, {3-dimethylcarbamoyl-4-t(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 1-phenyl-cyclopentylmethyl ester, 5 {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl- 2 -carbonyl) -amino] -phenyl} -acetic acid 3-hydroxy-2-hydroxymethy1-2-phenyl-propyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetic acid 3-acetoxymethyl-2-phenyl-propyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl]-2-thiophen-2-yl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-15 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl]-2-thiophen-3-yl-malonic acid diethyl ester, 2-(2-{4-dimethylcarbamoyl-5-[(4'-trifluoromethyl-biphenyl -2 -carbonyl) -amino] -pyridin-2-yl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 20 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl -2-carbonyl)-amino]-phenyl}-acetoxymethyl]-2-(3-methyl-thiophen-2-yl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(5-25 methyl-thlophen-2-yl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl -2 -carbonyl ) -amino] -phenyl }- acetoxymethyl) -2-thiazol-2-yl-malonic acid diethyl ester, 2-(2-{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2- 91 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl ester {3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl ester 2-(2-{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-10 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis propylcarbamoyl-ethyl ester, 15 {3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetic acid 3,3-bis ethylcarbamoyl-3-phenyl-propyl ester, {3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl ester, {3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)- amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, 2-(2-{3-Isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2 25 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl ester. 92 {3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis- ethylcarbamoyl -3-phenyl-propyl es ter, {3-propoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl -2 -phenyl- ethyl ester, {3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl -2-phenyl-ethyl ester, 2-(2-{3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-{2-[3-methoxy-4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, {3-dimethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl- 2-phenyl-ethyl ester, {3-piperidin-l-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl -2 -phenyl-ethyl ester, {3-pyrrolidin-l-yl-4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl- 2 -phenyl-ethyl ester, 2-phenyl-2-(2-{3-piperidin-l-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}- 93 acetoxymethyl)- malonic acid diethyl ester, 2-phenyl-2-(2-{3-pyrrolidin-l-yl-4-[ (4 ' -trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- malonic acid diethyl ester, 5 2-(2-{3-dimethylamino-4-[(4'-trifluoromethyl- biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-morpholin-4-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-10 phenyl-malonic acid diethyl ester, 2-(2-{3-diethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-15 carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-(2-{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-phenyl-2-[2-(2-{3-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-malonic acid diethyl ester, {3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-25 propyl ester, {3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoyl-propyl ester, 2-[2-(2-{4-methyl-3-[(4'-trifluoromethyl-biphenyl-2- 94 carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{2-methyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic 5 acid diethyl ester, {3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-isopropylcarbamoyl-3 phenyl-propyl ester, {2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-10 carbonyl)-amino]-phenyl}-acetic acid 3,3-bis ethylcarbamoyl-3-phenyl-propyl ester, {2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 4,4-bis ethylcarbamoyl-4-phenyl-butyl ester, 15 {2-methyl-3-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetic acid 3-phenyl-3,3-bis propylcarbamoyl-propyl ester, {2-methoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis ethylcarbamoyl-3-phenyl-propyl ester, 2-[2-(2-{2-methoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, {2-ethoxy-3-[(4'-trifluoromethyl-biphenyl-2-25 carbonyl)-amino]-phenyl}-acetic acid 3,3-bis ethylcarbamoyl-3-phenyl-propyl ester, 2-[2-(2-{2-ethoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester. 95 2-[2-(2-{2-isopropoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{2-methoxycarbonyl-3-[(4'-trifluoromethyl-5 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{2-ethoxy-5-methyl-3-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -acetoxy) -ethyl]-2-phenyl-malonic acid diethyl ester, 10 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- benzoic acid 2-[(biphenyl-2-carbonyl)-amino]-ethyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-(2-biphenyl-2-yl-acetylamino)-ethyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-15 benzoic acid 3-naphthalen-l-yl-3-(2,2,2 trifluoroethylcarbamoyl)-propyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-[2-(2,2,2-trifluoro ethylcarbamoyl)-naphthalen-l-yl]-propyl ester, 20 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- benzoic acid 3,3-diphenyl-3-(2,2,2-trifluoro-ethylcarbamoyl )-propyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-biphenyl-2-yl-3-(2,2,2-trifluoro-25 ethylcarbamoyl)-propyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-phenyl-3-(2,2,2-trifluoro ethylcarbamoyl)-propyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- 96 benzoic acid 2-[8-(2,2,2-trifluoro-ethylcarbamoyl)- naphthalen-l-yl]-ethyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-(2,6-dichloro-phenyl)-3-(2,2,2-trifluoro-ethylcarbamoyl) -propyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-(2-chloro-phenyl)-3-(2,2,2-trifluoro-ethylcarbamoyl) -propyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-malonic acid diethyl ester, 2-(2-{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{2-chloro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-{2-[4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-benzoyloxy]-ethyl}-malonic acid diethyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3-bi s-ethylcarbamoyl-3-phenyl-propoxycarbony1)-2-chloro-phenyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3-bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-phenyl ester, 4 ' -trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3-bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-2,6-dichloro-p 97 henyl ester, 2-(2-{3-ethoxycarbony1- 4 -[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(3-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl -2-carbonyl)-amino]-phenyl}-propionyloxymethyl)-2-phenyl-malonic acid diethyl ester, 3-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-propionic acid ethylcarbamoyl-phenyl- methyl ester, -(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid benzyl ester, -(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-15 methyl)-2-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid, -(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid ethyl ester, 20 5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl methyl) -2- [(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid methyl ester, 2-(2-{3-benzyloxycarbonyl-4-[(4'-trifluoromethyl-biphenyl -2-carbonyl)-amino]-phenyl}-acetoxymethyl)-25 2-phenyl-malonic acid diethyl ester, 2-(2-{3-carboxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-isopropoxycarbonyl-4-[(4'-trifluoromethyl- 98 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-methoxycarbony1-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- 2-5 phenyl-malonic acid diethyl ester, 2-(2-{3-acetylamino-4-[(4'-trifluoromethyl-biphenyl -2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-methoxycarbonylamino-4-[(4'-trifluoromethyl-10 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- 2-phenyl-malonic acid diethyl ester, 2-(2-{3-(4-methyl-thiazol-2-yl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- 2-phenyl-malonic acid diethyl ester, 15 2-phenyl-(2-{6—[(4*-trifluoromethyl-biphenyl-2- carbonyl)-amino]-biphenyl-3-yl}-acetoxymethyl)- malonic acid diethyl ester, 2-(2-{3-formyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic 20 acid diethyl ester, 2-(2-{3-dimethylaminomethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-(methoxy-methylcarbamoyl)-4-[(4'-25 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-isobutyryl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, and 99 2-(2-{3-(1-hydroxy-2-methyl-propyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester; (25) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (1), which is selected from the group consisting of {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl 10 ester, {3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl-2-phenyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-15 phenyl}-acetic acid 2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl) -ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-cyclohexylcarbamoyl-2- phenyl-ethyl ester, 20 {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- phenyl}-acetic acid 2-phenyl-2,2-bis-phenylcarbamoyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-isopropylcaramoyl-2-phenyl-25 ethyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-[2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester, biphenyl-2-carboxylic acid 4-[2-phenyl-2,2-bis- 100 (2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester, {4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl 5 ester, 2-phenyl-2-(2-{2-trifluoromethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-10 phenyl}-acetic acid 2,2-bis-methylcarbamoyl-2-phenyl-ethyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl)-phenyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- phenyl}-acetic acid 2,2-bis- butylcarbamoyl-2-phenyl-ethyl-ester, {3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl-2-phenyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-25 phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoyl-propyl ester, {4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl ethyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(2,2- 101 bis-ethylcarbamoyl- 2 -phenyl-ethoxycarbonylmethyl)-2-chloro-phenyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-isobutylcarbamoyl-2-phenyl ethyl 5 ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-(3-methyl-butylcarbamoyl)-2-phenyl ethyl ester, {4-t(4'-chloro-biphenyl-2-carbonyl)-amino]-phenyl}-10 acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl ethyl ester, {4-[(3',4'-dichloro-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl)-2-phenyl-ethyl ester, {3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-15 carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl)-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-(2-methoxy-ethylcarbamoyl)-2-phenyl-ethyl ester, 20 {3-isopropyl-4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- e thy1carbamoy1-phenyl-ethyl ester, {3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis- ethylcarbamoyl-3-phenyl-propyl ester, {3-isobutyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl -2-phenyl-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- 102 biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl 2,2-bis-propylcarbamoyl-ethyl ester, {3-methylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis ethylcarbamoyl-3-phenyl-propyl ester, {3-benzylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-10 carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -ace tic acid 4,4-bis ethylcarbamoyl-4-phenyl-butyl ester, 15 {3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl ester, {3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -acetic acid 2,2-bis 20 ethylcarbamoyl-2-phenyl-ethyl ester, {3-(isopropyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl-2-phenyl-ethyl ester, {3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-25 biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl ester, {3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis ethylcarbamoyl-3-phenyl-propyl ester, 103 {3-(piperidin-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl ester, {3-(pyrrolidin-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl ester, {3-(methyl-propylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl ester, {3-(methyl-propylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis ethylcarbamoyl-3-phenyl-propyl ester, {3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl ester, {3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl es ter, {3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis propylcarbamoyl-ethyl ester, {3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis ethylcarbamoyl-3-phenyl-propyl ester, {3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis ethylcarbamoyl-2-phenyl-ethyl ester, {3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis 104 ethylcarbamoyl-3-phenyl-propyl ester, {3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl- 2 -phenyl-ethyl ester, 5 {3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetic acid 3,3-bis- e thylcarbamoy1-3-phenyl-propyl ester, {3-propoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl-2-phenyl-ethyl ester, {3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl -2-phenyl-ethyl ester, {3-dimethylamino-4-[(4'-trifluoromethyl-biphenyl-2-15 carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl -2 -phenyl -ethyl ester, {3-piperidin-l-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl- 2 -phenyl-ethyl ester, 20 {3-pyrrolidin-l-yl-4-[(4'-trifluoromethyl-biphenyl- 2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl- 2 -phenyl -ethyl ester, {3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl 25 ester, {3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoyl-propyl ester, {3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- 105 phenyl}-acetic acid 3,3-bis-isopropylcarbamoyl-3-phenyl propyl ester, {2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl -3-phenyl-propyl ester, {2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- phenyl}-acetic acid 4,4-bis-ethylcarbamoyl-4-phenyl-butyl ester, {2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoyl -propyl ester, {2-methoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- phenyl}-acetic acid 3,3-bis-ethylcarbamoyl -3-phenyl-propyl es ter, {2-ethoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl- 3 -phenyl -propyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3 bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-2-chloro-phenyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3 bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-phenyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3 bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-2,6-dichloro-phenyl ester, -(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl) -2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)- 106 amino]-benzoic acid benzyl ester, -(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl) -2- [ (4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid, -(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl) -2- [(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid ethyl ester, and -(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl) -2-1(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid methyl ester; (26) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (1), which is selected from the group consisting of 2-phenyl-2-{2-[4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-malonic acid diethyl ester, 2-(2-{3-methyl-4-1(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[methyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-(2-{4—[(4*-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diisopropyl ester. 107 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dimethyl ester, 2-cyclopentyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-phenyl-2-(2-{4-I(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dicyclohexyl ester, 2-benzyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-(2-{2-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-cyclohexyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-phenyl-2-(2-{2-trifluoromethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-pyridin-2-yl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-pyridin-3-yl-2-(2-{4-t(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetoxymethyl)- malonic acid diethyl ester, 2-phenyl-2-(2-{3-trifluoromethyl-4-t(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}- 108 acetoxymethyl)- malonic acid diethyl ester, 2-(2-{4-[(4'-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2—(2—{4—[(4'-methoxy-biphenyl-2-carbonyl)-amino]-5 phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-(2-{4-[(3'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-(2-{4-[isopropyl-(4'-trifluoromethyl-biphenyl-2-10 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[cyclohexyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-(2 — {4—£(4*-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dipropyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diisobutyl ester, 2-(2-{4-[ethyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-ethyl-4-£(4 *-trifluoromethyl-biphenyl-2-25 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-isopropyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 109 2-(2-{3-isobutyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-chloro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-bromo-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, {3-(pyrroldine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl- 2 -phenyl-ethyl ester, 2-phenyl-2-(2-{3-(pyrroldine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-phenyl-2-(2-{3-(piperldine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}- 110 acetoxymethyl)-malonic acid diethyl ester, 2-[2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluorome thyl- biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 5 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(4'-bromo-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic 10 acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-cyclopentyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-15 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-cyclohexyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 20 2-(2-{4-[(4'-chloro-biphenyl-2-carbonyl)-amino]-3- dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(4*-acetyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-25 malonic acid diethyl ester, 2-(2-{4-[(4'-cyano-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4-methyl-4'- Ill trifluoromethyl-biphenyl- 2 -carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(5-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-5 acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-[3-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-propyl]-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[{5-methoxy-4'-10 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2—(2—{4—[(5-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 15 2-(2-{3-dimethylcarbamoyl-4-[{6-methyl-4'- trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -acetoxymethyl) -2-20 phenyl-malonic acid di-2,2,2-trifluoroethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(2'-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{5-dimethylcarbamoyl-2-fluoro-4-[(4'-25 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-bromo-5-dimethylcarbamoyl-4-1(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester. 112 2-(2-{3-chloro-5-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(3'-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2—(2—{4—[(3'-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -ace toxyme thyl) -2-(5-nitro-pyridin-2-yl)-malonic acid diethyl ester, 2-(5-amino-pyridin-2-yl)-2-(2-{3-dimethylcarbamoyl t(4 ' - trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl} acetoxymethyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-pyridin-2-yl-malonic acid diethyl ester, 2-(2-{3-chloro-5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl} acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-bromo-5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl} acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-o-tolyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-m- 113 tolyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl -2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-p-tolyl-malonic acid diethyl ester, 5 2-(3-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4- t(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl} acetoxymethyl)-malonic acid diethyl ester, 2-(3-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl} 10 acetoxymethyl)-malonic acid diethyl ester, 2-(4-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl} acetoxymethyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-15 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-succinic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-t(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(2-methoxy-phenyl)-malonic acid diethyl ester, 20 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- b ipheny1-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(3-methoxy-phenyl)-malonic acid diethyl ester, 2-(2 -{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(4-25 methoxy-phenyl)-malonic acid diethyl ester, 2-(2-{4-[(5,4'-bis-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl)-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(6-chloro-4'-trifluoromethyl-biphenyl-2- 114 carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(6-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-5 acetoxymethyl)-2-phenyl)-malonic acid diethyl ester, 2-[2-(2-{3-dimethylcarbamoyl-4-[(5-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(5-ethoxy-4'-10 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(5-isopropoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl)-malonic acid diethyl ester, 15 2-[2—(2—{4—[(5,4'-bis-trifluoromethyl-biphenyl-2- carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(6-methoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-20 acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(3-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-£2-[4-(2,4-bis-trifluoromethyl-benzoylamino)-3-25 dimethylcarbamoyl-phenyl]-acetoxymethyl}-2-phenyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4*-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 115 2-{2-[3-dimethylcarbamoyl-4-[(2-ethyl-4-trifluoro-methyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-ethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropenyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-{2-[3-dimethylcarbamoyl-4-[(4'-trifluoromethyl--biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-thiophen-2-yl- malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-thiophen-3-yl- malonic acid diethyl ester, 2-(2-{4-dimethylcarbamoyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-pyridin-2-yl}-acetoxymethyl)-2-phenyl- malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl -2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-2-(3-methyl-thiophen-2-yl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-2-(5- 116 methyl-thiophen-2-yl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethy1-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-thiazol-2-yl-malonic acid diethyl ester, 5 2-(2-{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic 10 acid diethyl ester, 2-(2-{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2-15 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 20 2-{2-[3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2- carbonyloxy)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-(2-{3-piperidin-l-yl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-25 malonic acid diethyl ester, 2-phenyl-2-(2-{3-pyrrolidin-l-yl-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-(2-{3-dimethylamino-4-[(4'-trifluoromethyl- 117 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-morpholin-4-yl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-5 phenyl-malonic acid diethyl ester, 2-(2-{3-diethylamino-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-10 carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-(2-{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-phenyl-2-[2-(2-{3-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-malonic acid diethyl ester, 2-[2-(2-{4-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic 20 acid diethyl ester, 2-[2-(2-{2-methyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{2-methoxy-3-[(4'-trifluoromethyl-biphenyl-2-25 carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{2-ethoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester. 118 2-[2-(2-{2-isopropoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-[2-(2-{2-methoxycarbonyl-3-[(4'-trifluoromethyl-5 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 2-[2 -(2-{2-ethoxy-5-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester, 10 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-benzoyloxy}-ethyl]-malonic acid diethyl ester, 2-(2-{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-2-phenyl-malonic acid 15 diethyl ester, 2-(2-{2-chloro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-{2-[4-(4'-trifluoromethyl-biphenyl-2-20 carbonyloxy)-benzoyloxy]-ethyl}-malonic acid diethyl ester, 2-(2-{3-ethoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl -2-carbonyl)- amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(3-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-25 biphenyl-2-carbonyl)-amino]-phenyl}-propionyloxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-benzyloxycarbony-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester. 119 2-(2-{3-carboxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-isopropoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-methoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-acetylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2 -{3-methoxycarbonylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2—(2—{3—(4-methyl-thiazol-2-yl)-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-(2-{6-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-biphenyl-3-yl}-acetoxymethyl)-malonic acid diethyl ester, 2-(2-{3-formyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dlmethylamlnomethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-(methoxy-methylcarbamoyl)-4-[(4'-trifluorome thyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- 120 2-phenyl-malonic acid diethyl ester, 2-(2-{3-isobutyryl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, and 5 2-(2-{3-(1-hydroxy-2-methyl-propyl)-4-[(4'- trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester; (27) The ester compound or a prodrug thereof, or a 10 pharmaceutically acceptable salt of either according to the above (1), which is selected from the group consisting of {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, {3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)- amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-(2,2,2-trifluoro-20 ethylcarbamoyl)-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-cyclohexylcarbamoyl-2- phenyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-25 phenyl}-acetic acid 2-phenyl-2,2-bis-phenylcarbamoyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-isopropylcarbamoyl-2- phenyl-ethyl ester. 121 {4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl ester, 2-phenyl-2-(2-{2-trifluoromethyl-4-[(4'-trifluoro-5 methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-methylcarbamoyl-2-phenyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- phenyl}-acetic acid 2,2-bis-butylcarbamoyl-2-phenyl-ethyl ester, {3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethyl- carbamoyl-2-phenyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl-ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-20 phenyl}-acetic acid 3-phenyl-3,3-bis-propyl- carbamoyl-propyl ester, {4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-25 phenyl}-acetic acid 2,2-bis-isobutylcarbamoyl-2-phenyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-(3-methyl-butylcarbamoyl)-2-phenyl-ethyl ester. 122 {4-[(4'-chloro-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, {4-[(3',4'-dichloro-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl 5 ester, {3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester, {4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-10 phenyl}-acetic acid 2,2-bis-(2-methoxy-ethylcarbamoyl)-2-phenyl-ethyl ester, {3-isopropyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, 15 {3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl -3-phenyl-propyl ester, {3-isobutyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethyl-20 carbamoyl-2-phenyl-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester, {3-methylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-25 2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl ester, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl -3-phenyl-propyl es ter, 123 {3-benzylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl es ter, {3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -acetic acid 4,4-bis-ethylcarbamoyl-4-phenyl-butyl ester, {3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl es ter, {3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl -2 -carbonyl) -amino] -phenyl} -acetic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl ester, {3-(isopropyl-methylcarbamoyl-4-[(4'-trifluoromethyl -biphenyl- 2 -carbonyl) -amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, {3-(ethyl-methylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -acetic acid 3,3-bis-ethylcarbamoyl -3-phenyl-propyl ester, {3-(piperidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl ester, {3-(pyrrolidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl- 2 -phenyl-ethyl ester, {3-(methyl-propylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl ester, {3-(methyl-propylcarbamoyl)-4-[(4'-trifluoromethyl- 124 biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl- 3-phenyl-propyl ester, {3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl-2-phenyl-ethyl ester, {3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl ester, {3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-10 carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester, {3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, 15 {3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl ester, {3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-20 ethylcarbamoyl-3-phenyl-propyl ester, {3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl ester, {3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-25 carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, {3-propoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl ester, 125 {3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, {3-dimethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl ester, {3-piperidin-l-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2 -phenyl -ethyl ester, {3-pyrrolidin-l-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester, 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester, -(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl) -2- t(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid benzyl ester, -(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl) -2- [ (4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid, -(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid ethyl ester, and -(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid methyl ester; (28) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the 126 above (1), which is selected from the group consisting of 2-(2-{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 5 2-(2-{4-[methyl-(4'-trifluoromethyl-biphenyl- 2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diisopropyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-15 2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dimethyl ester, 2-cyclopentyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl- 2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dicyclohexyl ester, 2-benzyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-(2-{2-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-cyclohexyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl- 127 2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-phenyl-2-(2-{2-trifluoromethyl-4-[(4'-trifluorome thyl- biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-pyridin-2-yl-2-(2-{4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)- malonic acid diethyl ester, 2-pyridin-3-yl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- malonic acid diethyl ester, 2-phenyl-2-(2-{3-trifluoromethyl-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-(2-{4-[(4'-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(4'-methoxy-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-(2-{4-[(3'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-(2-{4-[isopropyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[cyclohexyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid 128 dipropyl ester, 2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diisobutyl ester, 5 2-(2-{4-[ethyl-(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-ethyl-4-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic 10 acid diethyl ester, 2-(2-{3-isopropyl-4-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-isobutyl-4-(4'-trifluoromethyl-biphenyl-2-15 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-chloro-4-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 20 2-(2-{3-bromo-4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-25 phenyl-malonic acid diethyl ester, 2-(2-{3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl- 129 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2 5 -phenyl-malonic acid diethyl ester, {3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2 -phenyl -ethyl ester, {3-(pyrrolidine-1-carbonyl)-4-[(4'-trifluoromethyl-10 biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl -2-phenyl-ethyl ester, 2-phenyl-2-(2-{3-(pyrrolidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 15 2-phenyl-2-(2-(3-(piperidine-1-carbonyl)-4-[(4'- trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-[2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-20 phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-fluoro-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(4'-bromo-biphenyl-2-carbonyl)-amino]}-3-25 dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -acetoxymethyl) -2-phenyl-malonic acid dimethyl ester, 130 2-cyclopentyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-cyclohexyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-5 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}--acetoxymethyl)-malonic acid diethyl ester, 2-(2-{4-[(4'-chloro-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 10 2-(2-{4-[(4'-acetyl-biphenyl-2-carbonyl)-amino]-3- dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(4*-cyano-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic 15 acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4-methyl-4'-trifluorome thyl -biphenyl -2 -carbonyl) -amino] -phenyl} -ace toxyme thyl) -2 -phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(5-methyl-4'-trifluoro-20 methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2 -phenyl-malonic acid diethyl ester, 2-[3-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxy)-propyl]-2-phenyl-malonic acid diethyl ester, 25 2-(2-{3-dimethylcarbamoyl-4-[(5-methoxy-4'- trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(5-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}- 131 acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(6-methyl-4'-trifluorome thyl -biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 5 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid 2,2,2-trifluoroethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(2'-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-10 acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{5-dimethylcarbamoyl-2-flutfro-4-[ (4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-bromo-5-dimethylcarbamoyl-4-[(2'-fluoro-4'-15 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-chloro-5-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 20 2-(2-{3-dimethylcarbamoyl-4-[(3'-fluoro-4'- trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(3'-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-25 acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)-2-(5-nitro-pyridin-2-yl)-malonic acid diethyl ester, 2-(5-amino-pyridin-2-yl)-2-(2-{3-dimethylcarbamoyl- 132 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-pyridin-2-yl-malonic acid diethyl ester, 2-(2-{3-chloro-5-dimethylcarbamoyl-2-fluoro-4-[(4' trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester, 2-(2-{3-bromo-5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl -2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-o-tolyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-m-tolyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl }- acetoxymethyl)—2 -p-tolyl-malonic acid diethyl ester, 2-(2-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl} acetoxymethyl)—malonic acid diethyl ester, 2-(3-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl} acetoxymethyl)—malonic acid diethyl ester, 2-(4-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl} acetoxymethyl)—malonic acid diethyl ester. 133 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl -2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-succinic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-(2 methoxy-phenyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)— 2-(3 methoxy-phenyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-(4 methoxy-phenyl)-malonic acid diethyl ester, 2-(2-{4-[(5,4'-bis-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester, 2-(2-{4-[(6-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(6-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester, 2-[2-(2-{3-dimethylcarbamoyl-4-[(5-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]—2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(5-ethoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(5-isopropoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}- 134 acetoxymethyl)—2-phenyl-malonic acid diethyl ester, 2-[2-(2-{4-(5,4'-bis-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxy)-ethyl)—2-phenyl-malonic acid diethyl ester, 5 2-(2-{3-dimethylcarbamoyl-4-(6-methoxy-4'-trifluoro methyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)— 2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-(3-methyl-4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino]-phenyl}-acetoxymethyl)— 10 2-phenyl-malonic acid diethyl ester, 2-{2-{4-(2,4-bis-trifluoromethyl-benzoylamino)-3-dimethylcarbamoyl-phenyl]-acetoxymethyl}—2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-methyl-biphenyl-2-15 carbonyl) -amino] -phenyl}-acetoxymethyl)— 2-phenyl-malonic acid diethyl ester, 2-{2-[3-dimethylcarbamoyl-4-(2-ethyl-4-trifluoro-methyl-benzoylamino) -phenyl]-acetoxymethyl}—2-phenyl-malonic acid diethyl ester, 20 2-(2-{3-dimethylcarbamoyl-4-[(4'-ethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropenyl-biphenyl-2-carbonyl)- amino]-phenyl}-acetoxymethyl)—2-25 phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropyl- biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- 135 biphenyl- 2 -carbonyl)-amino J -phenyl}-acetoxymethyl)—2-thiophen-2-yl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl -2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-5 thiophen-3-yl-malonic acid diethyl ester, 2-(2-{4-dimethylcarbamoyl—5—[(4* —trifluoromethyl-biphenyl-2-carbonyl)-amino]-pyridin-2-yl}-acetoxymethyl)— 2-phenyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-10 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-(3-methyl-thiophen-2-yl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)—2-(5-methyl-thiophen-2-yl)-malonic acid diethyl ester, 15 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)—2-thiazol-2-yl-malonic acid diethyl ester, 2-(2-{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic 20 acid diethyl ester, 2-(2-{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester, 2-(2 -{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-25 2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester, 2-(2-{3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester. 136 2-(2-{3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester, 2-phenyl-2-(2-{3-piperidin-l-yl-4-[(4'-trifluoro-5 methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)— malonic acid diethyl ester, 2-phenyl-2-(2-{3-pyrrolidin-l-yl-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)— malonic acid diethyl ester, 10 2-(2-{3-dimethylamino-4-[(4'-trifluoromethyl- biphenyl -2-carbonyl)- amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester, 2-(2-{3-morpholin-4-yl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl} -ace toxyme thyl)—2-15 phenyl-malonic acid diethyl ester, 2-(2-{3-diethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester, 2-(2-{2-chloro-4-[(4'-trifluoromethyl-biphenyl-2-20 carbonyl)-amino]-benzoyloxy}-ethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-ethoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl -2-carbonyl)- amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 25 2-(3-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl- 2 -carbonyl) -amino]-phenyl}-propionyloxymethyl)--2-phenyl-malonic acid diethyl ester, 2-(2-{3-benzyloxycarbonyl-4-[(4'-trifluoromethyl-biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2- 137 phenyl-malonic acid diethyl ester, 2-(2-{3-carboxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 5 2-(2-{3-isopropoxycarbonyl-4-[(4'-trifluoromethyl- biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-methoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-10 phenyl-malonic acid diethyl ester, 2-(2-{3-acetylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-methoxycarbonylamino-4-[(4'-trifluoromethyl-15 biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-(4-methyl-thiazol-2-yl)-4-[(4'-trifluoromethyl -biphenyl- 2 -carbonyl ) -amino] -phenyl }- acetoxymethyl ) --2-phenyl-malonic acid diethyl ester, 20 2-phenyl-2-(2-{6-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-biphenyl-3-yl}-acetoxymethyl)-malonic acid diethyl ester, 2-(2-{3-formyl-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic 25 acid diethyl ester, 2-(2-{3-dimethylaminomethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-(methoxy-methylcarbamoyl)-4-[(4'-trifluoro- 138 methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, 2-(2-{3-isobutyryl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2- phenyl-malonic acid diethyl ester, and 2-(2-{3-(l-hydroxy-2-methyl-propyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester; (29) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (1), which is selected from the group consisting of 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-[2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester, biphenyl-2-carboxylic acid 4-[2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl)-phenyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl)-2-chloro-phenyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3-bis -ethylcarbamoyl- 3 -phenyl -propoxycarbonylmethyl ) - 2 -chloro-phenyl ester, 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3-bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-phenyl ester, 139 and 4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3-bis - ethylcarbamoyl-3-phenyl-propoxycarbonyl)-2,6-dichloro-p henyl ester; (30) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (1), which is selected from the group consisting of 2-phenyl-2-{2-[4-(4'-trifluoromethyl-biphenyl-2-10 carbonyloxy)-phenyl]-acetoxymethyl}-malonic acid diethyl ester, 2-{2-[3-dimethylcarbamoyl-4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester, 15 2-{2-[3-methoxy-4-(4'-trifluoromethyl-biphenyl-2- carbonyloxy)-phenyl]-acetoxymethyl}-2-phenyl malonic acid diethyl ester, and 4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-[2-(2,2,2-trifluoro-ethylcarbamoyl)-20 naphthalen-l-yl]-propyl ester; (31) The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to the above (1), which is selected from the group consisting of 25 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl -2 -carbonyl ) -amino] -phenyl} -ace toxyme thyl) -2-isopropyl-malonic acid diethyl ester, 2-sec-butyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}- 140 acetoxymethyl)-2-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-isobutyl-malonic acid diethyl ester, 5 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-propyl-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl -2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-ethyl-10 malonic acid diethyl ester, 2-butyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- malonic acid diethyl ester, 2-allyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-15 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester, 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-2,2-bis-ethoxycarbonyl-propionic acid ethyl ester, and 20 2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl- 2 -carbonyl) -amino] -phenyl}-acetoxymethyl)-2-(1-methyl-butyl)-malonic acid diethyl ester; (32) A pharmaceutical composition, which comprises the ester 25 compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to any of the above (1) to (31) and a pharmaceutically acceptable carrier; (33) An MTP (microsomal triglyceride transfer protein) 141 inhibitor, which comprises the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to any of the above (1) to (31) as an active ingredient ; (34) An agent for the treatment or prophylaxis of hyperlipidemia, which comprises the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to any of the above (1) to (31) as an active ingredient; (35) An agent for the treatment or prophylaxis of arteriosclerosis, which comprises the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to any of the above (1) to (31) as an active ingredient; (36) An agent for the treatment or prophylaxis of coronary artery diseases, which comprises the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to any of the above (1) to (31) as an active ingredient ; (37) An agent for the treatment or prophylaxis of obesity, which comprises the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to any of the above (1) to (31) as an active ingredient; (38) An agent for the treatment or prophylaxis of diabetes, which comprises the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to any of the above (1) to (31) as an active ingredient; 142 (39) An agent for the treatment or prophylaxis of hypertension, which comprises the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to any of 5 the above (1) to (31) as an active ingredient; (40) An agent for the treatment or prophylaxis of hyperlipidemia, arteriosclerosis, coronary artery diseases, obesity, diabetes or hypertension, which comprises MTP inhibitor selectively 10 inhibiting MTP (microsomal triglyceride transfer protein) in the small intestine and a pharmaceutically acceptable carrier; (41) The agent for the treatment or prophylaxis according to the above (40), wherein the MTP inhibitor does not substantially 15 inhibit MTP in the liver but substantially inhibits only MTP in the small intestine; (42) The agent for the treatment or prophylaxis according to the above (41), wherein after the administered MTP inhibitor 20 inhibits MTP in the small intestine, it is metabolized in the small intestine, blood and liver to the amount at which the remaining MTP inhibitor in the liver does not substantially inhibit the MTP in the liver; (43) The agent for the treatment or prophylaxis according to the above (42), wherein the remaining MTP inhibitor in the liver is metabolized to the state where TG-releasing activity of the liver is kept at the level of about 80% or more of the normal level; 143 (44) The agent for the treatment or prophylaxis according to the above (40) to (43), wherein the MTP inhibitor is a compound having at least one ester bond; (45) The agent for the treatment or prophylaxis according to the above (44), wherein after the compound having at least one ester bond exerts MTP inhibitory activity, the ester moiety of the compound is metabolized in blood to become an inactive substance; (46) The agent for the treatment or prophylaxis according to the above (40) to (45), wherein the MTP inhibitor is the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either mentioned in any of the above (1) to (31); (47) A method for the treatment or prophylaxis of hyperlipidemia, arteriosclerosis, coronary artery diseases, obesity, diabetes or hypertension, which comprises administering a compound selectively inhibiting MTP (microsomal triglyceride transfer protein) in the small intestine; (48) The method according to the above (47), wherein after the compound inhibits MTP in the small intestine, it is metabolized in the small intestine, blood and liver to the amount at which remaining said compound in the liver does not substantially inhibit MTP in the liver; (49) The method according to the above (47), wherein the 144 remaining compound in the liver is metabolized to the state where TG-releasing activity of the liver is kept at the level of about 80% or more of the normal level; (50) The method according to the above (47) to (49), wherein the compound has at least one ester bond; (51) The method according to the above (50) , wherein after the compound having at least ester bond exerts MTP inhibitory activity, the ester moiety of the compound is metabolized in blood to become an inactive substance; (52) The method according to the above (47) to (52), wherein the compound is the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either mentioned in any of the above (1) to (31); (53) The agent for the treatment or prophylaxis according to the above (40) to (46), wherein the agent is an agent for the treatment or prophylaxis of hyperlipidemia which is used in combination with other antihyperlipidemic drug(s); (54) The agent for the treatment or prophylaxis according to the above (53), wherein other antihyperlipidemic drug is a statin-type drug; (55) The agent for the treatment or prophylaxis according to the above (54), wherein the statin-type drug is one or more drug(s) selected from the group consisting of lovastatin. 145 simvastatin, pravastatin, fluvastatin, atorvastatin and cerivastatin; (56) The agent for the treatment or prophylaxis according to 5 the above (40) to (46), wherein the agent is an agent for the treatment or prophylaxis of obesity which is used in combination with other anti-obesity drug(s); (57) The agent for the treatment or prophylaxis according to 10 the above (56), wherein other anti-obesity drug is mazindol or/and orlistat; (58) The agent for the treatment or prophylaxis according to the above (40) to (46), wherein the agent is an agent for the treatment or prophylaxis of diabetes which is used in combination with other anti-diabetic drug(s); (59) The agent for the treatment or prophylaxis according to the above (58), wherein other anti-diabetic drug is one or more drug(s) selected from the group consisting of insulin preparations, sulfonylurea drugs, insulin secretagogues, sulfonamide drugs, biguanide drugs, a-glucosidase inhibitors and insulin resistance-improving drugs; (60) The agent for the treatment or prophylaxis according to the above (59), wherein other anti-diabetic drug is one or more drug(s) selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole. 146 metformin hydrochloride, buformin hydrochloride, boglibose, acarbose and pioglitazone hydrochloride; (61) The agent for the treatment or prophylaxis according to 5 the above (40) to (46), wherein the agent is an agent for the treatment or prophylaxis of hypertension which is used in combination with other anti-hypertension drug(s); (62) The agent for the treatment or prophylaxis according to 10 the above (61), wherein other anti-hypertension drug is one or more drug(s) selected from the group consisting of loop diuretics, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, calcium antagonists, (3-blockers, a,|3-blockers and a-blockers; (63) The agent for the treatment or prophylaxis according to the above (62), wherein other anti-hypertension drug is one or more drug(s) selected from the group consisting of furosemide delayed release, captopril, captopril delayed release, enalapril maleate, alacepril, delapril hydrochloride, silazapril, lisinopril, benazepril hydrochloride, imidapril hydrochloride, temocapril hydrochloride, quinapril hydrochloride, trandolapril, perindopril erbumine, losartan potassium, candesartan cilexetil, nicardipine hydrochloride, 25 nicardipine hydrochloride delayed release, nilvadipine, nifedipine, nifedipine delayed release, benidipine hydrochloride, diltiazem hydrochloride, diltiazem hydrochloride delayed release, nisoldipine, nitrendipine, manidipine hydrochloride, barnidipine hydrochloride, 147 efonidipine hydrochloride, amlodipine besylate, felodipine, cilnidipine, aranidipine, propranolol hydrochloride, propranolol hydrochloride delayed release, pindolol, pindolol delayed release, indenolol hydrochloride, carteolol 5 hydrochloride, carteolol hydrochloride delayed release, bunitrolol hydrochloride, bunitrolol hydrochloride delayed release, atenolol, asebutolol hydrochloride, metoprolol tartrate, metoprolol tartrate delayed release, nipradilol, penbutolol sulfate, tilisolol hydrochloride, carvedilol, 10 bisoprolol fumarate, betaxolol hydrochloride, celiprolol hydrochloride, bopindolol malonate, bevantolol hydrochloride, labetalol hydrochloride, arotinolol hydrochloride, amosulalol hydrochloride, prazosin hydrochloride, terazosin hydrochloride, doxazosin mesylate, bunazocin hydrochloride, 15 bunazocin hydrochloride delayed release, urapidil and phentolamine mesylate; (64) Use of the agent for the treatment or prophylaxis according to the above (34) to (46) and other antihyperlipidemic drug(s) for the treatment or prophylaxis of hyperlipidemia; (65) The use according to the above (64), wherein other antihyperlipidemic drug is a statin-type drug; (66) The use according to the above (64), wherein the statin-type drug is one or more drug(s) selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin and cerivastatin; 148 (67) Use of the agent for the treatment or prophylaxis according to the above (34) to (46) and other anti-obesity drug(s) for the treatment or prophylaxis of obesity; (68) The use according to the above (67), wherein other anti-obesity drug is mazindol or/and orlistat; (69) Use of the agent for the treatment or prophylaxis according to the above (34) to (46) and other anti-diabetic drug(s) for the treatment or prophylaxis of diabetes; (70) The use according to the above (69), wherein other anti-diabetic drugs are one or more drug(s) selected from the group consisting of insulin preparations, sulfonylurea drugs, insulin secretagogues, sulfonamide drugs, biguanide drugs, a-glucosidase inhibitors and insulin resistance improving drugs; (71) The use according to the above (70), wherein other 20 anti-diabetic drug is one or more drug(s) selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformin hydrochloride, boglibose, acarbose and pioglitazone 25 hydrochloride; (72) Use of the agent for the treatment or prophylaxis according to the above (34) to (46) and other anti-hypertension drug(s) for the treatment or prophylaxis of hypertension; 149 (73) The use according to the above (72), wherein other anti-hypertension drug is one or more drug(s) selected from the group consisting of loop diuretics, angiotension converting 5 enzyme inhibitors, angiotension II receptor antagonists, calcium antagonists, beta-blockers, alpha/beta blockers and alpha blockers; (74) The use according to the above (73), wherein other 10 anti-hypertension drug is one or more drug(s) selected from the group consisting of furosemide delayed release, captopril, captopril delayed release, enalapril maleate, alacepril, delapril hydrochloride, silazapril, lisinopril, benazepril hydrochloride, imidapril hydrochloride, temocapril 15 hydrochloride, quinapril hydrochloride, trandolapril, perindopril erbumine, losartan potassium, candesartan cilexetil, nicardipine hydrochloride, nicardipine hydrochloride delayed release, nilvadipine, nifedipine, nifedipine delayed release, benidipine hydrochloride, 20 diltiazem hydrochloride, diltiazem hydrochloride delayed release, nisoldipine, nitrendipine, manidipine hydrochloride, barnidipine hydrochloride, efonidipine hydrochloride, amlodipine besylate, felodipine, cilnidipine, aranidipine, propranolol hydrochloride, propranolol hydrochloride delayed 25 release, pindolol, pindolol delayed release, indenolol hydrochloride, carteolol hydrochloride, carteolol hydrochloride delayed release, bunitrolol hydrochloride, bunitrolol hydrochloride delayed release, atenolol, asebutolol hydrochloride, metoprolol tartrate, metoprolol 150 tartrate delayed release, nlpradllol, penbutolol sulfate, tilisolol hydrochloride, carvedilol, bisoprolol fumarate, betaxolol hydrochloride, celiprolol hydrochloride, bopindolol malonate, bevantolol hydrochloride, labetalol hydrochloride, 5 arotinolol hydrochloride, amosulalol hydrochloride, prazosin hydrochloride, terazosin hydrochloride, doxazosin mesylate, bunazocin hydrochloride, bunazocin hydrochloride delayed release, urapidil and phentolamine mesylate; (75) A pharmaceutical composition comprising an effective amount of the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to any of the above (1) to (31), a pharmaceutically acceptable, appropriate amount of ethanol and propylene glycol fatty acid 15 ester; (76) The pharmaceutical composition according to the above (75), which comprises 25 to 35% by weight of ethanol and 65 to 75% by weight of propylene glycol fatty acid ester; (77) A capsule formulation comprising the pharmaceutical composition according to the above (75) or (76); (78) The capsule formulation according to the above (77), 25 wherein the capsule formulation is a hard capsule or soft capsule; (79) A biphenyl compound represented by the formula (100) 151 o jfSj/®1 0 XA N H (100) R3" R1' wherein R1 is hydrogen, Ci-C6 alkyl, halogen, halo Ci-C6 alkyl or Ci-C6 alkoxy; R2 is hydrogen, Ci-C6 alkyl, halogen, halo Ci-C6 alkyl or C2-C6 alkenyl; R3" is - CON (Rlla) (R12a) wherein Rlla and R12a are each independently hydrogen, Ci-C6 alkyl, optionally substituted C6-Ci4aryl, optionally substituted C7-Ci6 aralkyl, Ci-C6alkoxy, or Rlla and R12a may be taken together with the nitrogen to which they are attached to form (in which p is an integer of 0 to 2); R4 is hydrogen, halogen, C1-C6 alkyl or halo Ci-C6 alkyl; R50 is hydrogen, Ci-C6 alkyl, optionally substituted C6-Ci4 aryl or optionally substituted C7-Ci6 aralkyl; and la is an integer of 1 to 3, or a prodrug thereof, or a pharmaceutically acceptable salt of either; and (80) The biphenyl compound according to the above (79), 152 wherein R1 is hydrogen, R2 is halo Ci-C6 alkyl, R3" is -CON(Rllb) (R12b) wherein Rllb and R12b are each independently hydrogen or Ci-C6 alkyl, or Rllb and R12b may be taken together with the nitrogen to which they are attached to form (in which p is an integer of 0 to 2), R4 is hydrogen, and R50 is hydrogen or Ci-C6 alkyl, or a prodrug thereof, or a pharmaceutically acceptable salt of either.

The definitions of each substituent used in the present invention are as follows.

"Cx-Ce alkyl" refers to a straight- or branched-chain alkyl group having 1 to 6 carbon atom(s), and its example includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl or hexyl, etc., preferably a straight- or branched-chain alkyl group having 1 to 4 carbon atom(s), more preferably methyl, ethyl or isopropyl. Preferable examples for R1, R2, R2 and R2 include methyl, ethyl or isopropyl; preferable examples for R3 and R4 include methyl, ethyl, propyl, isopropyl, butyl or isobutyl; a preferable example for R5, R6 and R7 includes methyl; preferable examples for R8 and R9 include methyl or ethyl; preferable examples for R10 include methyl.

—N / I V 153 ethyl or isopropyl; preferable examples for R11 and R12 include methyl, ethyl, propyl or isopropyl; preferable examples for R13 and R14 include methyl or ethyl; a preferable example for R15 includes isopropyl; preferable examples for R16 and R17 include 5 methyl or ethyl; preferable examples for R18 and R19 include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl or isopentyl, more preferably ethyl; preferable examples for R20 include methyl, ethyl, propyl, isopropyl or isobutyl, more preferably ethyl; a preferable 10 example for R21 and R22 includes methyl; and preferable examples for D include ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, sec-pentyl, etc.

Examples of the substituent for "optionally substituted Ci-C6 alkyl" include halogen, carboxyl, hydroxy, amino, nitro, 15 cyano, Ci-Ce alkoxy, C7-Ci6 aralkyloxy, C2-C7 alkoxycarbonyl, C6-Ci4 aryl, Ci-C6 alkylthio, Ci-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, Ci-C6 alkylamino, acylamino and the like, among which hydroxy is preferable. The number of the substituents is 1 to 5, preferably 1 to 3.

"C3-C7 cycloalkyl" refers to a cycloalkyl having 3 to 7 carbon atoms, specifically cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-methylcyclohexyl or cycloheptyl. Preferable examples thereof include a cycloalkyl having 3 to 6 carbon atoms, specifically cyclopropyl, cyclobutyl, 25 cyclopentyl or cyclohexyl. More preferable examples thereof include cyclopropyl or cyclohexyl. A preferable example for R1 and R2 includes cyclohexyl; a preferable example for R10 includes cyclohexyl; a preferable example for R18 and R19 includes cyclohexyl; a preferable example for R20 includes 154 cyclohexyl; and preferable examples for ring C include cyclopentyl or cyclohexyl. It is also preferable that R8 and R9 are taken together to form cyclopentyl or cyclohexyl.

"Ci-C6 alkoxy" refers to a straight- or branched-chain 5 alkoxy group having 1 to 6 carbon atom(s), and its example includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy, tert-pentyloxy or hexyloxy, etc., preferably an alkoxy having 1 to 4 carbon atom(s), such as methoxy, ethoxy, isopropoxy, butoxy or tert-butoxy, and more 10 preferably methoxy or ethoxy. Preferable examples for R1, R2, R2 and R2 include methoxy, isopropoxy or butoxy; preferable examples for R3 and R4 include methoxy, ethoxy, propoxy or isopropoxy; preferable examples for R5, R6 and R7 include methoxy or ethoxy; a preferable example for R11 and R12 includes methoxy; 15 and preferable examples for R15 include methoxy, ethoxy, propoxy or isopropoxy.

"Halogen" refers to chlorine, bromine, fluorine or the like. Preferable examples for R1 include fluorine or chlorine; preferable examples for R2 and R2 include fluorine, chlorine 20 or bromine; preferable examples for R3 and R4 include chlorine or bromine; and preferable examples for R5, R6 and R7 include fluorine or chlorine.

"Halo Cx-C6 alkyl" refers to said Ci-C6 alkyl substituted with said halogen, and its example includes chloromethyl, 25 bromomethyl, fluoromethyl, trifluoromethyl, trichloromethyl, tribromomethyl, trichloroethyl, pentafluoropropyl or chlorobutyl, etc., preferably chloromethyl, bromomethyl, fluoromethyl, trifluoromethyl, trifluoroethyl or trichloromethyl, and more preferably trifluoromethyl. A 155 preferable example for R1, R2, R2 and R2" includes trifluoromethyl; a preferable example for R3 and R4 includes trif luorome thyl; a preferable example for R5, R6 and R7 includes trif luorome thyl; preferable examples for R16 and R17 include 5 trif luoromethyl or trif luoroe thyl; and preferable examples for R18 and R19 include trif luoromethyl or trif luoroe thyl.

"Halo Ci-C6 alkyloxy" refers to, for example, chloromethyloxy, bromomethyloxy, fluoromethyloxy, trifluoromethyloxy, trichloromethyloxy, tribromomethyloxy, 10 trichloroethyloxy, pentafluoropropyloxy or chlorobutyloxy, etc., preferably chloromethyloxy, bromomethyloxy, fluoromethyloxy, trifluoromethyloxy or trichloromethyloxy, and more preferably trifluoromethyloxy. A preferable example for R1, R2, R2 and R2 includes trifluoromethyloxy. 15 "C2-C12 alkoxyalkyl" refers to an alkoxyalkyl of which alkoxy moiety has the same meaning as said alkoxy and alkyl moiety has the same meaning as said alkyl, and its example includes methoxymethyl, ethoxymethyl, propoxymethyl, butoxymethyl, pentyloxymethyl, hexyloxymethyl, ethoxyethyl or 20 methoxyethyl, etc. A preferable example for R18 and R19 includes methoxyethyl.

"C2-C7 alkylcarbonyl" refers to acetyl, propionyl, butyryl or pivaloyl, etc., and a preferable example for R21 and R22 includes acetyl.

"C1-C7 alkylsulfonyl" refers to methanesulfonyl, ethanesulfonyl, propylsulfonyl, butylsulfonyl, pentylsulfonyl or hexylsulfonyl, etc., and a preferable example for R21 and R22 includes methylsulfonyl.

"C2-C7 alkoxycarbonyl" refers to an alkoxycarbonyl of 156 which alkyl moiety has 1 to 6 carbon atom(s) such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl, tert-pentyloxycarbonyl or hexyloxycarbonyl, etc. Preferable examples thereof include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl or butoxycarbonyl. A preferable example for R2 includes butoxycarbonyl; a preferable example for R5, R6 and R7 includes methoxycarbonyl; a preferable example for R13 and 10 R14 includes methoxycarbonyl; and a preferable example for D includes ethoxycarbonyl.

"Ci-C6 acyl" refers to formyl having one carbon atom, or an alkanoyl having 2 to 6 carbon atoms such as acetyl, propionyl, butyryl or pivaloyl, etc., and its preferable examples include 15 formyl, acetyl or pivaloyl. A preferable example for R2 and R2" includes acetyl; a preferable example for R3 includes formyl; a preferable example for R5, R6 and R7 includes acetyl; a preferable example for R13 and R14 includes acetyl; and a preferable example for R21 and R22 includes acetyl. 20 "Alkanediyl" has preferably 1 to 6 carbon atom(s), and its example includes methylene, ethane-1,2-diyl, ethane-1,1-diyl, propane-1,3-diyl, butane-1,4-diyl, pentane-1,5-diyl, hexane-1,6-diyl, 1,1-dimethylethane-1,2-diyl, 1,1-diethylethane-l,2-diyl, 25 2,2-dimethylethane-1,2-diyl, 2,2-diethylethane-1,2-diyl, 1.1-dimethylpropane-1,3-diyl, 1,1-diethylpropane-1,3-diyl, 2.2-dimethylpropane-1,3-diyl, 2,2-diethylpropane-1,3-diyl, 3.3-dimethylpropane-l,3-diyl or 3,3-diethylpropane-1,3-diyl, etc. Preferable examples for Alk1 and Alk2 include methylene. 157 ethane-1,2-diyl, ethane-1,1-diyl, propane-1,3-diyl, etc.

"Alkenediyl" has preferably 2 to 6 carbon atom(s), and its example includes ethylene-1,2-diyl, 1-propene-l,3-diyl, 2-propene-l,3-diyl, 1-butene-l,4-diyl, 2—butene-1,4-diyl, 5 3-butene-l,4-diyl or 1,3-butadiene-l,4-diyl, etc. Preferable examples for Alk1 and Alk2 include ethylene-1,2-diyl, 1-propene-l,3-diyl, 2-propene-l,3-diyl, etc.

"C6-Ci4aryl" refers to phenyl, naphthyl or biphenyl, etc. , preferably phenyl.

In the "optionally substituted C6-Ci4 aryl", the substituent(s) is/are not particularly limited, and may be the same or different each other and is/are arbitrarily positioned. The number of substituents is not particularly limited so long as they are chemically acceptable, while the number is 15 preferably around 1 to 3. Specifically, examples of the substituent include Ci-C6 alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, etc.), hydroxy, C1-C6alkoxy (e.g. methoxy, ethoxy, propoxy, butoxy, etc. ), halogen (e.g. fluorine, chlorine, bromine, etc.), nitro, cyano, Ci-C6acyl (e.g. formyl, 20 acetyl, propionyl, etc.), Ci-C6 acyloxy (e.g. formyloxy, acetoxy, propionyloxy, etc.), mercapto, Ci-C6 alkylthio (e.g. methylthio, ethylthio, propylthio, butylthio, isobutylthio, etc.), amino, Cx-C6 alkylamino (e.g. methylamino, ethylamino, propylamino, butylamino, etc.), di(Ci-C6 alkyl)amino (e.g. 25 dimethylamino, diethylamino, dipropylamino, dibutylamino, etc.), carboxyl, C2-C7 alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, etc.), amido, trifluoromethyl, Ci-C6 alkylsulfonyl(e.g. methylsulfonyl, ethylsulfonyl, etc.), aminosulfonyl, C3-C7 cycloalkyl (e.g. 158 cyclopentyl, cyclohexyl, etc.), phenyl, acylamido (e.g. acetamldo, propionylamido, etc.) and the like, among which hydroxy, Ci-C6 alkyl, Ci-C6 alkoxy, mercapto, Ci-C6 alkylthio, halogen, trifluoromethyl, Ci-C6 acyl, C2-C7 alkoxycarbonyl and 5 acylamido are preferable.

A preferable example for R1 and R2 includes phenyl which may be substituted with halo C1-C6 alkyl (e.g. trif luorome thyl, etc.), C1-C6alkyl (e.g. methyl, ethyl, etc.), halogen (e.g. fluorine, chlorine, bromine, etc.), Cx-C6alkoxy (e.g. methoxy, 10 etc.), Ci-C6 acyl (e.g. acetyl, etc.), C2-C6 alkenyl (e.g.isopropenyl, etc.) or cyano; a preferable example for R5, R6 and R7 includes phenyl which may be substituted with halo Ci-C6 alkyl (e.g. trifluoromethyl, etc.), Ci-C6 alkyl (e.g. methyl, etc. ), halogen (e.g. chlorine, etc.) or Ci-C6 alkoxy (e.g. 15 methoxy, etc.); a preferable example for R8 and R9 includes phenyl; a preferable example for R11 and R12 includes phenyl; a preferable example for R18 and R19 includes phenyl; a preferable example for R43 includes biphenyl; a preferable example for ring A includes phenyl; and preferable examples for ring C include 20 phenyl or naphthyl.

"C7-C16 aralkyl" refers to an arylalkyl, of which aryl moiety is phenyl (which may be substituted with 1 to 3 substituent(s) mentioned in the above description of aryl) and alkyl moiety is alkyl having 1 to 6 carbon atom(s). Examples 25 thereof include benzyl, phenethyl, phenylpropyl, phenylbutyl or phenylhexyl, etc., among which benzyl or phenylethyl is preferable. A preferable example for R1 and R2 includes benzyl; a preferable example for R11 and R12 includes benzyl; and a preferable example for ring C includes benzyl. 159 "C6-Ci4 aryloxy" refers to phenoxy, naphthyloxy, etc. (where the phenyl group or naphthyl group may be substituted with 1 to 3 substituent(s) mentioned in the above description of aryl), preferably phenoxy. A preferable example for R1 and R2 includes phenoxy, and a preferable example for R15 includes phenoxy.

"C7-Ci6 aralkyloxy" refers to an arylalkoxy of which alkoxy moiety has 1 to 4 carbon atom(s) (where the aryl group may be substituted with 1 to 3 substituent(s) mentioned in the above description of aryl), and example thereof includes benzyloxy, phenethyloxy, phenylpropyloxy, phenylbutyloxy, etc., preferably benzyloxy. A preferable example for R1 and R2 includes benzyloxy; a preferable example for R3 includes benzyloxy; and a preferable example for R15 includes benzyloxy.

"C7-C15 arylcarbonyl" refers to benzoyl, naphthoyl, etc. (where the phenyl group or naphthyl group may be substituted with 1 to 3 substituent(s) mentioned in the above description of aryl), preferably benzoyl. A preferable example for R1 and R2 includes benzoyl.

"C7-C15 arylcarbonylamino" refers to phenylcarbonylamino, naphthylcarbonylamino, etc. (where the phenyl group or naphthyl group may be substituted with 1 to 3 substituent(s) mentioned in the above description of aryl), preferably benzoyl. A preferable example for ring C includes phenylcarbonylamino.

"C8-Ci6 aralkylcarbonylamino" refers to benzylcarbonylamino, naphthylcarbonylamino, etc. (where the phenyl group or naphthyl group may be substituted with 1 to 3 substituent(s) mentioned in the above description of aryl), preferably benzylcarbonylamino. A preferable example for ring 160 C includes benzylcarbonylamino. "heterocycle" refers to a 5- to 6-membered heteroaromatic ring, a 5- to 6-membered saturated heterocycle or a 5- to 6-membered unsaturated heterocycle, any of which contains 1 to 5 3 heteroatom(s) selected from nitrogen, oxygen and sulfur as an atom constituting the ring other than carbon atom, or a fused heterocyclic ring in which said heterocycle and benzene ring are fused. Specifically, its example includes thiophen-2-yl, thiophen-3-yl, furan-2-yl, furan-3-yl, pyrrol-l-yl, 10 pyrrol-2-yl, pyrrol-3-yl, imidazol-l-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, pyrazol-l-yl, pyrazol-3-yl, pyrazol-4-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, pyrimidin-2-yl, pyrimidin-4-yl, 15 pyrimidin-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, benzothiophen-2-yl, benzothiophen-3-yl, benzofuran-2-yl, benzofuran-3-yl, indol-2-yl, indol-3-yl, benzimidazol-l-yl, benzimidazol-2-yl, benzothiazol-2-yl, benzoxazol-2-yl, quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, isoquinolin-l-yl, isoquinolin-3-yl, isoquinolin-4-yl, 1,3,4-thiadiazol-2-yl, morpholin-4-yl, etc.

A preferable example for R1 and R2 includes thiophen-3-yl; preferable examples for ring A include imidazol-5-yl, 25 thiazol-5-yl, pyridin-3-yl or pyrrolidin-2-yl; a preferable example for R3 includes thiazol-2-yl; and preferable examples for ring C Include pyridin-2-yl, pyridin-3-yl, thiophen-2-yl, thiophen-3-yl or thiazol-2-yl.

With regard to a substituent in "optionally substituted 161 heterocycle", the same substituents as those mentioned in the above description of aryl may be exemplified. The number of substituents is not particularly limited so long as they are chemically acceptable, while the number is preferably around 5 1 to 3.

"C2-C6 alkenyl" refers to a straight- or branched-chain alkenyl group having 2 to 6 carbon atoms, and its example includes vinyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, sec-butenyl, tert-butenyl, n-pentenyl, 10 isopentenyl, neopentenyl, 1-methylpropenyl, n-hexenyl, isohexenyl, 1,1-dimethylbutenyl, 2,2-dimethylbutenyl, 3,3-dimethylbutenyl, 3,3-dimethylpropenyl, 2-ethylbutenyl, etc. A preferable example for R2 and R2 includes n-propenyl, and a preferable example for D includes n-propenyl. 15 "Prodrug" of the compound refers to a derivative of the compound of the present invention, which has a group capable of being chemically or metabolically converted and shows pharmaceutical activity after it is hydrolyzed or solvolyzed or converted under physiological conditions. 20 For example, there may be listed a derivative in which a substituent such as -CO-Ci-C6 alkyl, -C02-Ci-C6 alkyl, -CONH-Ci-C6 alkyl, -CO-C2-C6 alkenyl, -C02-C2-C6 alkenyl, -CONH-C2-C6 alkenyl, -CO-C6-Ci4 aryl, -C02-C6-Ci4 aryl, -CONH-C6-Ci4 aryl, -CO-heterocycle, -C02-heterocycle, 25 -CONH-heterocycle, etc. (wherein any of said Ci-C6 alkyl, C2-Cs alkenyl, C6-Ci4 aryl and heterocycle may be substituted with halogen, Ci-C6 alkyl, hydroxy, Ci-C6 alkoxy, carboxyl, amino, amino acid residue, -P03H2, -S03H, -CO-polyethyleneglycol residue, -C02-polyethyleneglycol residue. 162 -CO-polyethyleneglycol monoalkyl ether residue or -C02-polyethyleneglycol monoalkyl ether residue) is attached to the hydroxy group of the compound.

Also, there may be exemplified a derivative in which a 5 substituent such as -CO-Cx-C6 alkyl, -C02-Ci-C6 alkyl, -CO-C2-C6 alkenyl, -C02-C2-C6 alkenyl, -C02-C6-Ci4 aryl, -CO-C6-Ci4 aryl, -CO-heterocycle, -C02-heterocycle, etc. (wherein any of said Ci-C6 alkyl, C2-C6 alkenyl, C6-Ci4 aryl and heterocycle may be substituted with halogen, Ci-C6 alkyl, hydroxy, C1-C6 alkoxy, 10 carboxyl, amino, amino acid residue, -P03H2, -S03H, -CO-polyethyleneglycol residue, -C02-polyethyleneglycol residue, -CO-polyethyleneglycol monoalkyl ether residue, -C02-polyethyleneglycol monoalkyl ether residue or -P03H2, etc.) is attached to the amino group of the compound. 15 Furthermore, there may be exemplified a derivative in which a substituent such as C1-C6 alkoxy, C6-Ci4 aryloxy, etc. (wherein said Ci-C6 alkoxy or C6-Ci4 aryloxy may be substituted with halogen, Ci-C6 alkyl, hydroxy, Ci-C6 alkoxy, carboxyl, amino, amino acid residue, -P03H2, -S03H, polyethyleneglycol residue 20 or polyethyleneglycol monoalkyl ether residue, etc.) is attached to the carboxyl group of the compound.

"Pharmaceutically acceptable salt" includes various inorganic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate or nitrate, etc.; various 25 organic acid addition salts such as acetate, propionate, succinate, glycolate, lactate, malate, oxalate, tartrate, citrate, maleate, fumarate, methanesulfonate, benzensulfonate, p-toluenesulfonate or ascorbate, etc.; or various salts with an amino acid such as aspartate or glutamate, etc., although 163 it is not limited thereto. It may be hydrated compound, hydrate or solvate depending on the circumstances.

"MTP in the small intestine" refers to the MTP existing in small intestinal epithelial cells.

"MTP in the liver" refers to the MTP existing in hepatic cells.

The expression "selectively inhibit MTP in the small intestine" means the level of inhibition is at least about 5 times higher, preferably about 10 times higher, than MTP 10 inhibition in other parts of body such as liver and heart, especially liver. To be more specific, on the basis of S9 metabolic stability test, it means that in the test using human or hamster S9 the remaining rate of unaltered form 10 minutes after the treatment with small intestine S9 is about 10 times 15 or more higher than that in the case of the treatment with liver S9 (see Test Example 7).

The expression "it is metabolized to the amount at which the remaining MTP inhibitor in the liver does not substantially inhibit the MTP in the liver" means that almost all of the orally 20 administered MTP inhibitors are metabolized to an inactive metabolite before arriving at the liver or at the moment of arriving at the liver and show substantially no MTP inhibitory activity in the liver, i.e. the MTP inhibitors are converted to those that do not substantially inhibit TG release from the 25 liver. More specifically, it means the condition where TG-releasing activity of the liver is kept at the level of about 80% or more, preferably about 90% or more, more preferably 100% of the normal level. In terms of metabolism, it means that the ratio of inactive metabolite to unaltered form in portal vein 164 blood is approximately 8 or more to 1 one hour after the oral administration to hamsters, i.e. about 80% or more of the agent (compound) is metabolized before arriving at the liver (see Test Example 6), or on the basis of liver S9 metabolic stability test, 5 it means that 10 minutes after the test using human or hamster S9 the remaining rate of unaltered form is about 20% or less, preferably about 10% or less, more preferably about 8% or less (see Test Example 7).

The expression "MTP inhibitor does not substantially 10 inhibit MTP in the liver" has essentially the same meaning with the above " it is metabolized to the amount at which the remaining MTP inhibitor in the liver does not substantially inhibit the MTP in the liver", and means the condition where TG-releasing activity of the liver is kept at the level of about 80% or more, 15 preferably about 90% or more, more preferably 100% of the normal level.

As "pharmaceutically acceptable carrier", various organic or inorganic carrier materials which are conventionally used as formulation material are used, and it is formulated as 20 excipient, lubricant, binder, disintegrating agent, solvent, solubilizer, suspending agent, isotonizing agent, buffer, soothing agent, etc. If desired, pharmaceutical additives such as preservative, antioxidant, coloring agent, sweetening agent, etc. may be also used. Preferable examples of said 25 excipient include lactose, sucrose, D-mannitol, starch, crystalline cellulose, light anhydrous silicic acid, etc. Preferable examples of said lubricant include magnesium stearate, calcium stearate, talc, colloidal silica, etc. Preferable examples of said binder include crystalline 165 cellulose, sucrose, D-mannitol, dextrin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, etc. Preferable examples of said disintegrating agent include starch, carboxymethylcellulose, 5 carboxymethylcellulose calcium, crosscarmellose sodium, sodium carboxymethylstarch, etc. Preferable examples of said solvent include water for injection, alcohol, propylene glycol, macrogol, sesame-seed oil, corn oil, propylene glycol fatty acid ester, etc. Preferable examples of said solubilizer 10 include polyethyleneglycol, propyleneglycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, etc. Preferable examples of said suspending agent include surfactants (e.g. stearyl triethanolamine, sodium lauryl 15 sulfate, lauryl aminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, glycerin monostearate, etc) , polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose sodium, methylcellulose, hydroxymethyl cellulose, etc. Preferable examples of said 20 isotonizing agent include sodium chloride, glycerin, D-mannitol, etc. Preferable examples of said buffer include phosphate, acetate, carbonate, citrate, etc. Preferable examples of said soothing agent include benzyl alcohol, etc. Preferable examples of said preservative include 25 paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid, etc. Preferable examples of said antioxidant include sulfites, ascorbic acid, etc. Preferable examples of said sweetening agent include aspartame, saccharin sodium, stevia, etc. 166 Preferable examples of said coloring agent include food colors such as food yellow No. 5, food red No. 2 and food blue No. 2, lake colors for food, iron oxide, etc.

Best mode for carrying out the invention Detailed description is given below with respect to various substituents.

R1 is preferably hydrogen; Ci-C6 alkyl such as methyl, ethyl, etc.; Ci-C6 alkoxy such as methoxy, isopropoxy, etc.; 10 halogen such as fluorine, chlorine, etc. ; halo Ci-C6 alkyl such as trif luorome thyl, etc.; or C2-C6 alkenyl such as isopropenyl, etc.

R2 is preferably phenyl (which may be substituted with halo Ci-C6 alkyl such as trif luorome thyme thyl, etc.; Ci-C6 alkyl 15 such as methyl, ethyl, etc.; halogen such as fluoro, chlorine, bromine, etc.; Ci-C6 alkoxy such as methoxy, etc.; Ci-C6 acyl such as acetyl, etc.; C2-C6 alkenyl such as isopropenyl, etc.; or cyano); Cj.-C6 alkyl such as ethyl, isopropyl, etc.; C3-C7 cycloalkyl such as cyclohexyl, etc.; Ci-C6 alkoxy such as butoxy, 20 etc.; halo Ci-C6 alkyl such as trif luoromethyl, etc.; halo Cj.-C6 alkyloxy such as trif luorome thoxy, etc.; C7-Ci6 aralkyl such as benzyl, etc.; C6-Ci4 aryloxy such as phenoxy (of which aryl moiety may be substituted with halo Ci-C6 alkyl such as trifluoromethyl, etc.), etc.; C7-Ci5 arylcarbonyl such as 25 benzoyl (of which aryl moiety may be substituted with halogen such as chlorine, etc.), etc.; heterocycle such as thiophen-3-yl, etc.; C2-C7 alkoxycarbonyl such as butoxycarbonyl, etc.; -N(R40) (R41) (wherein R40 and R41 are each independently hydrogen or optionally substituted phenyl). 167 R2 is preferably hydrogen or halogen such as chlorine, etc.

R2" is preferably hydrogen, halo Ci-C6 alkyl such as trif luorome thyl, etc. ; Cx-C6 alkyl such as methyl, ethyl, etc. ; halogen such as fluorine, chlorine, bromine, etc.; Ci-C6 alkoxy such as methoxy, etc.; Ci-C6 acyl such as methylcarbonyl, etc.; C2-C6 alkenyl such as isopropenyl, etc.; or cyano.

Ring A is preferably among which phenyl is especially preferred.

X is preferably -COO-, -N(R10)CO- or -CON(R10)- (wherein R10 is hydrogen; Ci-C6 alkyl such as methyl, isopropyl, etc.; or C3-C7 cycloalkyl such as cyclohexyl, etc.), among which -COO-or -CONH- is especially preferred.

Ring B is preferably 168 N=/ N— / or more preferably 'N— or § or most preferably — or R3 Is preferably hydrogen; hydroxy; halogen such as chlorine, bromine, etc.; Ci-C6 alkyl such as methyl, ethyl, isopropyl, isobutyl, etc.; substituted Ci-C6 alkyl such as isobutyl substituted with hydroxy, etc.; Cj.-C6 alkoxy such as methoxy, ethoxy, propoxy, isopropoxy, etc.; halo Ci-C6 alkyl such as trif luorome thyl, etc.; C7-Ci6 aralkyloxy such as benzyloxy, etc.; Ci-C^ acyl such as formyl, etc.; optionally substituted heterocycle such as 4-methyl-thiazol-2-yl, etc.; -CON(R ) (R ) (wherein R and R are each independently hydrogen; Ci-C6 alkyl such as methyl, ethyl, propyl, isopropyl, etc.; C6-Ci4 aryl such as phenyl, etc.; C7-Ci6 aralkyl such as benzyl, etc.; C1-C6 alkoxy such as methoxy, etc.; or R11 and R12 may be taken together with the nitrogen to form 169 —/ ())p (wherein p is an integer of 0 or 1)); -N(RiJ)(R14) or -CH2-N(R13) (R14) (wherein R13 and R14 are each independently hydrogen; Ci-C6 alkyl such as methyl, ethyl, etc.; C2-C7 alkoxycarbonyl such as methoxycarbonyl, etc.; Ci-C6 acyl such as acetyl, etc.; or R13 and R14 may be taken together with the nitrogen to which they are attached to form r An ' \ —N ())p —N 0 \ / \ / or (wherein p has the same meaning as defined above)); or -CO(R15) (wherein R15 is Ci-C6 alkyl such as isopropyl, etc.; Ci-C6 alkoxy such as methoxy, ethoxy, propoxy, isopropoxy, etc.; C7-Ci6 aralkyloxy such as benzyloxy, etc.; or hydroxy). Alternatively, R3 and R10 may be taken together with the nitrogen to which R10 is attached and ring B to form —N —N or R4 is preferably hydrogen or halogen such as fluorine, chlorine, bromine, etc.

Alkl1 is preferably methylene or ethane-1,1-diyl. 1 is preferably 0, 1 or 2.

Alkl2 is preferably methylene. m is preferably 0 or an integer of 1 to 3. 170 D is preferably Ci-C6 alkyl such as ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, sec-pentyl, etc.; C2-C6 alkenyl such as n-propenyl, etc.; C2-C7 alkoxycarbonyl such as ethoxycarbonyl, etc.; -N(R42)-CO(R43) (wherein R42 is hydrogen 5 or Ci-C6 alkyl; R43 is C6-C14 aryl such as biphenyl, etc. ; or C7-C16 aralkyl); or a group of the formula shown below: (wherein ring C, R5, R6 and R7 each has the same meaning as defined above).

Ring C is preferably C6-Ci4 aryl such as phenyl, naphthyl, etc.; C3-C7 cycloalkyl such as cyclopentyl, cyclohexyl, etc.; C7.Ci6 aralkyl such as benzyl, etc.; or heterocycle such as pyridine-3-yl, thiophen-3-yl, thiazol-2-yl, etc. Alternatively, ring C may be take together with R7 and R8 to 15 form R5 is preferably hydrogen; Ci-C6 alkyl such as methyl, etc.; Ci-C6 alkoxy such as methoxy, etc.; halogen such as chlorine, etc.; nitro; amino; C6-Ci4 aryl such as phenyl, etc.; or -CON(R16) (R17) or -CH2-CON(R16) (R17) (wherein R16 and R17 are each independently hydrogen; Ci-C6 alkyl such as ethyl, etc.. 171 or halo-Ci-C6 alkyl such as 2,2,2-trifluoroethyl, etc.).

R6 is preferably hydrogen or halogen such as chlorine, etc.

R7 is preferably hydrogen.

R8 and R9 are each independently preferably hydrogen; Ci-C6 alkyl such as ethyl, etc.; C6-C14 aryl such as phenyl, etc.; hydroxy-Ci-C6 alkyl such as hydroxymethyl, etc.; - CON (R18) (R19) (wherein R18 and R19 are each independently hydrogen; Ci-C6 alkyl such as methyl, ethyl, propyl, isopropyl, 10 butyl, isobutyl, etc.; C3-C7 cycloalkyl such as cyclohexyl, etc.; halo Ci-C6 alkyl such as 2,2,2- trifluoroethyl, etc.; C2-C12 alkoxyalkyl such as methoxyethyl, etc.; or C6-Ci4 aryl such as phenyl, etc.); -COO(R20) or -(CH2)n-OCO(R20) (wherein R20 is hydrogen; Ci-C6 alkyl such as methyl, ethyl, propyl, isopropyl, 15 isobutyl, etc.; or C3-C7 cycloalkyl such as cyclohexyl, etc., and n is an integer of 0 or 1); -N(R21) (R22) (wherein R21 and R22 are each independently hydrogen; C1-C6 alkyl such as methyl, isopropyl, etc.; Ci-C6 acyl such as acetyl, propionyl, butyryl, etc.; Cx-C6 alkylsulfonyl such as methylsulfonyl, etc.; or R21 20 and R22 may be taken together with the nitrogen atom to which they are attached to form 0 —N 0 ). or R8 and R9 taken together may form C3-C7 cycloalkyl such as cyclopropyl, cyclohexyl, etc.

Preferred embodiments of various substituents and the 172 substitution site will be illustrated below.

R1 is preferably hydrogen, halo Ci-C6 alkyl or Cx-C6 alkyl, among which hydrogen is especially preferred.

R2 is preferably phenyl (which may be substituted with halo Ci-C6 alkyl such as trif luorome thyl, etc.; Ci-C6 alkyl such as methyl, etc.; halogen such as chlorine, etc.; or Ci-C6 alkoxy such as methoxy, etc.).

R2 is preferably hydrogen.

R2" is preferably hydrogen, halo-Ci-C6 alkyl, halogen, Ci-C6 alkyl or Ci-C6 alkoxy, and trifluoromethyl is especially preferred.

X is preferably -COO- or -CON(R10)- (R10 has the same meaning as defined above), among which -CONH- is especially preferred.

Ring B is preferably phenyl.

R3 is preferably Ci-C6 alkyl, Ci-C6 alkoxy, -CON(R11) (R12) (wherein R11 and R12 are each independently preferably hydrogen or Ci-C6 alkyl) or -CO(R15) (wherein R15 is preferably Ci_C6 alkoxy).

R4 is preferably hydrogen or methyl, and especially preferably methyl.

Alk1 is preferably methylene.

Alk2 is preferably methylene. 1 is preferably 0 or 1, especially 1. m is preferably 1 or 2, especially 1 or 2.

D is preferably Ci-C6 alkyl or a group of the formula shown below: 173 (wherein ring C, R5 , R6 and R7 each has the same meaning as defined above).

Ring C is preferably phenyl, pyridin-3-yl, thiophen-3-yl, 5 thiophen-2-yl and thiazol-2-yl, among which phenyl is especially preferred.

R5, R6 and R7 each is preferably hydrogen, halogen or Ci-C6 alkyl, among which hydrogen is especially preferred.

R8 and R9 each is preferably hydrogen, Ci-C6 alkyl, C6-Ci4 10 aryl, -CON(R18) (R19) (wherein R18 and R19 each is preferably hydrogen or Ci-C6 alkyl) or -COO(R20) (wherein R20 is preferably « hydrogen or Ci-C6 alkyl) , among which -CON(R18) (R19) (wherein R18 and R19 each is preferably hydrogen or Ci-C6 alkyl) or -COO(R20) (wherein R20 is preferably hydrogen or Ci-C6 alkyl) are 15 more preferred, and -COO(R20) (wherein R20 is preferably Ci-C6 alkyl) is especially preferred.

The substitution site of -(CH2)i- on the benzene ring in the formula (1') is preferably i-position.

The compounds of the present invention may include hydrates or solvates, depending on the case, and may further include their metabolites. Furthermore, the compounds of the present invention include racemates and optically active compounds. The optically active compounds are preferably 25 those wherein one of enantiomers is in enantiomer excess of 174 about 90% or higher, more preferably in enantiomer excess of about 99% or higher.

When the compounds of the present invention are used as 5 an agent for the treatment or prophylaxis of hyperlipidemia or arteriosclerosis, they can be administered systemically or locally, and orally or parenterally. Though the dose may vary depending on the age, body weight, symptoms, therapeutic effect, etc., the daily dose per adult is in the range of 0.1 mg to lg 10 per one dose and can be administered one to several times per day. Also, the compounds of the present invention can be administered to human beings as well as animals other than human beings, especially mammals, for the treatment or prevention of said diseases. The compounds of the present invention can be 15 used in the same way for the treatment or prevention of coronary artery diseases, obesity, diabetes or hypertension.

In the formulation of the compounds of the present invention into solid compositions and liquid compositions for oral administration or injections, etc., for parenteral 20 administration, there may be added appropriate additives such as diluents, dispersants, adsorbents, solubilizers, etc. In addition, the composition of the present invention may take the known form such as tablets, pills, powders, granules, suppositories, injections, eye drops, solutions, capsules, 25 troches, aerosols, elixirs, suspensions, emulsions, syrups, etc.

When the compounds of the present invention are formulated into solid preparations such as tablets, pills, powders, granules, etc. , examples of such an additive include 175 lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalllne cellulose, starch, polyvinylpyrrolidone, magnesium aluminometasilicate or powdery silicic anhydride. In the case where the compounds of the present invention are 5 formulated into tablets or pills, they may be coated with a gastroenteric or enteric coating film containing a substance such as sucrose, gelatin, hydroxypropyl cellulose or hydroxymethyl cellulose phthalate. Furthermore, the tablets or pills may be multi-layered tablets comprising two or more 10 layers.

As the pharmaceutical compositions of the present invention, there are also exemplified capsules in which are filled liquid, semi-solid or solid contents prepared by dissolving the compounds of the present invention in a solvent 15 and adding an additive thereto. Examples of said solvents are purified water, ethanol, vegetable oil, etc., among which ethanol or a mixture of purified water and ethanol is preferably used. Any additives commonly used in the preparation of capsules can be used without any particular limitation. Such 20 additives include, for example, propylene glycol fatty acid esters; low molecular weight polyethylene glycols such as polyethylene glycol 200 to 600, etc., glycerine fatty acid esters thereof, and medium chain fatty acid triglycerides thereof; alcohols/polyols such as stearyl alcohol, cetanol, 25 polyethylene glycol, etc., or esters thereof; lipids such as sesame oil, soy bean oil, peanut oil, corn oil, hydrogenated oil, paraffin oil, bleached wax; fatty acids such as triethyl citrate, triacetin, stearic acid, palmitic acid, myr is tic acid, etc., and derivatives thereof. These additives are suitable 176 for preparing liquid or semi-solid contents. In the capsules of the present invention, propylene glycol fatty acid esters are preferable as such an additive. Examples of the propylene glycol fatty acid esters are propylene glycol monocaprylate 5 (Capmul PG-8 (Brand name), Sefol 218 (Brand name), Capryo 190 (Brand name), propylene glycol monolaurate (Lauroglycol FCC (Brand name), propylene glycol monooleate (Myverol P-06 (Brand name)), propylene glycol myristate, propylene glycol monostearate, propylene glycol lisinolate (Propymuls (Brand 10 name)), propylene glycol dicaprylate/dicaprate (Captex (Trademark) 200 (Brand name)) propylene glycol dilaurate, propylene glycol distearate and propylene glycol dioctanoate (Captex (Trademark) 800 (Brand name)). Although there is no particular limitation to the materials constituting the 15 capsules of the present invention, they include, for example, polysaccharides derived from natural products such as agar, alginic acid salt, starch, xanthan, dextran, etc; proteins such as gelatin, casein, etc.; chemically processed products such as hydroxystarch, pullulan, hydroxypropyl cellulose, 20 hydroxypropyl methylcellulose, polyvinyl alcohol or derivatives thereof, polyacryl derivatives, polyvinylpyrrolidone or derivatives thereof, polyethylene glycol, etc.

In the case where the pharmaceutical compositions of the 25 present invention are liquid formulations for oral administration such as pharmaceutically acceptable emulsions, solubilizers, suspensions, syrups or elixirs, etc., diluents to be used include, for example, purified water, ethanol, vegetable oils, emulsifiers, etc. In addition to such diluents, 177 auxiliary agents such as wetting agents, suspending agents, sweeteners, condiments, flavors or antiseptics may be added to said liquid formulations.

In the case where the pharmaceutical compositions of the present invention are parenteral formulations such as injections, there are employed sterilized aqueous or non-aqueous solutions, solublllzers, suspending agents, emulsifiers, etc. Examples of the aqueous solutions, solublllzers and suspending agents include distilled water for injections, physiological saline, cyclodextrin, and derivatives thereof; organic amines such as triethanolamine, diethanolamine, monoethanolamine, triethylamine, etc.; and inorganic alkaline solutions. When aqueous solutions are employed, for example, propylene glycol, polyethylene glycol or vegetable oils such as olive oil, or alcohols such as ethanol may be further added. Further, surfactants (for mixed micelle formation) such as polyoxyethylene hydrogenated castor oils, sucrose fatty acid esters, or lecithin or hydrogenated lecithin (for liposome formation), etc. can be used as a solubilizer. Furthermore, with regard to the parenteral formulations of the present invention, they may be formulated into emulsions comprising non-aqueous solublllzers such as vegetable oils, together with lecithin, polyoxyethylene hydrogenated castor oil or polyoxyethylene-polyoxypropylene glycol, etc.

Further, the present invention provides a novel agent for the treatment or prophylaxis of hyperlipidemia, arteriosclerosis, coronary artery diseases, obesity, diabetes or hypertension with new functions that have never been known before. The agents of the present invention for the treatment 178 or prevention of said diseases are characterized in that they selectively inhibit MTP (microsomal triglyceride transfer protein) in the small intestine. Among these agents, an agent which does not substantially inhibit MTP in the liver, while 5 inhibits only MTP in the small intestine is desirable. Specifically, it is preferable that MTP inhibition of the agent in the liver is approximately 1/3 or less, preferably 1/100 or less when compared to that in the small intestine as estimated in terms of ED50 or ED2o- As one preferred embodiment of the 10 therapeutic or prophylactic agents of the present invention for said diseases, they inhibit MTP in the small intestine, and they are then metabolized in the small intestine, blood, and liver to the amount at which the residual agent arriving at the liver does not substantially inhibit MTP in the liver. It is 15 particularly preferable that, when 300mg/kg of the compound of the present invention is administered orally, the rate of liver TG release inhibition exerted by the residual compound reaching the liver is about 20% or less, preferably less than about 10%, more preferably about 0%. Specifically, it is desirable that 20 the agent has about 40% or less, preferably about 20% or less inhibition rate of liver TG release when assayed by the method of Test Example 4 which will be hereinafter mentioned.

The pharmaceutical compositions or agents of the present 25 invention can be used in combination with other pharmaceutical compositions or agents. As other agents, there may be exemplified drugs for the treatment or prophylaxis of hyperlipidemia, arteriosclerosis, coronary artery disease, obesity, diabetes, or hypertension, and they can be used solely 179 or in combination with two or more kinds of said drugs. Examples of the antihyperlipidemic drugs include a statin-type drug, more specifically, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin or cerivastatin. Examples of the anti-obesity drugs include mazindol or olristat. Examples of the anti-diabetic drugs include insulin preparations, sulfonylurea drugs, insulin secretion-promotor drugs, sulfonamide drugs, biguanide drugs, a-glucosidase inhibitors, insulin resistance-improving drugs, etc., more specifically insulin, glibenclamid, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glibuzol, metformin hydrochloride, buformin hydrochloride, voglibose, acarbose, pioglitazone hydrochloride, etc. Examples of the anti-hypertension drugs include loop diuretics, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, Calcium antagonists, p-blockers, a,|5-blockers and a-blockers, and more specifically, furosemide delayed release, captopril, captopril delayed release, enalapril maleate, alacepril, delapril hydrochloride, silazapril, lisinopril, benazepril hydrochloride, imidapril hydrochloride, temocapril hydrochloride, quinapril hydrochloride, trandolapril, perindopril erbumine, losartan potassium, candesartan cilexetil, nicardipine hydrochloride, nicardipine hydrochloride delayed release, nilvadipine, nifedipine, nifedipine delayed release, benidipine hydrochloride, diltiazem hydrochloride, diltiazem hydrochloride delayed release, nisoldipine, nitrendipine, manidipine hydrochloride, barnidipine hydrochloride, efonidipine hydrochloride. 180 amlodipine besylate, felodipine, cilnidipine, aranidipine, propranolol hydrochloride, propranolol hydrochloride delayed release, pindolol, pindolol delayed release, indenolol hydrochloride, carteolol hydrochloride, carteolol 5 hydrochloride delayed release, bunitrolol hydrochloride, bunitrolol hydrochloride delayed release, atenolol, asebutolol hydrochloride, metoprolol tartrate, metoprolol tartrate delayed release, nipradilol, penbutolol sulfate, tilisolol hydrochloride, carvedilol, bisoprolol fumarate, 10 betaxolol hydrochloride, celiprolol hydrochloride, bopindolol malonate, bevantolol hydrochloride, labetalol hydrochloride, arotinolol hydrochloride, amosulalol hydrochloride, prazosin hydrochloride, terazosin hydrochloride, doxazosin mesylate, bunazocin hydrochloride, bunazocin hydrochloride delayed 15 release, urapidil, and phentolamine mesylate, etc.

There is no particular limitation to the timing for the administration of pharmaceutical compositions or agents and other drugs for combination use according to the present invention, and they may be administered simultaneously or 20 intermittently.

The amount of such drugs for combination use can be determined based on their clinical doses, and can be chosen depending on the age, weight, condition, medication time, dosage form, method of administration, combination, etc. 25 There is no particular limitation to the dosage form of the drugs for combination use, and it may be sufficient that the pharmaceutical compositions or agents and other drugs for combination use according to the present invention are combined at the time of administration. 181 Next, a process for preparing an ester compound represented by the formula (1) will be illustrated below as an example, but the process of the present invention is not limited 5 thereto. In the process mentioned below, D is a group of the formula (2): (wherein ring C, R5, R6 and R7 each has the same meaning as defined above), and when D is Cx-C6 alkyl, C2-C6 alkenyl, C2-C7 10 alkoxycarbonyl or -N(R42)-CO(R43) (R42 and R43 each has the same meaning as defined above), the compound can be prepared in the same.

In addition, the functional groups other than those to be reacted may be optionally protected in a previous stage and 15 may be deprotected in an appropriate stage.

Further, the reaction in each step may be carried out in the usual manner, and separation and purification may be conducted by the appropriate selection or combination of conventional methods such as crystallization, 20 recrystallization, column chromatography, preparative HPLC, etc.

Process 1 process for preparing compounds in which X is -CONH-(CH2)n- (2) Among the compounds represented by the formula (1), a 182 will be illustrated below. Process 1 R' R' In the above reaction scheme, R1, R2, R3, R4, R5, R6, R7, R8, R9, 1, m, n, Alk1, Alk2, ring A, ring B, and ring C each has the same meaning as defined above and R23 is Ci-C6 alkyl. 183 Step 1-1 A carboxylic acid of the formula (2) is reacted with oxalyl chloride or thionyl chloride in a solvent to give an acid chloride of the formula (3).

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon 10 tetrachloride, 1,2-dichloroethane, etc.; and esters such as ethyl acetate, methyl acetate, butyl acetate, etc., and they may be used solely or in combination thereof. Preferred solvents in the present reaction include methylene chloride, chloroform or toluene, all of which contain a catalytic amount 15 of N,N-dimethylformamide.

The reaction temperature is about -20°C to 120°C, preferably about 0°C to room temperature.

The reaction time is about 10 minutes to 8 hours, preferably about 30 minutes to 4 hours.

Step 1-2 This step is a general reduction process for the nitro group attached directly to the aromatic ring. A nitro compound of the formula (4) is hydrogenated in a solvent in the presence of a catalyst to give a compound of the formula (5). 25 The solvent used in the reaction includes, for example, ethers such as tetrahydrofuran, dioxane, 1,2-dimethoxyethane, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc.; and esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and they are used solely or in 184 combination thereof. Preferred solvents in the present reaction include alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc., and a mixture of said alcohol solvent and tetrahydrofuran and/or water.

The catalyst used in the reaction includes, for example, palladium-carbon, palladium hydroxide, Raney-Ni, platinum oxide, and among which palladium-carbon or reduced iron is preferred.

The reaction temperature is about 0°C to 120°C, preferably 10 about room temperature to 100°C.

The reaction time is about 30 minutes to 8 days, preferably about one hour to 96 hours.

Step 1-3 This step is a general condensation reaction between acid 15 chlorides and amines. An acid chloride of the formula (3) is condensed with an amine of the formula (5) in a solvent in the presence of a base to give a compound of the formula (6).

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 20 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; and esters such as ethyl acetate, methyl acetate, butyl acetate, etc., and they 25 can be used solely or in combination thereof. Preferred solvents in the present reaction include methylene chloride, chloroform, toluene, ethyl acetate or tetrahydrofuran.

Examples of the bases used in the present invention include organic bases such as triethylamine, pyridine. 185 N-methylmorpholine, etc.; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.; and alkali metal carbonates such as sodium carbonate, potassium carbonate, sodium bicarbonate, potassium 5 bicarbonate, etc. , among which triethylamine, sodium hydroxide or sodium bicarbonate is preferable.

The reaction temperature is about 0°C to 80°C, preferably about 0°C to room temperature.

The reaction time is about 10 minutes to 48 hours, 10 preferably about 30 minutes to 24 hours.

In the case of a compound of the formula (5) wherein R23 is hydrogen, a compound of the formula (7) can be prepared by one step of condensation between an aminocarboxylic acid and an acid chloride (Schotten-Baumann reaction). 15 Alternatively, a compound of the formula (6) can be prepared by using a condensing agent (e.g. WSC-HOBT, DCC-HOBT) for a compound of the formula (2) and a compound of the formula (5). Further, a compound of the formula (6) may be provided by converting a compound of the formula (2) into its mixed 20 anhydride, followed by the reaction in the presence of a base. Step 1-4 This step is a general ester hydrolysis reaction using alkali. A compound of the formula (6) is hydrolysed in a solvent in the presence of a base to give a compound of the formula (7). 25 The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; and alcohols such as methanol, ethanol, isopropyl alcohol, etc.; and they can be used solely or in combination thereof. Preferred solvents in the 186 present reaction include a mixture of tetrahydrofuran and ethanol or methanol. Examples of the bases are aqueous solutions of alkali metal carbonates such as sodium carbonate, potassium carbonate, etc., or aqueous solutions of alkali metal 5 hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc., among which sodium hydroxide or lithium hydroxide is preferable.

The reaction temperature is about 0°C to 120°C, preferably about room temperature to 80°C.

The reaction time is about 1 hour to 24 hours, preferably about 2.5 hours to 12 hours.

Step 1-5 This step is a general condensation reaction of a carboxylic acid with an alcohol.

A carboxylic acid of the formula (7) is condensed with an alcohol of the formula (8) in a solvent in the presence of a base and a condensing agent to give a compound of the formula (1-1) which is one of the objective compounds.

The solvent used in the reaction includes, for example, 20 ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; esters such as ethyl 25 acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, etc.; and they can be used solely or in combination thereof. Preferred solvents in the present reaction include tetrahydrofuran, acetone, methylene chloride or 187 N,N-dimethylformamide.

Examples of the bases used In the reaction Include organic bases such as triethylamine, pyridine, dimethylaminopyridine, N-methylmorpholine, etc., among which dimethylaminopyridine 5 is preferred.

Examples of the condensing agents used in the reaction include 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (WSC.HC1), dicyclohexylcarbodiimide (DCC), etc. among which l-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride is preferred.

The reaction temperature is about 0°C to 80°C, preferably about 0°C to room temperature.

The reaction time is about 1 hour to 48 hours, preferably about 3 hours to 24 hours.

As an alternative process, a carboxylic acid of the formula (7) may be converted into its mixed anhydride and then reacted with an alcohol of the formula (8) in the presence of a base.

Process la Process la as shown below is an alternative of Process 1. 188 Process la R3 R< 02N-(ch2)n tbj—(A I k Of^O- R23 (4) step la-1 o2n-(ch2) Rl I .R7 step la-2 v - j (8) r6 r1 (1-1) 189 In the above reaction scheme, R1, R2, R3, R4, R5, R6, R7, R8, R9, R23, 1, m, n, Alk1, Alk2, ring A, ring B and ring C each has the same meaning as defined above.

Step la-1 A compound of the formula (105) can be prepared from a compound of the formula (4) in a similar manner to Step 1-4 of Process 1.

Step la-2 A compound of the formula (106) can be prepared by condensing a carboxylic acid of the formula (105) with an alcohol of the formula (8) in a similar manner to Step 1-5 of Process 1.

Step la-3 A compound of the formula (107) can be prepared from a compound of the formula (106) in a similar manner to Step 1-2 of Process 1.

Step la-4 A compound of the formula (1-1) which is one of the objective compounds can be prepared by condensing an amine of the formula (107) with an acid chloride of the formula (3) in a similar manner to Step 1-3 of Process 1.

Process 2 Among the compounds represented by the formula (1), a process for preparing compounds in which X is -COO-(CH2)n- will be illustrated below. 190 Process 2 rj r< R« R24 0 (ch2)n——(alko'j^^oh (9) rs^j^^r7 (8) h0-(alk2)7 R» R' step 2-1 R8 (10) (11) ri (1-2) In the above reaction scheme, R1, R2, R3, R4, R5, R6, R7, R8, R9, 1, m, n, Alk1, Alk2, ring A, ring B and ring C each has the same meaning as defined above, and R24 is a hydroxy-protecting group (for example, benzyl, p-methoxybenzyl, tert-butyl, trialkylsilyl, etc.)- 191 Step 2-1 This step is a condensation reaction of a carboxylic acid with an alcohol similar to Step 1-5 of Process 1. A compound of the formula (10) can be prepared by condensing a carboxylic 5 acid of the formula (9) with an alcohol of the formula (8) in a solvent in the presence of a base and a condensing agent.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as 10 benzene, toluene, hexane, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, 15 water, etc.; and they can be used solely or in combination thereof. Preferred solvents in the present reaction include tetrahydrofuran, methylene chloride or N,N-dimethylformamide.

Examples of the bases used in the reaction include organic bases such as triethylamine, pyridine, dimethylaminopyridine, 20 N-methylmorpholine, etc., among which dimethylaminopyridine is preferred.

Examples of the condensing agents used in the reaction include 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (WSC'HCl), dicyclohexylcarbodiimide (DCC), etc., 25 among which l-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride is preferred.

The reaction temperature is about 0°C to 80°C, preferably about 0°C to room temperature.

The reaction time is about 2 hours to 48 hours, preferably 192 about 6 hours to 24 hours.

Step 2-2 This step is a general deprotection method for hydroxy groups. For example, when R24 is benzyl in a compound of the 5 formula (10), the compound of the formula (10) is hydrogenated in a solvent in the presence of a catalyst to give a compound of the formula (11).

The solvent used in the reaction includes, for example, ethers such as tetrahydrofuran, dioxane, 1,2-dimethoxyethane, 10 diglyme, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc.; and esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and they can be used solely or in combination thereof. Preferred solvents in the present reaction are alcohols such as methanol, ethanol, 15 isopropyl alcohol, t-butanol, etc.

Examples of the catalyst used in the reaction include palladium carbon, palladium hydroxide, Raney-Ni, platinum oxide, etc., among which palladium carbon is preferred.

The reaction temperature is about 0°C to 80°C, preferably 20 about 0°C to room temperature.

The reaction time is about 1 hour to 16 hours, preferably about 2 hours to 8 hours.

Step 2-3 This step is a condensation reaction between a carboxylic 25 acid and an alcohol similar to Step 1-5 of Process 1. A compound of the formula (11) is condensed with an alcohol of the formula (2) in a solvent in the presence of a base and a condensing agent to give a compound of the formula (1-2) which is one of the objective compounds. 193 The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, etc., and they can be used solely or in combination thereof. Preferred solvents in the present reaction are tetrahydrofuran, methylene chloride, dimethylformamide, etc.

Examples of the bases used in the reaction include organic bases such as triethylamine, pyridine, dimethylaminopyridine, N-methylmorpholine, etc., among which dimethylaminopyridine is preferred.

Examples of the condensing agents used in the reaction include 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (WSC.HC1), dicyclohexylcarbodiimide (DCC), etc., among which l-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride is preferred.

The reaction temperature is about 0°C to 80°C, preferably about 0°C to room temperature.

The reaction time is about 2 hours to 48 hours, preferably about 6 hours to 24 hours.

As an alternative process of Process 2, a phenol or an alcohol derivative derived from a compound of the formula (9) (wherein R24 is p-methoxybenzyl and the carboxyl group is protected by benzyl ester) is subjected to removal of the p-methoxybenzyl group with 2,3-dichloro-5,6- 194 dicyanobenzoquinone (DDQ), etc., followed by condensation with a compound of the formula (2). After removal of the benzyl group from the resulting compound, the deprotected compound is condensed with a compound of the formula (8) to give a compound 5 of the formula (1-2) which is one of the objective compounds.

Process A The following is an example of the process for preparing a compound of the formula (1) wherein ring B is (ch2)— (wherein R4 has the same meaning as defined above, R31 is Ci-C6 alkyl, and 1' is 1).

Process A < COOEt COOEt (13) step A-l °*N step A-2 o2n jjl^j^^COOH r» (15) step A-3 r25—x? (16) o2n COOEt R25 COOEt ouut step A-4 02n uJC J^V^COOH r31 (17) R" (18) In the above reaction scheme, R31 and R4 each has the same 15 meaning as defined above, R25 is Ci_6 alkyl, X2 and X3 each is halogen, and Et is ethyl. 195 Step A-1 A compound of the formula (14) can be prepared by reacting a compound of the formula (12) with a malonic acid ester of the formula (13) in a solvent in the presence of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc.; and 10 polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, etc. , and they can be used solely or in combination thereof. A preferred solvent in the present reaction is N,N-dimethylformamide.

Examples of the bases used in the reaction include alkali 15 metal hydrides such as sodium hydride, potassium hydride, etc.; alkali metal alkoxides such as sodium ethoxide, sodium methoxide, potassium t-butoxide, etc.; alkali metal amides such as sodium amide, lithium bistrimethylsilylamide, etc.; and alkali metal carbonates such as sodium carbonate, potassium 20 carbonate, etc., among which sodium hydride is preferable.

The reaction temperature is about 0°C to 120°C, preferably about room temperature to 100°C The reaction time is about 30 minutes to 24 hours, preferably about 1 hour to 12 hours.

Step A-2 This step is a hydrolysis reaction of esters, followed by decarboxylation. A compound of the formula (15) can be prepared by stirring a compound of the formula (14) under heating in a solvent in the presence of a base. 196 The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc.; and water; and 5 they can be used solely or in combination thereof. Preferred solvents in the present reaction are mixtures of an alcohol and water.

Examples of the bases used in the reaction include alkali metal carbonates such as sodium carbonate, potassium carbonate, 10 etc., and alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc., among which sodium hydroxide or potassium hydroxide is preferred.

The reaction temperature is about 0°C to 150°C, preferably about 60°C to 120°C 15 The reaction time is about 10 minutes to 12 hours, preferably about 30 minutes to 6 hours.

In accordance with the Steps la-2, la-3 and la-4 of the Process la, compounds of the present invention can be prepared from a compound of the formula (15) obtained in the above Step 20 A-2.

An example in the case where Alk1 is a branched alkanediyl or alkenediyl will be illustrated below.

Step A-3 A compound of the formula (17) can be prepared by reacting 25 a compound of the formula (14) with a compound of the formula (16) in a solvent in the presence of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as 197 benzene, toluene, hexane, xylene, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc.; and polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, etc., and they can be used solely or in combination thereof. Preferred solvents in the present reaction are N,N-dimethylformamide, etc.

Examples of the bases used in the reaction include alkali metal hydrides such as sodium hydride, potassium hydride, etc.; alkali metal alkoxides such as sodium ethoxide, sodium methoxide, potassium t-butoxide, etc.; alkali metal carbonates such as sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, etc.; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.; alkali metal carboxylates such as sodium acetate, potassium acetate, etc.; and alkali metal phosphates such as sodium phosphate, potassium phosphate, etc., among which sodium hydride is preferred.

The reaction temperature is about 0°C to 120°C, preferably about room temperature to 100°C The reaction time is about 10 minutes to 24 hours, preferably about 30 minutes to 12 hours.

Step A-4 In a similar manner to Step A-2, a compound of the formula (18) can be prepared from a compound of the formula (17).

In accordance with the Steps la-2, la-3 and la-4 of the Process la, the compounds of the present invention can be prepared from a compound of the formula (18) obtained in the above Step A-4. 198 Process B The following is an example of the process for preparing a compound of the formula (1) wherein ring B is R4 (wherein R3 and R4 each has the same meaning as defined above, and 1" is 2 or 3). 199 .COOMe R4 COOBn iPV""81 (2i) R3 step B-1 R3 (19) (20) step B-2 R3 step B-3 r3 (22) (23) in case of ln=3 -COOMe Br COOBn step B-2' COOMe In the above reaction scheme, R3 and R4 each has the same meaning as defined above. Me is methyl, and Bn is benzyl. Step B-l A compound of the formula (20) can be prepared by reacting a compound of the formula (19) with a brominating agent in a solvent in the presence of a radical initiator (for example, 2,2'-azobisisobutyronitrile or benzoyl peroxide).

The solvent used in the reaction includes, for example. 200 hydrocarbons such as benzene, etc., and halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc. , and they can be used solely or in combination thereof. Preferred solvents in the 5 present reaction are methylene chloride or carbon tetrachloride.

The brominating agent used in the reaction includes, for example, bromine, N-bromosuccinimide, etc., among which N-bromosuccinimide is preferred.

The reaction temperature is about room temperature to 120°C, preferably about 60°C to 100°C The reaction time is about 10 minutes to 8 hours, preferably about 30 minutes to 4 hours.

Step B-2 In a similar manner to Step A-l of Process A, a compound of the formula (22) can be prepared by reacting a compound of the formula (20) with a compound of the formula (21).

Step B-2' In a similar manner to Step A-l of Process A, a compound of the formula (22' ) can be prepared by reacting a compound of the formula (20' ) (prepared from a compound of the formula (15) and a compound of the formula (22) via several steps) with a compound of the formula (21).

Step B-3 A compound of the formula (23) can be prepared by hydrogenating a compound of the formula (22) for debenzylation in a solvent, followed by decarboxylation.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane. 201 1, 2-dime thoxye thane, diglyme, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc.; and water; and they can be used solely or in combination thereof. Preferred solvents in the present reaction are alcohols.

Examples of the catalyst used for the debenzylation include palladium carbon, palladium hydroxide, Raney-Ni, platinum oxide, etc., among which palladium carbon is preferred.

The reaction temperature in the debenzylation is 10 preferably about room temperature to 80°C, and the reaction temperature in the decarboxylation is preferably 10°C to 150°C.

The reaction time in the debenzylation is about 1 hour to 16 hours , preferably about 2 hours to 8 hours, and the reaction time in the decarboxylation is about 5 minutes to 4 hours, 15 preferably about 10 minutes to 2 hours.

Step B-3' In a similar manner to Step B-3 of Process B, a compound of the formula (23') can be prepared from a compound of the formula (22').

In accordance with the Steps 1-3, 1-4 and 1-5 of the process 1, the compounds of the present invention can be prepared from a compound of the formula (23) or (23* ) obtained in Step B-3 or B-3'.

Process C The following is an example of the process for preparing a compound of the formula (1) wherein ring B is 202 ch2)— (wherein R4 has the same meaning as defined above, R32 is -CON(Rlx) (R12) in which R11 and R12 each has the same meaning as defined above, and 1' is 1).

Process C /R11 (24) R12 (26) < COOt-Bu COOMe (27) step C-2 step C-3 Jr o^N-r11 R12 (29) COOMe Jy COOMe step C-4 o^N/r11 I R12 (30) In the above reaction scheme, R4, R11 and R12 each has the same meaning as defined above. Me is methyl and t-Bu is tert-butyl.

Step C-l An acid chloride can be prepared from a compound of the formula (24) in a similar manner to Step 1-1 of Process 1. The resulting acid chloride is reacted with a compound of the formula (25) in a similar manner to Step 1-3 of Process 1 to 203 give a compound of the formula (25).

Also, a compound of the formula (26) can be prepared by condensing a compound of the formula (24) with a compound of the formula (25) using a condensing agent (for example, WSC, HOBT). Alternatively, a compound of the formula (24) is converted into its mixed anhydride, followed by reaction with a compound of the formula (25) in the presence of a base, to give a compound of the formula (26).

Step C-2 In a similar manner to Step A-l of Process A, a compound of the formula (28) can be prepared by reacting a compound of the formula (26) with a compound of the formula (27).

Step C-3 A compound of the formula (29) can be prepared by treating a compound of the formula (28) with an acid (trifluoroacetic acid, toluenesulfonic acid, methanesulfonic acid, etc.) in the presence or absence of a solvent under heating or at room temperature to convert the tert-butyl ester moiety into the carboxylic acid moiety, followed by decarboxylation.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; and water; and they can be used solely or in combination thereof. Preferred solvents in the present reaction are methylene chloride, chloroform or toluene. 204 The reaction temperature is about 0°C to 120°C, preferably about room temperature to 100°C The reaction time is about 1 hour to 24 hours, preferably about 2 hours to 12 hours.

Step C-4 In a similar manner to Step 1-2 of Process 1, a compound of the formula (30) can be prepared from a compound of the formula 1, the compounds of the present invention can be prepared from a compound of the formula (30) obtained in the above Step C-4.

Process D (29) .

In accordance with the Steps 1-3, 1-4 and 1-5 of Process The following is an example of the process for preparing 15 a compound of the formula (1) wherein ring B is R< {33 (wherein R4 has the same meaning as defined above, R33 is Ci_6 alkoxy or C7-i6 aralkyloxy, and 1' is 1). 205 Process D X2— R" 02N j^,C00Me (16) R4 V — J? COOMe oh (31) & COOH step D-l 0—R26 o—R26 step D-2 step D-3 (32) Ci (33) 0—R26 (34) step D-4 o2n 0—-R26 (35) o2n step D-5 j^Cpj^^COOEt Q R26 step D-6 COOEt (36) 0—R26 (37) In the above reaction scheme, R , X2, Me and Et each has the same meaning as defined above and R26 is Ci_6 alkyl or C7-i6 aralkyl.

Step D-l A compound of the formula (32) can be prepared by reacting a compound of the formula (31) with a compound of the formula (16) in a solvent in the presence of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and polar solvents such as acetone, N,N-dimethylformamide, dimethyl 206 sulfoxide, etc.; and they can be used solely or in combination thereof. A preferred solvents in the present reaction is N, N-dimethylformamide.

Examples of the bases used in the reaction include alkali 5 metal hydrides such as sodium hydride, potassium hydride, etc. , and alkali metal carbonates such as sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, etc., among which sodium hydride is preferred.

The reaction temperature is about 0°C to 100°C, preferably 10 about room temperature to 80°C The reaction time is about 2 hour to 48 hours, preferably about 6 hours to 24 hours.

Step D-2 A compound of the formula (33) can be prepared by 15 hydrolyzing the ester moiety of a compound of the formula (32) in a solvent in the presence of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxye thane, diglyme, etc.; alcohols such as methanol, 20 ethanol, isopropyl alcohol, etc.; and water, and they can be used solely or in combination thereof. Preferred solvents in the present reaction are tetrahydrofuran or a mixture of tetrahydrofuran and ethanol or methanol.

Examples of the bases used in the reaction include alkali 25 metal carbonates such as sodium carbonate, potassium carbonate, etc.; aqueous solutions of alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc., among which sodium hydroxide is preferred.

The reaction temperature is about 0°C to 120°C, preferably 207 about room temperature to 80°C The reaction time is about 1 hour to 24 hours, preferably about 2.5 hours to 12 hours.

Step D-3 In a similar manner to Step 1-1 of Process 1, a compound of the formula (34 ) can be prepared from a compound of the formula (33).

Step D-4 This process is a conversion reaction from acid chlorides 10 to diazoketones . A compound of the formula (35) can be prepared by reacting a compound of the formula (34) with diazomethane in a solvent in the presence of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 15 1,2-dimethoxyethane, diglyme, etc., and they can be used solely or in combination thereof. Preferred solvents in the present reaction are diethyl ether or tetrahydrofuran.

Examples of the bases used in the reaction include organic bases such as triethylamine, pyridine, dimethylaminopyridine, 20 N-methylmorpholine, etc., among which triethylamine is preferred.

The reaction temperature is about -20°C to 50°C, preferably about 0°C to room temperature.

The reaction time is about 2 hours to 48 hours, preferably 25 about 6 hours to 24 hours.

Step D-5 This process is one carbon homologation (Arndt-Eistert synthesis) by a-diazoketone rearrangement (Wolff rearrangement). A compound of the formula (35) is reacted by 208 use of a silver catalyst (for example, silver benzoate, silver oxide) in an alcohol in the presence of a base to give a compound of the formula (36).

The solvent (also served as the reaction reagents) used 5 in the reaction includes , for example, alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc., and they can be used solely or in combination thereof. Preferred solvents (also served as the reaction reagents) in the present reaction are methanol or ethanol.

Examples of the bases used in the reaction include organic bases such as triethylamine, pyridine, dimethylaminopyridine, N-methylmorpholine, etc., among which triethylamine is preferred.

The reaction temperature is about room temperature to 15 120°C, preferably about 60°C to 120°C.

The reaction time is about 2 hours to 36 hours, preferably about 4 hours to 18 hours.

Step D-6 In a similar manner to Step 1-2 of Process 1, a compound 20 of the formula (37) can be prepared from a compound of the formula (36).

In accordance with the Steps 1-3, 1-4 and 1-5 of the above Process 1, the compounds of the present invention can be prepared from a compound of the formula (37) obtained in the 25 above Step D-6. The resulting compound of the present invention is further subjected to the reactions of Step 2-2 of Process 2, whereby the substituent -OR26 can be converted into -OH.

Process E 209 The following is an example of the process for preparing a compound of the formula (1) wherein ring B is V^/^(CH2) | ■ R 34 (wherein R4 has the same meaning as defined above, R34 is -N(R13) (R14) in which R13 and R14 each has the same meaning as defined above), and 1' is 1).

Process E COOt-Bu ^COOMe (27) step E-l COOMe HN /R1 \.

R14 (41) step E-3 (42) (43) In the above reaction scheme, R4, R13, R14, Me and t-Bu each has the same meaning as defined above.

Step E-l In a similar manner to Step A-l of Process A, a compound of the formula (39) can be prepared by reacting a compound of the formula (38) with a compound of the formula (27).

Step E-2 In a similar manner to Step C-3 of Process C, a compound of the formula (40) can be prepared from a compound of the formula 210 (39).

Step E-3 A compound of the formula (42) can be prepared by reacting a compound of the formula (40) with a compound of the formula 5 (41) without or in a solvent and in the presence of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; halogenated 10 hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc.; esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and polar solvents such as N,N-dimethylformamide, dimethyl 15 sulfoxide, etc.; and they can be used solely or in combination thereof. A preferred solvent in the present reaction is tetrahydrofuran.

Examples of the bases used in the reaction include organic bases such as triethylamine, pyridine, dimethylaminopyridine, 20 N-methylmorpholine, etc., among which triethylamine or a mixture of triethylamine and dimethylaminopyridine is preferred.

The reaction temperature is about 0°C to 120°C, preferably about room temperature to 100°C.

The reaction time is about 2 hours to 48 hours, preferably about 6 hours to 24 hours.

Step E-4 In a similar manner to Step 1-2 of Process 1, a compound of the formula (43) can be prepared from a compound of the formula 211 (42).

In accordance with the Steps 1-3, 1-4 and 1-5 of the above Process 1, the compounds of the present invention can be prepared from a compound of the formula (43) obtained in the 5 above Step E-4.

Process F The following is an example of the process for preparing a compound of the formula (1) wherein ring B is R4 H?) r (wherein R4 has the same meaning as defined above and R35 is -COO(R25) in which R25 is Ci-C6 alkyl, and 1' is 1).

Process F o2n ci r4 r25-oh 'C1 (46) COOH o2n step F-l O^^Cl step F-2 (44) (45) COOBn ^COOBn (48) step F-3 (49) O—R25 (50) In the above reaction scheme, R4, R25 and Bn each has the 15 same meaning as defined above.

Step F-l 212 In a similar manner to Step 1-1 of Process 1, a compound of the formula (45) can be prepared from a compound of the formula (44).

Step F-2 A compound of the formula (47) can be prepared by reacting a compound of the formula (45) with a compound of the formula (46) in a solvent in the presence of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 10 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; and esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and they 15 can be used solely or in combination thereof. A preferred solvent in the present reaction is tetrahydrofuran.

Examples of the bases used in the reaction include organic bases such as triethylamine, pyridine, dimethylaminopyridine, N-methylmorpholine, etc., among which triethylamine is 20 preferred.

The reaction temperature is about -30°C to 80°C, preferably about -20°C to room temperature.

The reaction time is about 2 hours to 48 hours, preferably about 6 hours to 24 hours.

Step F-3 In a similar manner to Step A-l of Process A, a compound of the formula (49) can be prepared by reacting a compound of the formula (47) with a compound of the formula (48).

Step F-4 213 A compound of the formula (49) was reacted in a similar manner to Step 1-2 of Process 1, followed by debenzylation and decarboxylation to give a compound of the formula (50).

In accordance with the alternative process described in 5 Step 1-3 and Step 1-5 of Process 1, the compounds of the present invention can be prepared from a compound of the formula (50) obtained in the above Step F-4.

Process G The following is an example of the process for preparing a compound of the formula (1) wherein ring B is (wherein R3 and R4 each has the same meaning as defined above and 1' is 1). 214 Process G step G-5 (55' ) In the above reaction scheme, R3, R4 and Et each has the same meaning as defined above.

Step G-l In a similar manner to Step 1-1 of Process 1, a compound of the formula (52) can be prepared from a compound of the formula (51).

Step G-2 In a similar manner to Step D-4 of Process D, a compound 10 of the formula (53) can be prepared from a compound of the formula (52).

Step G-3 In a similar manner to Step D-5 of Process D, a compound 215 of the formula (54) can be prepared from a compound of the formula of the formula (55) can be prepared from a compound of the formula In accordance with Steps 1-3, 1-4 and 1-5 of the above Process 1, the compounds of the present invention can be prepared from a compound of the formula (55) obtained above in Step G-4.

Step G-5 In a similar manner to Step 1-4 of the above Process 1, a compound of the formula (55') can be prepared from a compound of the formula (54).

In accordance with Steps la-2, la-3 and la-4 of the above Process la, the compounds of the present invention can be prepared from a compound of the formula (55') obtained in the above Step G-5.

Process H The following is an example of the process for preparing a compound of the formula (1) wherein ring B is (53).

Step G-4 In a similar manner to Step D-6 of Process D, a compound (54).

V^/CCHz) 13 (wherein R3 and R4 each has the same meaning as defined above 25 and 13 is 0). 216 Process H R* R4 o2n-(ch2.

R23 (56) I step H-l HO—(Alk2): ri In the above reaction scheme, R1, R2, R3, R4, R5, R6, R7, R8, R9, R23, Alk2,ring A, ring B, ring C, m and n each has the same meaning as defined above.

Step H-l 217 In a similar manner to Step 1-2 of Process 1, a compound of the formula (57) can be prepared from a compound of the formula (56) .

Step H-2 In a similar manner to Step 1-3 of Process 1, a compound of the formula (58) can be prepared by reacting a compound of the formula (57) obtained in Step of H-l (or commercially available product) with a compound of the formula (3).

Step H-3 In a similar manner to Step 1-4 of Process 1, a compound of the formula (59) can be prepared from a compound of the formula (58) . step H-4 In a similar manner to Step 1-5 of Process 1, a compound 15 of the formula (1-3) which is one of the objective compounds can be prepared by reacting a compound of the formula (59) with a compound of the formula (8).

Process I The following is an example of the process for preparing a compound of the formula (1) wherein ring B is R" R3 (wherein R3 and R4 each has the same meaning as defined above and 14 is 1 to 3). 218 Process I H2N"(CH2)^ / Bn 'Bn R3 step 1-1 (60) (61) step 1-2 Rr — H R3 (62) Xf—(AIk') l4 "COOMe (63) step 1-3 (64) step 1-4 R' (65) step 1-5 (1-4) In the above reaction scheme, R1. R2, R3, R4, R5, R6, R7, 5 R8, R9, 14, m, n, ring A, ring C, Bn, Me, Alk1, Alk2 and X2 each 219 has the same meaning as defined above.

Step 1-1 In a similar manner to Step 1-3 of Process 1, a compound of the formula (61) can be prepared by reacting a compound of 5 the formula (60) with a compound of the formula (3).

Step 1-2 Under conditions similar to Step 1-2 of Process 1, with the proviso that palladium hydroxide is used as a catalyst, a compound of the formula (62) can be prepared from a compound 10 of the formula (61).

Step 1-3 A compound of the formula (64) can be prepared by reacting a compound of the formula (62) with a compound of the formula (63) in a solvent in the presence of a base. Alternatively, 15 X2-(Alk1) 14-COOEt (in the formula, X2, Alk1, 14 and Et each has the same meaning as defined above) may be used in place of a compound of the formula (63).

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 20 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc.; esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, 25 dimethyl sulfoxide, etc.; and they can be used solely or in combination thereof. A preferred solvent in the present reaction is N,N-dimethylformamide.

Examples of the bases used in the reaction include alkali metal hydrides such as sodium hydride, potassium hydride, etc.; 220 alkali metal alkoxides such as sodium ethoxide, sodium methoxide, potassium t-butoxide, etc.; alkali metal carbonates such as sodium carbonate, potassium carbonate, etc.; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, 5 potassium hydroxide, etc.; alkali metal carboxylates such as sodium acetate, potassium acetate, etc.; and alkali metal phosphates such as sodium phosphate, potassium phosphate, etc., among which potassium carbonate or sodium hydride is preferred.

The reaction temperature is about 0°C to 150°C, preferably 10 about room temperature to 100°C.

The reaction time is about 1 hour to 48 hours, preferably about 2 hours to 24 hours.

Step 1-4 In a similar manner to Step 1-4 of Process 1, a compound 15 of the formula (65) can be prepared from a compound of the formula (64).

Step 1-5 In a similar manner to Step 1-5 of Process 1, a compound of the formula (1-4) which is one of the objective compounds 20 can be prepared by reacting a compound of the formula (65) with a compound of the formula (8).

Process J The following is an example of the process for preparing 25 a compound of the formula (1) wherein ring B is 221 and 14 is 1 to 3).

Process J X2— (AlkOu-COOMe R' <«) in O-N^f^N—(AlkO —COOMe step J-l W (67) (66) In the above reaction scheme, R3, R4, Me, Alk1, 14 and X2 each has the same meaning as defined above.

Step J-l In a similar manner to Step 1-3 of Process I, a compound of the formula (67) can be prepared by reacting a compound of 10 the formula (66) with a compound of the formula (63). Alternatively, X2-(Alk1)i4-COOEt (in the formulaX2, Alk1, 14 and Et each has the same meaning as defined above) may be used in place of a compound of the formula (63).

Step 3-2 222 In accordance with the Step 1-4 of Process I, a compound of the formula (68) can be prepared from a compound of the formula la, the compounds of the present invention can be prepared from a compound of the formula (68) obtained in the above Step J-2.

Process K The following is an example of the process for preparing 10 a compound of the formula (1) wherein ring B is (wherein R3, R4, 14 and Alk1 each has the same meaning as defined above).

Process K (67).

In a similar manner to Steps la-2 , la-3 and la-4 of Process 02n nh n=< X2—(AlkOl4-COOMe (63) 0,n N—(Alk1) u—COOMe \ step K-l (69) (70) (71) 223 In the above reaction scheme, R3, R4, Me, 14, Alk1 and X2 each has the same meaning as defined above.

Step K-l In a similar manner to Step 1-3 of Process I, a compound 5 of the formula (70) can be prepared by reacting a compound of the formula (69) with a compound of the formula (63). Alternatively, X2-(Alk1)i4-COOEt (in the formula X2, Alk1, 14 and Et each has the same meaning as defined above) may be used in place of a compound of the formula (63).

Step K-2 In a similar manner to Step 1-4 of Process I, a compound of the formula (71) can be prepared from a compound of the formula (70). above Process la, the compounds of the present invention can be prepared from a compound of the formula (71) obtained in the above Step K-2.

Process L a compound of the formula (1) wherein R3 of the ring B, and R10 of the X are taken together to form In accordance with the Steps la-2, la-3 and la-4 of the The following is an example of the process for preparing 0 (wherein R4, 14 and Alk1 each has the same meaning as defined 25 above). 224 Process L R< 0 k y aV^NV H OH d-5) step L-l R6 W R* 0 0 —(AlkOu^^O—(Alk2)- R« R' (1-6) In the above reaction scheme, R1, R2, R4, R5, R6, R7, R8, R9, 14, m, ring A, ring C, Alk1 and Alk2 each has the same meaning as defined above.

Step L-l A compound of the formula (1-5) obtained by debenzylation of a compound (wherein R26 is benzyl) obtained in the Process 1 and the Process D is reacted with a phosgene equivalent reagent (for example, triphosgene or diphosgene, etc. ) in a solvent in 10 the presence of a base to give a compound of the formula (1-6).

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; halogenated 15 hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; and they can be used solely or in combination thereof. A preferred solvent in the present reaction is chloroform. 225 Examples of the bases used in the reaction include organic bases such as triethylamine, pyridine, dimethylaminopyridine, N-methylmorpholine, etc., among which triethylamine is preferred.

The reaction temperature is about -20°C to 100°C, preferably about 0°C to room temperature.

The reaction time is about 10 minutes to 4 hours, preferably about 30 minutes to 2 hours.

Process M The following is an example of the process for preparing a compound of the formula (1) wherein R10 is other than hydrogen. Process M aV^N-(CH2)t-C B VoukO.^O-R"- (6) X2— Rio' (72) step M-l ^Ay^N-(CH2)7r( B j— (AikO^o—R" (73) In the above reaction scheme, R1, R2, R3, R4, R23, 1, n, X2, ring A, ring B, and Alk1 each has the same meaning as defined above, and R10 is Ci-C6 alkyl or C3-C7 cycloalkyl).

Step M-l A compound of the formula (73) can be prepared by reacting 226 a compound of the formula (6) obtained in the Step 1-3 of Process 1 with a compound of the formula (72) in a solvent in the presence of a base.

The solvent used in the reaction includes, for example, 5 ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and polar solvents such as acetone, N,N-dimethylformamide, dimethyl 10 sulfoxide, etc.; and they can be used solely or in combination thereof. A preferred solvent in the present reaction is N,N-dimethylformamide.

Examples of the bases used in the reaction include alkali metal hydrides such as sodium hydride, potassium hydride, etc.; 15 alkali metal alkoxides such as sodium ethoxide, sodium methoxide, potassium t-butoxide, etc.; alkali metal carbonates such as sodium carbonate, potassium carbonate, etc.; alkali metal carboxylates such as sodium acetate, potassium acetate, etc.; and alkali metal phosphates such as sodium phosphate, 20 potassium phosphate, etc., among which sodium hydride is preferred.

The reaction temperature is about 0°C to 100°C, preferably about room temperature to 80°C.

The reaction time is about 1 hour to 24 hours, preferably 25 about 2 hours to 8 hours.

In accordance with the above Steps 1-4 and 1-5, the compounds of the present invention can be prepared from a compound of the formula (73) obtained in the above Step M-l. 227 Process N The following is an example of the process for preparing a compound of the formula (1) wherein R8 and R9 are each -CONH(R19 ) (wherein R19 is Ci~C6 alkyl).

Process N ru-n cooh —x y—ci (76) 8s<; \ nh ■2SX. - ^E>v., — 0 0 R 25 step N-l step N-2 (74) (75) (77) step N-3 (78) In the above reaction scheme, R5, R6, R7, R25 and ring C each has the same meaning as defined above.

Step N-l A compound of the formula (75) can be prepared by reacting a compound of the formula (74) with thionyl chloride or oxalyl chloride in a solvent.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 15 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; and esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and they 20 can be used solely or in combination thereof. A preferred 228 solvent used in the present reaction is toluene containing a catalytic amount of N,N-dimethylformamide.

The reaction temperature is about room temperature to 120°C, preferably about 50°C to 100°C.

The reaction time is about 10 minutes to 6 hours, preferably about 30 minutes to 3 hours.

Step N-2 A compound of the formula (77) can be prepared by reacting a compound of the formula (75) with a compound of the formula (76) in a solvent in the presence of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; and esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and they can be used solely or in combination thereof. Preferred solvents in the present reaction are methylene chloride or tetrahydrofuran.

Examples of the bases used in the reaction include organic bases such as triethylamine, pyridine, dimethylaminopyridine, N-methylmorpholine, etc., among which triethylamine is preferred.

The reaction temperature is about -40°C to 60°C, preferably about -30°C to room temperature.

The reaction time is about 2 hours to 48 hours, preferably about 6 hours to 24 hours.

Step N-3 229 A compound of the formula (78) can be prepared by reacting a compound of the formula (77) with paraformaldehyde or formalin without or in a solvent in the presence of a catalytic amount of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon 10 tetrachloride, 1,2-dichloroethane, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc.; esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, etc.; and they can be used solely or in combination 15 thereof. A preferred solvent in the present reaction is tetrahydrofuran.

Examples of the bases used in the reaction include alkali metal hydrides such as sodium hydride, potassium hydride, etc.; alkali metal alkoxides such as sodium ethoxide, sodium 20 methoxide, potassium t-butoxide, etc.; alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, lithium hydroxide, etc.; alkali metal carbonates such as sodium carbonate, potassium carbonate, etc.; and organic bases such as triethylamine, diethylamine, pyridine, etc., among which 25 potassium t-butoxide, sodium ethoxide or potassium hydroxide is preferred.

The reaction temperature is about 0°C to 100°C, preferably about room temperature to 80°C.

The reaction time is about 10 minutes to 24 hours. 230 preferably about 30 minutes to 12 hours.

In accordance with the above Processes 1, la and 2, the compounds of the present invention can be prepared using a compound of the formula (78) obtained in the above Step N-3 in 5 place of a compound of the formula (8).

Process O The following is an example of the process for preparing a compound of the formula (1) wherein R8 and R9 are each -COOR25 10 (wherein R25 is Ci-C6 alkyl).

Process O o ;^>ro — R7"^-—' V \ step 0-1 0 R25 (79) (80) In the above reaction scheme, R5, R6, R7, R25 and ring C each has the same meaning as defined above.

Step O-l In a similar manner to Step N-3 of Process N, a compound of the formula (80) can be prepared from a compound of the formula (79) .

In accordance with the above Processes 1, la and 2, the compounds of the present invention can be prepared using a 20 compound of the formula (80) obtained in the above Step 0-1 in place of a compound of the formula (8).

Process P The following is an example of the process for preparing 231 a compound of the formula (1) wherein m is 2 or 3. In this process, tert-butyldimethylsilyl (TBS) may be used in place of benzyl (Bn).

Process P X—(CH2)m — OBn (82) —- R^£xTyAcH> -°Bn R7-^—S R9 step P-1 (81) R9 (83) /R! RB-PC W-(CH2)m —OH step P-2 (84) In the above reaction scheme, R5, R6, R7, R8, R9, X2, m, Bn and ring C each has the same meaning as defined above. Step P-1 A compound of the formula (83) can be prepared by reacting a compound of the formula (81) with a compound of the formula 10 (82) in a solvent in the presence of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; halogenated 15 hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc.; esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and polar solvents such as N,N-dimethylformamide, dimethyl 20 sulfoxide, etc.; and they can be used solely or in combination 232 thereof. Preferred solvents in the present reaction are N,N-dimethylformamide or tetrahydrofuran.

Examples of the bases used in the reaction include alkali metal hydrides such as sodium hydride, potassium hydride, etc. ; alkali metal alkoxides such as sodium ethoxide, sodium methoxide, potassium t-butoxide, etc.; alkali metal carbonates such as sodium carbonate, potassium carbonate, etc.; and organoalkali metals such as lithium diisopropylamide, etc., among which sodium hydride or lithium diisopropylamide is 10 preferred.

The reaction temperature is about 0°C to 100°C, preferably about room temperature to 80°C The reaction time is about 30 minutes to 48 hours, preferably about 2 hours to 24 hours.

Step P-2 In a similar manner to Step 2-2 of Process 2, a compound of the formula (84) can be prepared from a compound of the formula (83) .

In accordance with the above Processes 1, la and 2, the 20 compounds of the present invention can be prepared using a compound of the formula (84) obtained in the above Step P-2 in place of a compound of the formula (8).

Examples The present invention is illustrated in more detail by Examples given below, but it goes without saying that the present invention is not limited thereto. In the Examples, Me is methyl, Et is ethyl, tBu is t-butyl and TBS is tert-butylmethylsilyl. 233 Example 1 4-[(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]phenyl-acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester a) phenylmalonic acid dichloride COOH COCI [f^V^COOH f^f^C0C\ [II ^ Thionyl chloride (13. 7 mL) was added dropwise to a mixture of phenylmalonic acid (11.31 g), dimethylformamide (230 jxL) and toluene (27 mL) under ice-cooling. The mixture was 10 stirred at 80°C for 70 minutes, and the solvent was removed off by evaporation. After azeotropic distillation with toluene, the residue was dried in vacuo to give the title compound (11.61 g). b) Phenylmalonic acid diethylamide H COCI 0 Of''"" O 1 To a mixed solution of ethylamine in tetrahydrofuran (2M, 45.5 mL), triethylamine (l3.9mL) and methylene chloride (80 mL) was dropwise added the phenylmalonic acid dichloride (8.99 g) obtained in Example 1-a) at -20°C. The mixture was stirred 20 overnight while the temperature was raised to room temperature, and then diluted with ethyl acetate after addition of 3N hydrochloric acid. The organic layer was washed with saturated brine, saturated aqueous sodium bicarbonate and 234 saturated brine, dried over sodium sulfate and concentrated. The resulting solid was washed with ethyl acetate and hexane to give the title compound (4.85 g) as a white powder, c) 2-Hydroxymethyl-2-phenylmalonic acid diethylamide h OyN. -oh The phenylmalonic acid diethylamide (2.34 g) obtained in Example 1-b) and paraformamide (390 mg) were suspended in tetrahydrofuran (20 ml), and to this suspension was added potassium hydroxide (catalytic amount) at 60°C. The mixture was stirred for 5 hours and concentrated to remove the solvent. The residue was chromatographed on a column of silica gel with ethyl acetate:hexane=l:1 to give the title compound (2.31 g). d) 4'-Trifluoromethylbiphenyl-2-carboxylic acid chloride CF, To a mixture of 4' -trifluoromethylbiphenyl-2-carboxylic acid (5.06 g), dimethylformamide (catalytic amount) and methylene chloride (30 mL) was added dropwise oxalyl chloride (2.43 mL) under ice-cooling. The mixture was stirred at room temperature for 100 minutes and the solvent was removed by evaporation. After azeotropic distillation with toluene, the residue was dried in vacuo to give the title compound (5.40 g). 235 e) 4-[(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]phenyl-acetic acid ethyl ester + ci h2n 0^- 0^/ To a mixture of 4-aminophenylacetic acid ethyl ester (3.41 g), triethylamine (3.2 mL) and methylene chloride (30 mL) was added dropwise a solution of the 4' -trifluoromethylbiphenyl-2-carboxylic acid chloride (5.40 g) obtained in Example 1-d) in methylene chloride (10 mL) under ice-cooling, and the mixture was stirred at room temperature overnight. After addition of IN hydrochloric acid, the reaction mixture was diluted with ethyl acetate, and the organic layer was washed with saturated brine, saturated aqueous sodium bicarbonate and saturated brine, dried over sodium sulfate, and then concentrated to give the title compound (8.12 g). f) 4 — [(4 *-Trifluoromethylbiphenyl-2-carbonyl)amino]phenyl-acetic acid The 4-[(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]phenylacetic acid ethyl ester (8.12 g) obtained in Example 1-e) was dissolved in 40 mL of tetrahydrofuran and 20 mL of ethanol. After addition of 4N sodium hydroxide (5 mL), 236 the solution was stirred at room temperature for 5 hours and concentrated. The powder formed upon addition of IN hydrochloric acid was collected by filtration and dried in vacuo to give the title compound (7.48 g). g) 4-[(4'-Trifluoromethylbiphenyl-2-carbonyl) amino]phenyl-acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester cf, '.XTT h oh The 4-[(4'-Trifluoromethylbiphenyl-2-carbonyl) amino ]pheny lace tic acid (519 mg) obtained in Example 10 1-f), the 2-hydroxymethyl-2-phenylmalonic aid diethylamide (317 mg) obtained in Example 1-c), dimethylaminopyridine (171 mg) and l-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (WSC.HC1)(268 mg) were dissolved in methylene chloride (5 ml) . The solution was stirred at room temperature 15 for 6 hours and the solvent was removed off by evaporation. The residue was purified by column chromatography on silica gel with ethyl acetate:hexane=l: 1 to 3:2 to give the title compound (725 mg)(see Table 1).

Example 1-2 237 2-Phenyl-2-{2-[4-(4'-trifluoromethylbiphenyl-2-carbonyloxy)phenyl]acetoxymethyl}malonic acid diethyl ester a) 2-Hydroxymethyl-2-phenylmalonic acid diethyl ester Paraformaldehyde (720 mg) was suspended in phenylmalonic acid diethyl ester (4.73 g), and a catalytic amount of potassium hydroxide was added thereto at 60°C. After stirring for 1.5 hours, the reaction mixture was purified by column chromatography on silica gel with ethyl acetate :hexane=l: 5 to 1:2 to give the title compound (4.96 g). b) 2-[2-(4-(Benzyloxyphenyl)acetoxymethyl]-2-phenylmalonic acid diethyl ester 4-Benzyloxyphenylacetic acid (1.09 g) was suspended in methylene chloride (50 mL) and the suspension was dissolved by addition of dimethylaminopyridine (0.511 g). To the solution was added the 2-hydroxymethyl-2-phenylmalonic acid diethyl ester (1.20 g) obtained in Example 1-2 a), and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (0.864 g) was portionwise added thereto. The mixture was stirred at room temperature overnight and then 238 concentrated. The residue was purified by column chromatography on silica gel with ethyl acetate :hexane=l: 4 to give the title compound (1.95 g) as a colorless oil. c) 2-[2-(4-(Hydroxyphenyl)acetoxymethyl]-2-phenylmalonic acid diethyl ester ho £To o The 2-[2-(4-(Benzyloxyphenyl)acetoxymethyl]-2-phenylmalonic acid diethyl ester (1.95 g) obtained in Example 1-2 b) was dissolved in methanol (2.5 mL). The solution was subjected 10 to hydrogenation in the presence of 7.5% palladium-carbon (0.200 g) under normal pressure for 4 hours. The reaction solution was filtered through a Celite pad and concentrated to give the title compound (1.71 g) as a colorless oil. d) 2-Phenyl-2-{2-[4-(4'-trifluoromethylbiphenyl-2-15 carbonyloxy)phenyl]acetoxymethyl}malonic acid diethyl ester HO k jOY o*S>°"A k 4'-Trifluoromethylbiphenyl-2-carboxylic acid (0.266 g) was suspended in methylene chloride (10 mL), and the suspension was dissolved by addition of 4-dimethylaminopyridine (0.122 g). To the solution was added the 239 2 -[2-(4-(hydroxyphenyl)acetoxymethyl]-2-phenylmalonic acid diethyl ester (0.400 g) obtained in Example 1-2 c), and 1-ethyl-3-(3'- dimethylaminopropyl)carbodiimide hydrochloride (0.192 g) was portionwise added thereto. The mixture was stirred at room temperature overnight and then concentrated. The residue was purified by column chromatography on silica gel with ethyl acetate :hexane=l: 3 to give the title compound (0.55 g) as an amorphous powder (see Table 1).

Example 1-3 2-(2-{3-Methyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetoxymethyl)-2-phenylmalonic acid diethyl ester a) 2-(3-Methyl-4-nitrophenyl)malonic acid diethyl ester .COOEt COOEt COOEt rj^^V^COOEt o^-V °'N T ' ie »• Sodium hydride (60% mineral oil; 0.599 g) was suspended in dimethylformamide (10 mL), and a solution of malonic acid diethyl ester (2.00 g) in dimethylformamide (10 mL) was added 20 dropwise thereto under ice-cooling. After foam generation is stopped, a solution of 4-fluoro-2-methylnitrobenzene (1.94 g) in dimethylformamide (5 mL) was added thereto, and the reaction temperature was raised to 100°C, followed by stirring for 6 hours. The reaction mixture was concentrated, acidified with IN 25 hydrochloric acid and extracted with ethyl acetate. The extract was washed successively with water and saturated brine. 240 dried over sodium sulfate and concentrated. The residue was purified by column chromatography on silica gel with ethyl acetate:hexane=l:5 to give the title compound (1.65 g) as a yellow oil. b) (3-Methyl-4-nitrophenyl)acetic acid COOEt (fYj"C00Et (f^Y^COOH V Me Me o2n Potassium hydroxide (0.168 g) was dissolved in 7 mL of methanol and 1 mL of water, and the 2-(3-methyl-4-nitrophenyl)malonic acid diethyl ester (0.250 g) obtained in 10 Example 1-3 a) was dissolved in the solution. The solution was stirred at 100°C for 2 hours and concentrated. The residue was acidified with 2N hydrochloric acid and extracted with ethyl acetate. The extract was washed with saturated brine, dried over sodium sulfate and concentrated to give the title compound 15 (0.143 g) as a yellow solid. c) 2-[2-(3-Methyl-4-nitrophenyl)acetoxymethyl]-2-phenyl- t malonic acid diethyl ester o 02N^f 2 T I Me ^ The (3-Methyl-4-nitrophenyl)acetic acid (0.143 g) obtained in Example 1-3 b) was dissolved in methylene chloride (5 mL). To the solution were added 2-(3-methyl-4-nitrophenyl)malonic acid diethyl ester (0.195 241 g) obtained in Example 1-2 a), 4-dimethylaminopyridine (0.090 g) and 1-ethyl-3-(3 ' - dimethylaminopropyl)carbodiimide hydrochloride (0.141 g), and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated and the residue was purified by column chromatography on silica gel with ethyl acetate:hexane=l:4 to give the title compound (0.219 g) as a yellow oil. d) 2-[2-(4-Amino-3-methylphenyl)acetoxymethyl]-2-phenyl-malonic acid diethyl ester The 2-[2-(3-Methyl-4-nitrophenyl}acetoxymethyl]-2-phenyl-malonic acid diethyl ester (0.219 g) obtained in Example 1-3 c) was dissolved in methanol (3 mL) . The solution was subjected to hydrogenation in the presence of 7.5% palladium-carbon (0.030 g) under normal pressure to give the title compound (0.197 g) as a yellow oil. e) 2-(2-{3-Methyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetoxymethyl)-2-phenylmalonic acid diethyl ester 242 rw N 0 0_X Me k In a similar manner to Example 1 d), 4'-trifluoromethyl -2 -biphenylcarboxylic acid (0.124 g) was converted into its corresponding acid chloride. On the other hand, the title compound (0.215 g) was obtained as a colorless amorphous from the 2-[2-(4-amino-3-methylphenyl)acetoxymethyl]-2-phenylmalonic acid diethyl ester (0.197 g) obtained in Example 1-3 d) in a similar manner to Example 1 e)(see Table 1).

Example 1-4 2-(2-{4-[Methyl-(4'-trifluoromethylbiphenyl-2- carbonyl)amino]phenyl}acetoxymethyl)-2-phenylmalonic acid diethyl ester a) {4-[Methyl-(4'-trifluoromethylbiphenyl-2-15 carbonyl)amino]phenyl}acetic acid ethyl ester CF' f3 .0 - XJUOHr" H U i ch3 Sodium hydride (51 mg) was dissolved in dimethylformamide (5 mL), and the solution was cooled to 0°C. To the solution was added the 4-[(4'-trifluoromethylbiphenyl-2- 243 carbonyl)amino]phenylacetic acid ethyl ester (500 mg) obtained in Example 1 e), and the mixture was stirred for one hour. After addition of iodomethane (183 mg), the mixture was stirred at room temperature for 3 hours and water was then added.

The reaction solution was concentrated, diluted with ethyl acetate, and washed with water. The resulting solution was dried over sodium sulfate and purified by column chromatography on silica gel with hexane: ethyl acetate=4:l to give the title compound (141 mg). b) 2-(2-{4- [Methyl-(4 ' -trif luoromethylbiphenyl^- carbony^aminolphenyljacetoxymethyl) -2-phenylmalonic acid diethyl ester The {4-[Methyl-(4 '-trifluoromethylbiphenyl^- carbonyljaminolphenyljacetic acid ethyl ester (141 mg) obtained in Example 1-4 a) was subjected to reactions similar to those in Examples If) and 1 g) to give the title compound (56 mg)(see Table 1).

Example 1-5 {3-Ethyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester 25 a) 3-Ethyl-4-nitrophenylacetic acid ethyl ester 244 CO-Et CO.Et To a solution of 4-nitrophenylacetic acid ethyl ester (1. 63 g) in tetrahydrofuran (100 mL) was dropwise added 2M ethyl magnesium chloride in tetrahydrofuran (3 mL) at -15°C under argon atmosphere, and the mixture was stirred at the same temperature for 30 minutes. After further dropwise addition of 2M ethyl magnesium chloride in tetrahydrofuran (3 mL), the mixture was stirred at -15°C for one hour, and 2 ,3-dichloro-5, 6-dicyano-1,4-benzoquinone (3.0 g) was added thereto at the same temperature. The mixture was stirred overnight, and water (300 mL) was added thereto, followed by extraction with chloroform (150 mL x 3). The organic layers were combined, washed with saturated brine, dried over sodium sulfate and purified by column chromatography on silica gel with hexane:ethyl acetate=10:l to give the title compound (1.09 g). b) {3-Ethyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester The 3-ethyl-4-nitrophenylacetic acid ethyl ester (1.05 g) obtained in Example 1-5 a) was subjected to reactions similar to those in Example 1-3 d), Example 1 e) , Example If) and Example 245 1 9) to give the title compound (1.60 g)(see Table 1). a Examples 1-6 to 1-83 Compounds of Examples 1-6 to 1-85 were obtained in a similar manner to Examples 1 to 1-5. The compounds obtained were shown in Tables 2 to 17. 246 Table 1 Example Structure /S kiu " ^ O O NH CH, m.p. 88.4-91.2 NMR (8. 300MHz,CDC13) 1.05(6H, t, J=7.3Hz), 3.18-3.29(4H, m), 3.53(2H, S), 4.83(2H, s), 6.95(1H, br-s), 7.02-7.23(8H, m) , 7.27-7.36(3H, m), 7.41-7.47(1H, m) , 7.49-7.63(4H, m) , 7.65-7.72(2H, m), 7.77-7.84(1H, m) 1-2 8 J CH, 1.19(6H, t, J=9.2Hz), 3.53(2H, s), 4.18(4H, J=9.2Hz), 4.82(2H, s) 6.79(2H, d, J=12Hz), 7.14(2H, d, J=12Hz), 7.29(5H, brs), 7.38-7.73(7H, m), 8.09(1H, dd, J=1.2Hz, J=7.5Hz). 1-3 J CH3 1.21(6H, t, J=7.1Hz), 1.67(3H, s). 3.47(2H, s), 4 . 20(4H, q, J=7.1Hz), 4.82(2H, s), 6.89((1H, brs), 6.92(1H, brs), 7.00(1H, d, J=10.6Hz), 7.30(5H, brs), 7.42-7.84( 9H, m). 1-4 1.22(6H, t, J=7.2Hz), 3.23(3H, s), 3.40(2H, s), 4.21(4H, q, J=7.2Hz), 4.83(2H, s), 6.10(2H, d.

J=8.3Hz) J=8.3Hz) m) 6.70(2H, d, 7.07-7.61(13H, 1-5 ® ° NH ^CH, 0.93(3H, t, J=7.5Hz), 1.05(6H, t, J=7.3Hz), 1. 94(2H, q, J=7.5Hz), 3.13-3.28(4H, m), 3.53(2H, s), 4.83(2H, s), 6. 80-7.84(19H, m) m.p. 105-109 247 Table 2 Example Structure NMR (6,300MHZ,CDC13) 1-6 3.56(2H, s), 3.65-3.78(2H, s), 4.55(2H, s), 5.49(1H, br), 7.01(1H, brs), 7.05-7.83(20H, m). 1-7 1.39(3H, d, J=7.2Hz), 3.48-3.68(2H, m), 3 . 70-3.89(2H, m), 4.44(1H, d, J=10.6Hz), 4.66(1H, d, J=10.6Hz), 5.46(1H, br), 6.96((1H, brs), 7.02-7•84(20H, m). 1-8 3.50(2H, S), 3.68-4.00(3H, m), 4.42(1H, dd. J=6.0, ll.OHz), 4.62(1H, dd, J=7.9,ll.OHz), 5.68(1H, t, J=6.8Hz), 6.95(1H, s), 7.03-7.17(4H, m), 7 .17-7.36(5H, m), 7.44(1H, dd, J=1.5, 7.6Hz), 7.48-7.64(4H, m), 7.65-7.71(2H, m), 7.80(1H, dd, J=1.5, 7.6Hz) 1-9 1.20(6H, t, J=7.2Hz), 3.51(2H, s), 4.20(4H, q, J=7.2Hz), 4.81(2H, s), 6.92(1H, br-s), 7 .04-7.18(4H, m), 7.24-7.35(5H, m), 7.44(1H, dd, J=1.5, 7.1Hz), 7 . 48-7.64(4H, m), 7. 65-7.73(2H, m), 7.81(1H, dd, J=1.5, 7.1Hz) 1-10 F F 1.47-1.76(6H, m), 1.90-2.03(2H, m), 3.60(2H1 s), 3.71-3.85(2H, m), 4.10(2H, S), 6.94(1H, br-s), 7.12-7.20(4H, m), 7.44(1H, dd, J=1.2, 7.4Hz), 7 .49-7.64(4H, m), 7 . 65-7.72(2H, m), 7.80(1H, dd, J=1.2, 7.4Hz) H U Q O o o m UO % * H X X rH X •*? * x PC rH s X rH PC cm * *-*» co pc cm X rH co rH co N c.

J- x N X Tf N X o VO rH O 00 r» on on <""S O 00 X X E s rH 00 * cm m X rH H G r^ in - rH 00 N N cm • • e* r- co • E vo rH X n * co r- X co "e in pc pc »w VO vo vo w rr X II rH © o II II in o * * «. «-s •» » * •» „ rH cm «w rH M * • * co * % % • • 00 »"3 pc y»^S N rs. pc s N r- ov vo ^-s s N • Xi co pc [•s *"N o"N vo vo « y in E £ E pc cm E E E £ X • • rH E e E E X r* g « o\ E E E E (N U e E a E a h II % «• hs w rH ro CO w m co VO • cm II % cj1 • « W m •"3 «P +J i cm « % • r- * * « % • r> * •i •» % • n s % VO % * % «• * % 0« ft „ ro X X pc * Ik o X X X pc X X pc X r- o * co PC pc pc pc 00 «» pc pc s pc re * <D a) <■*»» • rH cm <•—s pc • vo cm m w rH cm \ rH H X U 00 m ro cm • pc H cm rH 'd *d co co co co r^ w w * co <N w s«^ w w « to CO o w w s«>« w «.

+J w w 0} xi w w w co 0) rH *—• W r- co cm m w o r* cm in « in VO co rH m rH co w co rH O ' rH r- co cm ro « * * * «. r- VO r- • «, o cm TT VO 1^ • « r- ro VO r- • % 00 m co * oo VO on cm * cm vo r- 00 pc PC PC X X (m • • • rH X 00 o • • • • rH X X • t « • rH PC « • rH X s • • • • r- X on • • • • • vo vo cm H h rH • r- II cm • • r- r^ II (N cm % r- r- r- II vo H cm • cm r- rH rH rH • cm • r* r- r- w «W •w <w w r- *-> w <e* r- <WK> <*>/ t^S w s«« i co w VO i 00 o o 00 00 cm H on m ro on rH on m h iH co cm iH on m o on O 00 on r- VO on r- o o on m r-» rH <N m o o <J\ * VO * in % o co *r VO in 00 cm Tf vo cm cm rr rH co cm r- o •» H vo r^ • • • • « • n»—> • • • ■d • • • • • •0 • • m • • • • •d • • • • • • • • • • • • • • • rH h co in in vo E r- r* »d ro e CO r> r^ 'd co r- t3 rH rH cm co r- rH rH rH CO a r- r- <D U 3 +J o S3 H •P 03 01 iH a K « CO rH I rH I m rH 249 Table 4 Example Structure NMR (8, 300MHz, CDC13) 1-16 F^ c >Fu rr^0^o°^cH3 m.p. 93-95 1.22(6H, t, J=7.2Hz), 3.57(2H, s), 4.21(4H, q, J=7.2Hz), 4.83(2H, s), 7.20(IH, d, J=8.5Hz), 7.28-7.67(12H, m), 7.76(IH, d, J=7.4) 1-17 0 0 °^rH m.p. 99-103 1.20(6H, t, J=7.1Hz), 3.53(2H, s), 4.19{4H, q, J=7.1Hz), 4.82(2H, s), 6.91(IH, d. J=8.3Hz), 7.11-7.56(16H, m), 8.33(IH, dd, 3=7.8, 1.8Hz), 9.62(IH, br.s) 1-18 H3C ix xrr [f^| H ^CH, 1.05(3H, m), 1.22(6H, t, J=7.2Hz), 1.58(2H, m), 1.99(2H, m), 3.57(2H, s), 4.21(6H, m), 4.85(2H, s), 7. 04-7.60(12H, m), 8.30(IH, m), 10.07(IH, br.s) 1-19 c 9, 1.22(6H, t, J=6.9Hz), 3.60(2H, s), 4.20(4H, q, J=6.9Hz), 4.85(2H, s), 7.12-7.37(9H, m), 7.63-7.73(2H, m), 7.79-7.86(IH, m), 7.90-8.00(IH, m). 1-20 n 9/ "Txcrr^ **c 1.18(6H, t, J=6.8Hz), 3.51(2H, s), 4.17(4H, q, J=6.8Hz), 4.80(2H, s), 6.70(2H, d, J=12Hz), 7.09(2H, d, J=12Hz), 7.27(5H, brs), 7.41-7.83(8H, m), 8.21(IH, d, J=10Hz). 250 Table 5 Example Structure NMR (8, 300MHz,CDCI3) 1-21 1.18(6H, t, J=7.2Hz), 3.49(2H, s), 4.15{4H, J=7.2Hz), 4.80(2H, s) 7.07(IH, d, J=8.6Hz), 7.27-7.54(17H, m), 7.88(IH, d, J=6.2Hz) q» 1-22 1.16-1.83(20H, m), 3.50(2H, S), 4.80-4.91(2H, m), 4.82{2H, s), 6.93(1H, br-s), 7.05-7.17(4H, m), 7.27-7.34(5H, m), 7.41-7.47(IH, m), 7.49-7.63(4H, m). 7.65-7.72(2H, m), 7.80(1H, dd, J=1.5, 7.2Hz) 1-23 0 CK^NH^ O 0.95-1.22(6H, m), 1.23-1.43(4H, m), 1.50-1.71(6H, m), 1.71-1.90(4H, m). 3.52(2H, s), 3.69-3.83(2H, m), 4.84(2H, s), 6.95(IH, br-s), 7.04-7.35(11H, m), 7.41-7.48(IH, m). 7.49-7.65(4H, m), 7.66-7.73(2H, m), 7.77-7.84(IH, m) 1-24 cAnhH^_/ 3.58(2H, S), 5.06(2H, s), 6.81(IH, br-s), 6.99-7.05(4H, m), 7 .08-7 .16 (2H, ni), 7.24-7.47(14H, m), 7.50-7.67(6H, m), 7.80(1H, dd, J=1.5, 7.5Hz), 9.08(2H, br-s) 1-25 1.04(6H, d, J=6.4Hz), 1.09(6H, d, J=6.8Hz), 3.52(2H, s), 3.95-4.09(2H, m), 4.83(2H, s), 6.92-7.03(3H, m), 7.03-7.10(2H, m), 7.11-7.23(4H, m), 7.27-7.36(3H, m), 7.41-7.47(IH, m), 7.49-7.64(4H, m), 7.65-7.72(2H, m), 7.80(1H, dd, J=1.5, 7.5Hz) V Q U o o ro «© (N co 3 00 oo — a N CN a -- rH ON • m r- .

M ro »-s ■p co X X vo <n •w «w on rH <N vo -I 0 - > n- (f) *—>, rs r- « U a a ii VO >"D h * a a <^S MO d1 co --h w ' w oo ro - « ro cm oo a a o\ • • ■*j" in • r- w w vo i i in N H on h ro • h n h ro ^ ^ E r- 2C N CM X <— rl rH • lO r* • ii co i"3 co U n a a -h rH ^ • r- t- oo ii • i-j vo see ■p co o1 — N O a a a ro in oo a a vo ro rH •<* (S rH a a •>* CM ON O rH 00 ■>* in ro oo rh cm u1 vo p- Is- ro E S S E S E ^ a co <n « r-~ a oo cm • v— T* vo in ■> a a CM 1" <w w ro o\ OO rH • • vo i i m m t- o ffl « vo CO o ^ vO • • r- i i ov CM Tf X X co h W »"■»» co cn rH • • r- oo i i cm m vo o ro gvor^r^r-r^oo S <«—s g ^E 6 E EE CO » * «a * * > a a a cm a a a CM CM CM rH rH rH CM w w w w w W w o\ oo vo h vo r» o h m vo o oo •••••« • vo r** r* i*- i*- oo i i i i i i H r| rl ^ Is ^ * P- O H CM in 0\ co 6 ^ Is h> c-" Is Is X cs CM VO • CO a £ » » cm cm 4J w w O 00 « vo 00 w • • ro h h in vo r- e£ W • ^ vo w II I- "D ON • « CO -M I o\ - r- X • CM CO W oo * o X CM VO •i £ a . vo * CM <-» • 0) - o X «-H CM • w h- o C\ * O H rH W g re vo Ov ,^-s N a a w o as w oo m h H vo 00 ^ in • • • rH r- H i i rH 00 co ^ - • • r- r» >0 0) M 3 +J 0 p u ■p CO VO (1) rH £> ft) Eh (0 H a u VO cn I rH r-(n I CO cn O. 21 O- JZ.2 o ^ n=/ o u.

OS cn I 0 m 1 252 Table 7 Example Structure NMR (5,300MHz,CDCI3) 1-31 0. 97-1.10(6H, m), 1.12(6H, t, J=6.8Hz), 1.54-1.78(4H, m), 2.05-2.17(IH, m), 3.54(2H, s), 4.13(4H, q, J=6.8Hz), 4.50(2H, s), 6.93(1H, brs), 7.14(4H, brs). 7.40-7.82(8H, m). 1-32 3.51(2H, s). 3.85(4H, m), 4.86(2H, s), 6.88(IH, s), 7.00-7.54(19H, m), 7.89(IH, m) 1-33 3.56(2H, s), 3.84(4H, m), 4.86(2H, s), 6.91(IH, d, J=8.3Hz), 7.07-7.55(18H, m), 8.32(IH, dd, 3=1.9, 1.9Hz), 9.64(IH, s) 1-34 1.23(6H, t, 3=1.1Hz), 3.70(2H,s), 4.22(4H, t, 3=1.1Hz), 4.81(2H, s), 7.02(IH, brs). 7.13-7.97(16H, m). 1-35 m.p. 100.5-104.0 0.85(6H, t, J=7.5Hz), 1.37-1.51(4H, m), 3.13-3.22(4H, m), 3.53(2H, s). 4.84(2H, s), 6.96(IH, br-s), 7.02-7.09(2H, m), 7.10-7.24(6H, m), 7.27-7.35(3H, m), 7.41-7.47(1H, m), 7.49-7.63(4H, m), 7.65-7.72(2H, m), 7.80(1H, dd, J=1.6, 8.0Hz) 253 Table 8 Example Structure NMR (5, 300MHz,CDCI3) 1-36 X N—CH, o cr^HH 2. s) br 7. 7. 7. 7. 7. J= 73(6H, d, J-, 4.81(2H, -s), 7.01-7 11-7.21(4H, 27-7.35(3H, 41-7.47(IH, 49-7.63(4H, 66-7.72(2H, 1.5, 7.5Hz) 4.9Hz), 3.53(2H, S), 6.94(IH, .09(4H, m), m), m), m) , m) , m). 7.81(1H, dd. 1-37 1. s) 4. 7. 7. 7. 7. 7. J= m) (6H, t. J= , 4.21(4H, 90(2H, s), 04-7.15(4H, 15-7.21(IH, 38-7.47(2H, 49-7.64(5H, 66-7.72(2H, 1.5, 7.5Hz) 7.0Hz), 3.50(2H, q, J=7.0Hz), 6.93(IH, br-s), m), m) , m) , m), m), 7.81 (IH, dd, , 8.46-8.51(IH, 1-38 1.22(6H, t, J=7.2Hz), 3.51(2H, s), 4.21(4H, q, J=7.2Hz), 4.82(2H, s), 6.98(IH, br-s), 7.03-7.17(4H,m), 7.22(1H, dd, J=5.0, 8.5Hz), 7.41-7.47(IH, m), 7.48-7.63(5H, m) , 7.64-7.72(2H, m), 7.77-7.83(IH, m), 8.50-8.57(2H, m) 1-39 ij CT^NH^ V CH, 1.04(6H, t, J=7.4Hz), 3.16-3.29(4H, m), 3.55(2H, s), 4.84(2H, s), 6.75-6.83(2H, m), 7.04-7.14(4H, m), 7.17-7.22(2H, m), 7.27-7.35(3H, m), 7.41(1H, dd, J=l.l, 7.6Hz), 7.47-7.54(2H, m), 7.56(IH, dd, J=1.5, 7.6Hz), 7.61-7.72(3H, m), 8.08(IH, dd, J=l.l, 7.6Hz) 1-40 1.20(6H, t, J=7.1Hz), 3.55(2H, s), 4.21(4H, q, J=7.1Hz), 4.84(2H, s), 7.20-7.77(16H, m), 8.16(IH, br) 254 Table 9 Example Structure NMR (8,300MHz,CDC13) 1-41 h3c—\ Iff ? V H^F 1.01(3H, t, J=7.2Hz), 1.60(2H, m), 1.96(2H, m), 3.59(2H, s). 3.84(4H, m), 4.21(2H, t, J=6.5Hz), 4.89(2H, s), 7.00(IH, d. J=8.3Hz), 7.09-7.16(5H, m), 7.32-7.58(8H, m), 8.26(1H, dd, J=8.0, 1.9Hz), 10.07(IH, br.s) 1-42 x a £ucnr^ qt - ^ 0.88(6H, t, J=7.1Hz), 1.19-1.34(4H, m), 1.35-1.48(4H, m), 3.16-3.26(4H, m) , 3.52(2H, S), 4.84(2H, s), 6.95(IH, br-s), 7.02-7.23(8H, m), 7.27-7.36(3H, m). 7.40-7.47(lH, m). 7.49-7.63(4H, m), 7.64-7.73(2H, m). 7.81(IH, dd. J=1.5, 7.5Hz) 1-43 a CH I OOf ^ CH° ° o^o ch3 1.22(6H, t, J=7.1Hz), 3.58(2H, s), 4.22(4H, q, J=7.1Hz), 4.85(2H, s), 6.23(2H, d. J=8.5Hz), 7.30-7.73(10H, m), 7.87(2H, d, J=8.5Hz), 8.36(1H, dd, J=6.8, 2.3Hz), 12.3(IH, brs) 1-44 ch, 1.24(6H, t, J=7.1Hz) , 3.58(2H, s), 4.23(4H, q, J=7.1Hz), 4.27(2H, s), 4.85(2H, s), 7.22(2H, d, J=8.5Hz), 7.27-7.98(13H, m), 7.61(2H, d, J=8.5Hz) 1-45 $v?^b m.p. 175-177 1.05(6H, t, J=7.3Hz),1.69(3H, S), 3.14-3.30(4H, m), 3.49(2H,s), 4.83(2H, s), 6.77(IH, brs), 6.89(1H, brs), 6.92-7.85(17H, m). 255 Table 10 256 Table 11 Example Structure NMR (6, 300MHz,CDCI3) 1-51 1.03(6H, t. J=7.1Hz), 3.16-3.28(4H, m), 3.56(2H, s), 4.82(2H, s), 6.88-6.94(IH, m), 7.02-7.34(13H, m). 7.39-7.49(3H, m), 7.51-7.59(2H, m), 8.34(1H, dd. J=1.9, 7.9Hz), 9.63(IH, br-s) 1-52 1.05(3H, t, J=7.2Hz), 1.07(6H, t, J=7.2Hz), 1.54-1.68(2H, m), 1.92-2.05(2H, m), 3.19-3.31(4H, m), 3.58(2H, s), 4.23(2H, q, J=6.4Hz), 4.85(2H, s), 7.02(IH, d, J=8.3Hz), 7.06-7.38(10H, m), 7.44-7.53(IH, m), 7.57-7.65(2H, m), 8.30(1H, dd, J=1.9, 7.9Hz), 10.08(1H, br-s) 1-53 1.23(6H, t, J=7.1Hz), 3.53(2H, s), 4.23(4H, q, J=7.1Hz), 4.84(2H, s), 6•95(IH, brs), 7.10(2H, d, J=8.3Hz), 7.17(2H, d, J=8.3Hz), 7.32(5H, brs), 7.41-7.87(8H, m). 1-54 1.19(6H, t, J=7.1Hz), 3.50(2H, s), 4.16(2H, q, J=7.1Hz), 4.17(2H, q, J=7•1Hz), 4.80(2H, s), 6.89-7.90(17H, m) 1-55 AmmK-V CH, 1.05(6H, t, J=7.2Hz), 3.19-3.31(4H, m), 3.54(2H, s), 4.86(2H, s), 6.90(IH, d, J=8.3Hz), 7.02-7.11(3H, m), 7.16-7.23(2H, m), 7.25-7.36(4H, m), 7.41(1H, dd, J=1.2, 7.5Hz), 7.48-7.61(3H, m), 7.62-7.71(3H, m), 8.21(1H, dd, J=1.5, 7.5Hz) 257 Table 12 Example Structure NMR (5, 300MHz,CDC13) 1-56 a ifYi J cH> H3C 1.21(6H, t, J=7.1Hz), 3.51(2H, s), 4.20(4H, q, J=7.1Hz), 4.82(2H, S), 6.99-7.57(16H, m), 7.84(IH, d, J=7.2Hz). 1-57 /° UL^AnJU o T J H CH, 1.23(6H, t, J=7.2Hz), 3.57(2H, s), 4.22(4H, q, J=7.2Hz), 4.85(2H, s), 7.19-8.08(19H,m) 1-58 if °~"x (Vr 0 0 °^' 0.94(6H, d, J=6.8Hz),1.22(6H, t, J=7.1Hz), 3.40(2H, s), 4.20(4H, q, J=7.1Hz), 4.82(2H, s), 4.99(IH, m), 6.16(1H, br.s), 6.78(2H, d, J=8.6Hz), 7.08(IH, dd, J=8.6, 1.5Hz), 7.20-7.74(13H, m) 1-59 xjjcrr?^ ^6 0.89(4H, m), 1.22(6H, t, J=7.1Hz), 1.28-1.78(6H, m), 3.40(2H, s), 4.20(4H, q, J=7.1Hz), 4.62(IH, m), 4.82(2H, s), 6.15(IH, br.s), 6.75(2H, m), 7.06-7.74(14H,m) 1-60 z° H,C^CH, o i-< ^ T 0 rri L o cHj 0 °^ 1.23(6H, t, J=6.9Hz),1.28(6H, d, J=6.9Hz), 3.40(IH, sep, J=6.9Hz), 3.56(2H, s), 4.22(4H, q, J=6.9Hz), 4.84(2H, s), 7.12-7.61(14H, m) 258 "able 13 Example Structure NMR (8, 300MHz,CDCI3) 1-61 ,jcnr 1.22(6H, t, J=7.1Hz), 3.53(2H, s), 4.22(4H, q, J=7.1Hz), 4.23(2H, s), 4.83(2H, s), 6.98-7.61(19H, m) 1-62 0.86(6H, t, J=7.3Hz), 1. 50-1.69(4H, m), 3.50(2H, s), 4.10(4H, t, J=6.6Hz), 4.83(2H, s), 6.93(IH, brs), 7.08(2H, d, J=8.6Hz), 7.13(2H, d, J=8.6Hz), 7.29(5H, brs), 7.40-7.83(8H,m).

H,C 1-63 0.84(12H, d, J=6.6Hz), 1.80-1.97(2H, m), 3.50(2H, s), 3.92(4H, d, J=6.6Hz), 4.84(2H, s), 6.93(IH, brs), 7.08(2H, d, J=5.5Hz), 7.13(2H, d, J=5.5Hz), 7.29(5H, brs), 7.40-7.84(8H, m). h,c 1-64 1.22(6H, t, J=7.1Hz), 3.57(2H, s), 4.21(4H, q, J=7.1Hz), 4.84(2H, S), 7.21(2H, d, J=8.5Hz), 7.23-7.60(8H, m), 7.57(2H, d, J=8.5Hz), 8.09(1H, dd, J=7.8, 1.8Hz), 8.26(IH, brs) 1-65 0.84(3H, t, J=7.3Hz), 1.23(6H, t, J=7.1Hz), 1.23-1.46(2H, m), 1.50-1.69(2H,m), 3.55(2H, s), 4.23(4H, q, J=7.1Hz), 4.25(2H, q, J=6.7Hz), 4.84(2H, s), 7.19(2H, d, J=8.4Hz), 7.21-7.37(5H, m), 7.44-7.64(3H, m), 7.56(2H, d, J=8.4Hz), 7.64(IH, brs), 7.95(IH, d, J=7.6Hz) 259 Table 14 Example Structure NMR (5, 300MHz,CDCI3) 1-66 0. 1. 2. 4. 7. 7. 7. 7. 7. 7. J= 84(12H, d, 63-1.79(2H, 97-3.15(4H, 86(2H, S), 01-7.08(2H, 10-7. 25 (6H, 27-7.36(3H, 40-7.47(IH, 48-7.63(4H, 64-7.72(2H, 1.5, 8.0Hz) J=6.8Hz), m), m), 3.52(2H, s) , 6.94(IH, br-s), m), m), m), m), m), m), 7.80(IH, dd. 1-67 H J CH, HjC CH, 0. 1. 1. 3. 4. 7. 7. 7. 7. 7. J= 87(12H, d, 27-1.38(4H, 46-1.61(2H, 18-3.28(4H, 84(2H, s), 01-7.22(8H, 27-7.35(3H, 41-7.47(IH, 49-7.63(4H, 65-7.72(2H, 1.5, 7.5Hz) J=6.8Hz), m), m), m), 3.52(2H, s), 6.94(IH, br-s), m), m), m), m), m), 7.80(IH, dd. 1-68 1. t, 3. q. 6. d, J= m) 07(3H, t, J= 3=1.1Hz), 72(2H, q, J=7.1Hz), 14(2H, d, J= J=8.3Hz), 9.1, 1.5Hz) 7.2Hz),1.22(6H, 3.40(2H, s), 7.2Hz), 4.20(4H, 4.83(2H, s), 8.3Hz), 6.74(2H, 7.07(IH, dd, , 7.23-7.61(12H, 1-69 1.09(6H, t, 3=1.1Hz), 1. 26-1.50 (6H, m), 1.81(4H,m), 2.99(IH, m), 3.26(4H, dq, 3=1.1, 7.1Hz), 3.59(2H, s), 4.85(2H, s), 7.10-7.42(14H, m) , 7.56(2H, d, J=8.3Hz) 1-70 Amu h^\ CH, 1.05(6H, t, 3=1.2Hz), 3.18-3.30(4H, m), 3.53(2H, s), 4.83(2H, s), 6.93(IH, br-s), 7.02-7.23(8H, m), 7.27-7.36(3H, m), 7.37-7.45(5H, m), 7.45-7.59(2H, m), 7.80(1H, dd, J-l.l. 7.5Hz) 260 Table 15 Example Structure NMR (6, 300MHz,CDCI3) 1-71 CH, 1.05(6H, t, J=7.2Hz), 3.18-3.30(4H, m), 3.54(2H, s) , 4.84(2H, s), 7.02-7.14(5H, m) , 7.17-7.35(8H, m), 7.37-7.62(5H, m), 7.74(1H, dd, J=1.5, 7.5Hz) 1-72 m.p. 126.4-127.8 0.85(6H, t, J=7.5Hz), 1.44(4H, tq, J=7.5, 7.5Hz), 1.68(3H, s), 3.12-3.22(4H, m), 3.49(2H, s), 4.85(2H, s), 6.77(IH, br-s), 6.87-6.92(IH, m), 6.94-7.01(IH, m), 7.11-7.25(4H, m), 7.27-7.36(3H, m), 7.40-7.47(IH, m), 7.50-7.73(6H, m), 7.75-7.85(2H, m) 1-73 ,xrr^ 3.29(6H, s), 3.36-3.48(8H, m) , 3.53(2H, s), 4.85(2H, s), 6.97(IH, br-s). 7.04-7.18(4H, m), 7.19-7.40(8H. m). 7.41-7.47(IH, m), 7.49-7.64(4H, m), 7.66-7.73(2H, m), 7.77-7.84(IH, m) 1-74 1.22(6H, t, J=7.1Hz), 2.78(3H, s), 3.52(2H, s), 4.21(4H, q, J=7.1Hz), 4.82(2H, s), 7.11(2H, d, J=8.5Hz), 7.19(2H, d, J=8.5Hz), 7.20-7.35(6H, m), 7.77(2H, d, J=8.3Hz), 7.86(2H, d, J=8.3Hz) 1-75 1.06(6H, t, J=7.3Hz), 2.78(3H, s) , 3.20-3.29(4H, m), 3.55(2H, s), 4.84(2H, s), 6.98-7.34(12H,m), 7.77(2H, d, J=8.3Hz), 7.86(2H, d, J=8.3Hz) 261 Table 16 Example Structure NMR (8, 300MHz,CDCI3) 1-76 1.06(6H, t, J=7.3Hz), 3.19-3.28(4H,m), 3.54(2H, s) , 4.83(2H, s), 6.99-7.48(13H, m), 7.71(2H, d. J=8.2Hz), 7.86(2H, d, J=8.2Hz), 8.05-8.13(IH, m), 8.75-8.84(IH, m) 1-77 1.06(6H, t, J=7.2Hz), 1.64(3H, s). 3.12-3.33(4H, m), 3.51(2H. S), 4.84(2H, s), 6.84(IH, brs), 6.91(IH, brs), 6.98-7.98(12H, m), 8.16(1H, d, J=8.1Hz), 8.84(IH, d, J=4.4Hz). 1-78 0.92(3H, t, J=7.5Hz), 1.20(6H, t, J=7.1Hz), 1.94(2H, q, J=7.5Hz), 3.50(2H, s), 4.20(4H, q, J=7.1Hz), 4.82(2H, s), 6.79-7.83(17H, m) s? o o o \chj 1-79 0.96(6H, d, J=6.6Hz), 1.05(6H, t, J=7.1Hz), 2.15(IH, sep, J=6.6Hz), 3.19-3.29(4H, m), 3.54(2H, S), 4.83(2H, s), 6.81-7.84(19H, m) HSC CH, 1-80 0.96(6H, d, J=6.8Hz),1.20(6H, t, J=7.1Hz), 2.16(IH, sep, J=6.8Hz), 4.20(4H, q, J=7.1Hz), 4.82(2H, s), 6.79-7.82(17H, m) 262 Table 17 Example Structure NMR (5,300MHz,CDCI3) 1-81 0•95(3H, t, J=7.7Hz),1.13(6H, t, J=7.2Hz), 1.99(2H, q, J=7.7Hz), 2.54(2H, t, J=7.9Hz), 3.20-3.38(4H, m), 3.53(2H, s), 4.11(2H, t, J=7.9Hz), 6.79-7.84(19H, m) NH NH ^CH, c£H3 V m.p. 147-158 1-82 0 0 NH ^CH, 0.72(6H, d, J=6.6Hz), 1.06(6H, t, J=7.2Hz), 1.26- 1.44(IH, m), 1.89(2H, d, J=7.3Hz). 3.20-3.27(4H, m), 3.52(2H, s), 4.83(2H, s), 6.82-7.88(19H, m) CH, 1-83 0.71(6H, d, J=6.5Hz) , 1.21(6H, t. J=7.1Hz), 1.26-1.43(IH, m) , 1.88(2H, d, J=7.3Hz), 3.49(2H, s), 4.21(4H, q, J=7.1Hz), 4.83(2H, s), 6.79-7.87(17H, m) 1-84 1.21(6H, t, J=7.2Hz), 3.48(2H, s), 4.22(4H, q, J=7.2Hz), 4.83(2H, s), 7.08(IH, d, J=8.7Hz), 7.12(IH, S), 7.25-7.67(13H, m), 7.84(1H, dd. J=1.5, 7.5Hz), 8.37(IH, d, J=8.7Hz) 1-85 1.21(6H, t, J=7.1Hz), 3.48(2H, s), 4.22(4H, q, J=7.1Hz), 4.83(2H, s), 7.13(IH, d, J=7.9Hz), 7.28-7.67(14H, m). 7.82(IH, dd, J=1.5, 7.5Hz), 8.35(IH, d, J=8.7Hz) 263 Example 2 {3-Dlmethylcarbamoyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester a) 5-Chloro-N,N-dimethyl-2-nitrobenzamide The acid chloride obtained from 5-chloro-2-nitrobenzoic acid (5.0 g) in a similar manner to Example 1 d) was subjected to reactions similar to those in Example 1 e) to give the title compound (5.5 g). b) 2-(3-Dimethylcarbamoyl-4-nitrophenyl)malonic acid tert-butyl ester methyl ester Sodium hydride (350 mg) was dissolved in dimethylformamide (10 mL), and the solution was cooled to 0°C. After addition of tert-butyl methyl malonate (1.52 g), the mixture was stirred for one hour, and the 5-chloro-N,N-dimethyl-2-nitrobenzamide (1.0 g) obtained in Example 2 a) was added thereto. The mixture was stirred at 70°C for 4 .5 hours and water was added thereto. The resulting solution was concentrated, diluted with ethyl acetate and washed with water. The organic layer was dried over sodium sulfate and purified by column chromatography on silica gel with ethyl COOH CO.tBu 264 acetate:hexane=l:1 to give the title compound (1.29 g). c) (3-Dimethylcarbamoyl-4-nitrophenyl)acetic acid methyl ester The 2-(3-dimethylcarbamoyl-4-nitrophenyl)malonic acid tert-butyl ester methyl ester (1.22 g) obtained in Example 2 b) was dissolved in dichloromethane (10 mL), and the solution was cooled to 0°C. After addition of trifluoroacetic acid (10 10 mL), the mixture was stirred at room temperature for 6 hours, and concentrated, followed by azeotropic distillation with toluene. The residue was purified by column chromatography on silica gel with ethyl acetate:hexane=3:1 to give the title compound (712 mg). 15 d) (4-Amino-3-dimethylcarbamoylphenyl)acetic acid methyl ester The (3-dimethylcarbamoyl-4-nitrophenyl)acetic acid methyl ester (683 mg) obtained in Example 2 c) was subjected 20 to reactions similar to those in Example 1-3 d) to give the title compound (627 mg). e) {3-Dimethylcarbamoyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetic acid 265 CF C02Me J H M ^ Me2N^0 OH The (4-amino-3-dimethylcarbamoylphenyl)acetic acid methyl ester (627 mg) obtained in Example 2 d) was subjected to reactions similar to those in Example 1 e) and Example If) to give the title compound (1.07 g)(see Table 65). f) {3-Dimethylcarbamoyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester biphenyl-2-carbonyl)amino]phenyl}acetic acid (517 mg) obtained in Example 2 e) was subjected to reactions similar to those in Example 1 g) to give the title compound (387 mg)(see Table 18).

The {3-Dimethylcarbamoyl-4-[(4'-trifluoromethyl- 266 Examples 2-2 to 2-119 Compounds of Examples 2-2 to 2-119 were obtained in a similar manner to Example 2. The compounds thus obtained were shown in Tables 18 to 41. In addition, compound of Example 2-17 e) was obtained in a similar manner to Example 2 e) and the compounds thus obtained were shown in Table 65. 267 Table 18 Example Structure NMR (5, 300MHz,CDCI3) 1.07(6H, t, J=7.2Hz), 2.85(3H, br.s), 2.95(3H, br.s), 3.26(4H, dq, 3=1.2. 7.2Hz), 3.54(2H, s), 4.84(2H, S), 7.04-7.68(17H, m), 8.37(IH, d, J=8.3Hz), 9.16(IH, br.s) 2-2 u'lrx-^eH, 0.86(6H, t, 3=1.2Hz), 1.46(4H, tq, 3=1.2, 7.2Hz), 2.85(3H, br.s), 2.95(3H, br.s), 3.19(4H, dt, J=7.2, 7.2Hz), 3.54(2H, s), 4.85(2H, S), 7.03-7.68(17H, m), 8.37(IH, d, J=8.7Hz), 9.17(IH, br.s) 2-3 I.07(6H, t. J=7.1Hz), 2.83(3H, d, J=4.5 Hz), 3.24(4H, dq, J=7.1, 7.1Hz), 3.59(2H, s), 4.80(2H, s). 7.10-7.76(18H, m), 8.53(IH, d, J=8.3Hz), II.55(IH, br.s) 2-4 1.12(6H, t, 3=1.3Hz), 2.53(2H, t, 3=1.7Hz), 2.86(3H, brs), 2.95(3H, brs), 3.20-3.40(4H, m), 3.54(2H, S), 4.12(2H, t, 3=1.7Hz), 7.09(IH, brs), 7.17-7.75(14H, m), 8.36(IH, d, J=8.4Hz), 9.24(IH, brs). m.p. 128-129 2-5 1.21(6H, t, J=7.1Hz), 2.81(3H, brs), 2.92(3H,brs), 3.50(2H, s), 4.20(4H, q, J=7.1Hz), 4.82(2H, s), 6.99(IH, brs), 7.17-7.71(14H, m), 8.33(IH, d, J=8.5Hz), 9.14(IH, brs). m.p. 114-116 268 Table 19 Example Structure NMR (5, 300MHz ,CDC13) 2-6 0.98(6H, t, 3=1.3Hz), 3.12(4H, dq, J=7.3, 7.3Hz), 3.58(2H, s), 4.50(2H, d, J=5.9Hz), 4.79(2H, s), 7.01-7.59(16H, m), 7.72(IH, dd, J=7.0, 1.8Hz), 8.23(IH, m), 8.51(IH, d, J=8.5Hz), 11.49(IH, br.s) 2-7 1.07(6H, t, J=7.3Hz), 1.66(2H, m), 2.28(2H, m), 2.87(3H, br.s), 2.93(3H, br.s), 3.24(4H, dq, 3=1.3, 1.3Hz), 3.57(2H, s), 4.11(2H, t, J=6.9Hz), 7.13-7.66(17H, m), 8.36(IH, d, J=8.4Hz), 9.08(IH, br.s) 2-8 1.08(6H, t, 3=1.2Hz), 0.98-1.21(6H, brd), 3.26(4H, dq, J=7.2, 7.2Hz), 3.12-3.51(4H, brd), 3.56(2H, S), 4.84(2H, s), 7.06-7.63(17H, m), 8.21(IH, d, J=8.7Hz), 8.88(IH, s) 2-9 1.07(6H, t, 3=1.1Hz), 0.93-1.59(6H, brd), 3.26(4H, dq, 3=1.2, 7.2Hz), 3.56(2H, s), 3.41-3.95(2H, brd), 4.84(2H, s),7.01-7.62(17H, m), 8.08(IH, d, J=8.3Hz), 8.70(IH, br.s) m.p. 108-117 2-10 1.21(6H, t, 3=1.1Hz), 0.95-1.27(6H, brd), 3.08-3.49(4H, brd), 3.52(2H, s), 4.21(4H, q, 3=1.1Hz), 4.83(2H, s),7.06(1H, d, J=1.9Hz), 7.19(IH, dd, J=8.7,1.9Hz), 7.31-7.63(13H, m), 8.19(IH, d, J=8.7Hz), 8.90(IH, br.s) 269 Table 20 Example Structure NMR (6, 300MHz ,CDC13) 2-11 1.21(6H, t, J=7.1Hz), 1.00-1.52(12H, brd), 3.52(2H, s), 3.49-3.92(2H, brd), 4.20(4H, q, J=7.1Hz), 4.82(2H, S), 7.02(IH, d, J=1.9Hz), 7.17(IH, dd, J=8.4, 1.9Hz), 7.31-7.64(13H, m), 8.06(1H, d, J=8.4Hz), 8.72(IH, br.s) 2-12 NH CH, 1.01-1.21(6H, m), 1.07(6H, t, J=7.3Hz), 2.78(3H, brs), 3.20-3.31(4H, m), 3.56(2H, s ), 3.82-4.27(IH, m), 4.84(2H, S), 6.99-7.63(17H, m), 8.19(IH, d, J=8.4Hz), 8.98(IH, br.s) 2-13 m.p.116.5-119.0 0.98-1.27(3H, br), 1.21(6H, t, J=7.1Hz), 2.73-2.96(3H, br), 3.05-3.49(2H, br), 3.51(2H, s), 4.21(4H, q, J=7.1Hz), 4.82(2H, s), 7.00-7.08(IH, m) , 7.19(IH, dd, J=1.9, 8.3Hz), 7.24-7.36(5H, m), 7.39(1H, dd, J-l.5, 7.9Hz), 7.43-7.70(7H, m), 8.28(IH, d, J=8.6Hz), 8.92-9.18(IH, br) 2-14 Anh H-\ CH, 1. 00-1.23(3H, br) J=7.2Hz), 2.79-2. 3.10-3.49(2H, br) dq, J=5.2, 7.2Hz) s), 4.84(2H, s), J=1.8Hz), 7.07-7. 7.15-7.24(3H, m), 7.28-7.37(3H, m), 7.37-7.43(IH, m), 7.44-7.69(7H, m), J=8.3Hz), 8.88-9. ,1.08(6H, t, 96(3H, br). , 3.26(4H, , 3.55(2H, 7.04(IH, d, 14(2H, m). 8.30(IH, d, 17(IH, br) 2-15 CH, 1.02-1.24(3H, br), 1.12(6H, t, J=7.2Hz), 2.47-2.59(2H, m), 2.80-2.96(3H, br), 3.10-3.51(2H, br), 3.30(4H, dq, J=5.7, 7.2Hz), 3.55(2H, s), 4.07-4.18(2H, m), 7.09(1H, d, J=1.5Hz), 7.22-7.43(7H, m), 7.43-7.70(9H, m), 8.28(1H, d, J=8.3Hz), 8.85-9.14(IH, br) 270 Table 21 Example Structure NMR (6, 300MHz.CDCI3) 2-16 1.07(6H, t, J=7.2Hz), 1.32-1.71(5H, br), 3.10-3.79(8H, m), 3.54(2H, s) , 4 . 84(2H, s), 7 . 03-7.79(15H, m), 8.28(IH, d, J=8.5Hz), 9.04(IH, brs). 2-17 1.07(6H, t, J=7.2Hz), 2.02-2.7 8(4H, br), 3.21-3.53(8H, m), 3.54(2H, m) , 4.84(2H, s), 7.03-7.72(15H, m), 8.34(IH, d, J=7.2Hz), 9.83(IH, brs).

^F 2-18 m.p. 106.8-109.4 0.65-1.01(3H, br), 1.21(6H, t. J=7.2Hz). 1.43-1.66(2H, br), 2.75-2.98(3H, br). 3.05-3.41(2H, br), 3.51(2H. s). 4.21(4H, q, J=7.2Hz), 4.82(2H, s), 7.04(IH, br-s), 7.19(1H, dd, J=1.9, 8.6Hz), 7.24-7.35(5H, m), 7.39(IH, dd, J=1.5. 7.5Hz). 7.43-7.69(7H,m), 8.18-8.31(IH. br), 8.94-9.18(lH, br) 2-19 O Qr^NH N Vh 1 CMa ^^CH, CH3 0.68-0.99(3H, br). 1.08(6H. t, J=7.1Hz), 1.42-1.69(2H, br), 2.79-2.98(3H, br). 3.06-3.42(2H, br). 3.26(4H, dq, J=5.6, 7.1Hz), 3.55(2H, s), 4.84(2H, s), 7.04(IH, d, J=1.8Hz), 7.11(2H, br-t, J=5.6Hz), 7.15-7.24(3H, m), 7.27-7.36(3H, m) , 7.37-7.43(IH, m), 7.44-7.69(7H, m). 8.21-8.35(IH, br), 8.92-9.18(IH, br) 2-20 0.67-1.00(3H, br), 1.13(6H, t, J=7.1Hz), 1.43-1.67(2H, br), 2.48-2.59(2H, m), 2.82-2.98(3H, br), 3.06-3.42(2H, br). 3.30(4H, dq. J=5.6, 7.1Hz). 3.54(2H, s). 4.07-4.17(2H, m), 7.09(1H, d, J=2.2Hz), 7.22-7.42(7H, m). 7.43-7.69(9H, m), 8.20-8.34(IH, br). 8.89-9.14(IH, br) 271 "able 22 Example Structure NMR (5,300MHz,CDCI3) 2-21 1.04(3H, t, J=7.2Hz), 2.84(3H, brs), 2.95(3H, brs), 3.16-3.29(2H, m), 3.50(2H, s), 3.64(IH, dd, 3=1.1, 6.5Hz), 3.91(IH, dd, J=10•9, 6.5Hz), 4.64(IH, dd, J=10.9, 7.7Hz), 5.28-5.38(IH, m), 7.00-7.71(15H, m), 8.34(1H, d, J=8.5Hz), 9.15(IH, brs) 2-22 1.21(6H, t, 3=1.1Hz), 1.73-2.00(4H, m), 3.22-3.53(4H, m), 3.51(2H, s), 4.20(4H, q, J=7.1Hz), 4.83(2H, s), 7.15-7.70(15H, m). 8.33(IH, d, J=8.9Hz), 9.84(1H, brs) . 2-23 1.21(6H, t, 3=1.1Hz), 1.35-1.70(6H, br), 3.00-3.76(4H, br), 3.51(2H, S), 4.20(4H, q, J=7.1Hz), 4.82(2H, s), 7.03(IH, d, 3=2.0Hz), 7.12-7.68(14H, m), 8.26(IH, d, J=8.5Hz), 9.06(1H, brs) . 2-24 1.11(3H, t, 3=1.6Hz), 2.19(2H, q, 3=1.6Hz), 2.84(3H, brs), 2.95(3H, brs). 3.54(2H, s), 4.28(IH, dd, J=ll.3, 4.9Hz), 4.41(IH, dd, J=ll.3, 7.0Hz), 5.25-5.33(IH, m), 5.87(1H, d, J=8.3Hz), 7.04-7.71(15H, m). 8.36(IH, d, J=8.5Hz), 9.14(1H, brs) 2-25 1.11(3H, t, 3=1.5Hz), 2.19(2H, q, J=7.5Hz), 2.84(3H, brs), 2.95(3H, brs), 3.54(2H, s), 4.29(IH, dd, J=ll.3, 4.9Hz), 4.41(IH, dd, J-11.3, 7.0Hz), 5.26-5.33(IH, m), 5.86(1H, d, J=7.9Hz), 7.04-7.71(15H, m), 8.36(IH, d, J=8.7Hz), 9.14(1H, brs) m.p. 95-98 272 Table 23 Example Structure NMR (5, 300MHz,CDCI3) 2-26 2.53(4H, s), 2.89(3H, brs), 2.96(3H, brs), 3.55(2H, s), 4.66(IH, dd, J=10.9, 5.3Hz), 5.10(IH, t, J=10.9Hz), 5.37(IH, dd, J=10.9,5.3Hz), 7.07-7.69(15H, m), 8.35(1H, d, J=8.7Hz), 9.17(IH, brs) m.p. 152-155 2-27 1.19(3H, t, J=7.2Hz), 2.70-3.01(6H, br), 3.41(2H, dq, J=5.6, 7.2Hz), 3.60(2H, s), 5.32(2H, s), 6.18(IH, br-t, J=5.6Hz), 7.04(1H, d, J=1.9Hz), 7.21-7.29(IH, m), 7.30-7.56(7H, m), 7.56-7.66(4H, m), 7.69(1H, dd, J=1.5, 7.1Hz), 8.35(IH, d, J=8.7Hz), 9.09(IH, br-s) 2-28 1.04(3H, t, J=7.1Hz), 2.70-3.00(6H, br), 3.22(2H, dq, J=5.7, 7.1Hz), 3.53(2H, s), 3.57(2H, s), 5.13(2H, s), .43-5.54(IH, br), 7.08(1H, d, J=1.9Hz), 7.21-7.43(6H, m), 7.44-7.66(6H, m), 7.69(IH, dd, J=1.5, 7.2Hz), 8.34(IH, d, J=8.6Hz), 9.10(1H, br-s) 2-29 1.26-1.68(6H, m), 2.61-3.00(6H, m), 2.93-3.12(IH, m), 3.58-4.01(IH, m), 4.28-5.03(3H, m), 7.09-8.32(17H, m) 9.14(IH, brs), 9.40-10.24(2H, m) 2-30 1.10(6H, t, J=7.3Hz), 3.06(6H, brs), 3.21-3.42(4H, m), 3.61(2H, S), 4.86(2H, s), 7.06-7.77(13H, m), 8.37(1H, d, J=8.5Hz), 9.21(1H, brs) 273 Table 24 Example Structure NMR (8, 300MHz , CDC13) 2-31 1.23(6H, t, J=7.1Hz), 2.98(3H, brs) 3.05(3H, brs), 4.22(4H, q, 3=1.1Hz), 4.85(2H, s), 7.11-7.75(11H, m), 8.35(1H, d, J=8.5Hz), 9.21(IH, brs) m.p 106-110 2-32 1.24(6H, t, J=7.2Hz), 2.61(2H, t, J=7.1Hz), 2.86(3H, br.s), 2.94(3H, br.s), 3.46(2H, s), 4.07(2H, t, J=7.1Hz), 4.23(4H, q, J=7.2Hz), 7.08(IH, d, J=1.9Hz), 7.23-7.68(14H, m), 8.36(IH, d, J=8.6Hz), 9.15(1H, br. s) 2-33 1.22(6H, t, J=7.2Hz), 2.83(3H, br.s), 2.9 4(3H, br.s), 3.51(2H, s), 4.21(4H, q, J=7.2Hz), 4.83(2H, s), 7.00-7.51(14H, m), 7.68(1H, dd, 3=1.6. 1.5Hz), 8.37(IH, d, J=8.3Hz), 8.93(IH, br.s) m.p. 125-128 2-34 1.22(6H, t, J=7.2Hz), 2.86(3H, br.s), 2.9 5(3H, br.s), 3.51(2H, s), 4.21(4H, q, 3=1.2Hz), 4.83(2H, s), 7.01(IH, d, 3=2.2Hz), 7.19-7.53(13H, m), 7.68(1H, dd, 3=1.6, 1.5Hz), 8.40(IH, d, J=8.3Hz), 9.01(IH, br.s) m.p. 124-128 2-35 1.96(3H, s), 2.84(3H, brs), 2.95(3H, brs), 3.54(2H, s), 4.29(IH, dd, J=ll.6, 5.0Hz), 4.39(IH, dd, J=ll.6, 7.1Hz), 5.23-5.33(IH, m), 5.90(1H, d, J=8.1Hz), 6.99-7.71(15H, m), 8.36(IH, d, J=8.5Hz), 9.14(1H, brs) 274 Table 25 Example Structure NMR (5. 300MHz, CDC13) 2-36 X 0? ° irw U " XA °\ O N ' CH, <*3 0.92(3H, t, J=7.4Hz), 1.56-1.68(2H,m), 2.14(2H, t, J=7.5Hz), 2.84(3H, brs), 2.95(3H, brs), 3.54(2H, s), 4.29(IH, dd, J=ll.4, 4.9Hz), 4.40(IH, dd, J=ll.4, 7.1Hz), 5.23-5.33(IH, m), 5.90(1H, d, J=8.1Hz), 7.05(IH, d, J=2.0Hz), 7.15-7.72(14H, m), 8.36(IH, d, J=8.5Hz), 9.15(1H, brs) 2-37 n S ^V° o rv^y0^ rY^K° X. ^cn, O N 3 1 CM, 2t NH k I NH CH, CH, 1.07(3H, t, J=7.3Hz), 1.08(3H, t, J=7.3Hz), 2.97(3H, s), 3.10(3H, s), 3.18-3.31(4H, m) , 3.59(2H, s), 4.87(2H, d, J=4.1Hz), 6.38(IH, d, J=8.2Hz), 6.92-7.64(18H, m), 7.83(IH, d, J=6.8Hz) 2-38 n ^ ^-V°» rVY0s/ I-VTT ° 0 kj H 0XN^, i CH, s k ° CH, CH, 1.21(6H, t, J=7.1Hz), 2.96(3H, s), 3.07(3H, S), 3.55(2H, d, J=2.1Hz), 4.19(2H, q, J=7.1Hz), 4.20(2H, q, J=7.1Hz), 4.82and4.89(2H, each d, J=11.2Hz), 6.36(1H, d, J=8.2Hz), 6.93-7.59(16H, m), 7.83(IH, d, J=6.8Hz) 2-39 i 8 oor ^ ch, AAnV 0 p U " X.CH, H»C ^ O N ' CH, m.p. 108.8-112.4 2.73-3.00(6H, br), 3.52(2H, s), 3.72(6H, s), 4.82(2H, s), 7.03(IH, d, J-l.9Hz), 7.16-7.36(6H, m), 7.40(1H, dd, J=1.5, 7.5Hz), 7.45-7.65(6H, m), 7.69(IH, dd, J-l.5, 7.2Hz), 8.35(1H, d, J=8.7Hz), 9.17(IH, br-s) 2-40 F^F 11Jf/Y^W rVVr 0 ^ <*k /CH- O N * m.p. 110-111 1.21(6H, t, J=7.1Hz), 1.31-1.60(6H, m), 1.67-1.82(2H, m), 2.40-2.57(IH, ,m), 2.88(3H, brs), 2.94(3H, brs), 3.53(2H, s), 4.14(4H, q, J=7.1Hz), 4.48(2H, s), 7.09(IH, d, J-1.8HZ), 7.21-7.72(9H, m), 8.37(IH, d, J=8.4Hz), 9.16(1H, brs) . 275 Table 26 Example Structure NMR (5,300MHz,CDC13) 2-41 0.95-1.19(6H, m), 1.21(6H, t, J=9.5Hz), 1.60-1.80(4H, m), 2.00-2.18(IH, m), 2.88(3H, brs), 2.95(3H, brs), 3.52(2H, s), 4.14(4H, q, J=9.5Hz), 4.50(2H, s), 7.09 (IH, d, J=2.7Hz), 7.19-7.73(9H, m), 8.38(IH, d, J=ll.3Hz), 9.18(IH, brs). m.p. 108-110 2-42 1.22(6H, t, J=7.2Hz), 2.84(3H, br.s), 2.94(3H, br.s), 3.51(2H, s), 4.21(4H, q, J=7.2Hz), 4.83(2H, s), 7.01(IH, d, J=1.9Hz), 7.20(IH, dd,J=8.7, 1.9Hz), 7.26-7.51(12H, m), 7.68(1H, dd, J=7.5, 1.5Hz), 8.40(1H, d, J=8.7Hz), 9.00(IH, br.s) m.p. 121-124 2-43 1.21(6H, t, J=7.2Hz), 2.57(3H, s), 2.75(3H, br.s), 2.94(3H, br.s), 3.50(2H, s), 4.20(4H, q, J=7.2Hz), 4.82(2H, s), 7.00(IH, d, J=1.9Hz), 7.18(IH, dd, J=8.6, 1.9Hz), 7.26-7.59(11H, m), 7.70(1H, dd, J=7.6, 1.5Hz), 7.95(IH, d, J=8.3Hz), 8.35(IH, d, J=8.6Hz), 9.13(IH, br.s) 2-44 1.07(6H, t, J=7.3Hz), 2.76(3H, S), 2.86(3H, S), 3.21-3.30(4H, m), 3.57(2H, s), 4.83(2H, s), 6.82(IH, d, J=8.3Hz), 6.98-7.45(16H, m), 8.24(1H, dd, J=7.8, 1.8Hz), 8.44(IH, d, J=8.5Hz), 10.4(IH, brs) 2-45 1.22(6H, t, J=7.1Hz), 2.75(3H, S), 2.82(3H, s), 3.54(2H, s), 4.21(4H, q, 3-1.1Hz), 4.83(2H, s), 6.82(IH, d, J=7.6Hz), 7.05(IH, d, 3=2.0Hz), 7.09-7.46(13H, m), 8.24(1H, dd, 3=1.8, 1.8Hz), 8.42(IH, d, J=8.5Hz), 10.4(IH, brs) 276 Table 27 Example Structure NMR (8, 300MHz, CDC13) 2-46 1.22(6H, t, J=7.2Hz), 2.90(3H, br.s), 2.97(3H, br.s), 3.52(2H, s). 4.21(4H, q, J=7.2Hz), 4.83(2H, s), 7.05(IH, d, J=1.9Hz), 7.20(1H, dd,J=8.7, 1.9Hz), 7.29-7.73(13H, m) , 8.33(1H, d, J=8.7Hz), 9.27(IH, br.s) 2-47 1.21(6H, t, J=7.2Hz), 2.44(3H, s), 2.77(3H, br.s), 2.91(3H, br.s), 3.50(2H, s), 4.20(4H, q, J=7.2Hz), 4.82(2H, s). 7.01(IH, d, J=2.2Hz), 7.19(1H, dd,J=8.7, 2.2Hz), 7.30-7.59(12H,m) , 8.35(1H, d, J=8.7Hz), 9.08(IH, br.s) 2-48 1.21(6H, t, J=7.1Hz), 2.44(3H, s), 2.80(3H, br.s), 2.94(3H, br.s), 3.50(2H, s), 4.20(4H, q, J=7.1Hz), 4.82(2H, s), 7.02(IH, d, J=2.2Hz), 7.16-7.30(8H, m), 7.56-7.63(5H, m), 8.35(1H, d, J=8.7Hz), 9.14(IH, br.s) m.p. 105-108 2-49 2.65(3H, s), 2.86(3H, brs), 2.95(3H, brs), 3.61(2H, s), 4.23-4.30(2H, m), 4.71-4.79(1H,m), 4.98((1H, d, J=7.1Hz), 7.09(IH, d, J=1.9Hz), 7.18-7.71(14H, m), 8.37(IH, d, J=8.7Hz), 9.16(1H, brs) 2-50 1.19(3H, t, J=7.1Hz), 2.86(3H, brs), 2.95(3H, brs), 3.52(2H, s), 3.89(IH, dd, J=9.1, 6.0Hz), 4.02-4.19(2H, m), 4.34(IH, dd, J=10.9, 6.0Hz), 4.58(1H, dd, J=10.9, 9.1Hz), 7.06(1H, d, J=2.3Hz), 7.18-7.71(14H, m), 8.36(1H, d, J=8.6Hz), 9.17(IH, brs) 277 Table 28 Example Structure NMR (5,300MHz.CDCI3) 2-51 1.12-1.18(3H, m). 2.21-2.46(2H, m), 2.64-3.49(9H. m). 3.55-3.58(2H, m), 4.45-5.29(2H, m), 6.11-6.19(1H, m), 7.12-7.70(15H, m), 8.33-8.38(IH, m), 9.17(1H, brs) Conformer 2-52 1.24(6H, t, J=7.0Hz), 1.50-1.64(2H, m), 2.25-2.36<2H, m), 2.77-3•02(6H, br) , 3.54(2H, s). 3.99-4.08(2H, m), 4.16-4.29(4H, m), 7.10(1H. d. J=1.9Hz), 7.24-7.43(7H, m). 7.44-7.57(2H, m) , 7.59-7.64(4H, m), 7.68(1H, dd. J=1.5. 7.2Hz), 8.36(IH, d. J=8.7Hz). 9.16(1H. s) 2-53 1.21(6H, t. J=7.0Hz), 2.82(3H, br.s). 2.95(3H, br.s). 3.50(2H, S). 3.88(3H, s). 4.21(4H, q, J=7.0Hz), 4.82(2H, s). 6.87(1H. d. J=2.6Hz), 6.99(IH, dd.J=8.5, 2.6Hz), 7.03(IH, d, J=1.8Hz). 7.18(IH, dd. J=8.5, 1.8Hz), 7.29-7.69(10H, m). 8.35(1H. d. J=8.8Hz). 9.17(IH, br.s) 2-54 1.21(6H, t, J=7.0Hz), 2.81(3H. br.s), 2.94(3H, br.s), 3.51(2H, s), 4.20(4H, q, J=7.0Hz), 4.83(2H, s), 7.04(IH, d, J-2.2Hz), 7.19(1H, dd,J=8.4, 2.2Hz), 7.30-7.66(12H, m), 8.33(1H, d, J=8.5Hz), 9.29(IH, br.s) 2-55 "N' CHj mp 102-105 1.20(6H, t, J=7.1Hz), 2.11(3H, s), 2.88(3H. brs). 3.04(3H, brs), 3.48(2H,s), 4.19(4H, q, J=7.1Hz), 4.81(2H, s), 7.04(IH, d. J=2.0Hz), 7.12(IH, dd. J=2.0Hz, J=8.5Hz), 7 .24-7 .50(10H, m), 7.60(2H, d, J=8.1Hz), 8.10(IH, d. J-8.5Hz), 9.06(IH, brs). 278 [■able 29 Example Structure NMR (8, 300MHz, CDCI3) 2-56 2.81(3H, brs), 2.93(3H, brs). 3.52(2H,s), 4.45-4.60(4H, m), 4.88(2H, s), 7•02(IH, d, J=2.0Hz), 7.19(IH, dd, J=2.0Hz, J=8.7Hz), 7.23-7.64(12H, m), 7.68(1H, dd, J=2.0Hz, J=8.1Hz), 8.34(IH, d, J=8.1Hz), 9.10(IH, brs). 2-57 N I ^ mp 116.5-119.5 1.21(6H, t, J=7.1Hz), 2.95(3H, brs), 3.01(3H, brs), 3.52(2H, s), 4.21(4H, q. J=7.1Hz), 4.83(2H, s), 7.10(IH, s), 7.14-7.63(12H, m), 7.75((1H, d, J=6.6Hz), 8.22(IH, d, J=8.7Hz), 9.34(IH, brs). 2-58 1.23(6H, t, J=7.1Hz), 2.85(6H, br-s), 3.55(2H, s), 4.22(4H, q, J=7.1Hz), 4.83(2H, s), 7.03((IH, d, J=7.6Hz), 7.24-7.74(13H, m), 8.36(1H, d, J=12.2Hz), 9.45(IH, br-s). mp 119-121 2-59 1.22(6H, t, 3=1.1Hz), 2.87(3H, s), 2.96(3H, s), 3.51(2H, s), 4.22(4H, q, J=7.1Hz), 4.85(2H, s), 7.06(IH, brs), 7.25-7.68(14H, m), 7.77(1H, d, J=7.1Hz). 2-60 1.22(6H, t, 3=1.1Hz), 2.86(3H, brs), 2.95(3H, s), 3.50(2H, S). 4.22(4H, q, J=7.1Hz), 4.85(2H, s), 7.00(1H, d, J=1.5Hz), 7.20-7.66(13H, m), 7.73(1H, dd, J=1.5Hz, J=7.1Hz), 7.97(IH, brs). 279 rable 30 Example Structure NMR (5, 300MHz, CDC13) 2-61 X l jfXY rVSiV 0 ^ i C". mp 131-133 1.21(6H, t, J=7.2Hz), 2.88(3H, brs), 2.97(3H, brs). 3.52(2H, s). 4 .20(4H, q. J=7.2Hz), 4.83(2H, s), 7.07(IH, d. J=2.2Hz), 7.18-7.72(13H, m), 8.33(IH, d. J=8.4Hz), 9.33(1H. brs). 2-62 N^P xi jonr^* Js. o 0 \ frYj ^CH, cA^ CH. mp 120-125 1.21(6H. t, J=7.1Hz) , 2.87(3H, brs). 2.96(3H, brs), 3.52(2H, s). 4 .21(4H, q, J=7.1Hz), 4.83(2H, s), 7.07(IH, d, J=1.8Hz), 7.17-7.72(13H, ra), 8.32(IH, d, J=8.4Hz). 9.32(1H, br-s). 2-63 fj®.

T ! /L .A^ o o \ n N V._.

H CH, -CH, ^ O'^N 3 CH, 1.22(6H, t. J=7.2Hz), 2.83(3H, brs). 2.94(3H, brs). 3.48(2H, s), 4.23(4H, q. J=7.21Hz). 4.94(2H, s), 6.98(IH, d, J=1.9Hz), 7.12-7.76(10H, m), 8.30(IH, d. J=8.3Hz), 8.38(1H, dd. J=2.6Hz, J=8.9Hz), 9.08(1H, brs), 9.22(1H, d, J=2.6Hz). 2-64 ■n x i rrY"5A A. /"x. J o o \ if \ H ^CH, ^CH, o Y CH. 1.21(6H, t, J=7.2Hz), 2.83(3H, brs), 2.94(3H, brs). 3.48(2H, s). 3.49(IH, brs). 3.71(1H, brs). 4.20(4H, q. J=7.2Hz), 4.88(2H, s), 6.83(IH, dd, J=3.0Hz, J=8.3Hz), 7.03(IH, d. J=1.9Hz), 7•11-7.72(10H, m). 7.83(IH. d, J=3.1Hz), 8.25(IH, d. J=8.6Hz), 9.14(IH, brs). 2-65 0 0 °^CH, 11 XJ S cT~0V ^ (11 K J ^CH, W cA^' <*> mp 149-155 1.21(6H, t. J=7.2Hz), 2.83(3H, brs). 2.93(3H, brs). 3.49{2H. s), 4.21(4H, q, J=7.2Hz), 4.93(2H, s), 7.03(IH, d. J=1.9Hz), 7.13-7.73(12H, m), 8.33(1H. d, J=8.6Hz). 8.47(1H, d. J=3.8Hz), 9.17(IH. brs). 280 fable 31 Example Structure NMR (5, 300MHz , CDC13) 2-66 1.23(6H, t, J=7.2Hz), 2.88(3H, s), 2.97(3H, s), 3.61(2H, s), 4.23(4H, q, J=7.2Hz), 4.85(2H, s), 7.03(IH, d, J=7.1Hz), 7.23-7.68(12H, m), 7.74(1H, dd, J=1.1Hz, J=7.5Hz). 7.84(IH, brs). 2-67 S? 0 O o CH, 1,23(6H, t, J=7.2Hz), 2.88(3H, s), 2.96(3H, s), 3.62(2H, s), 4.23(4H, q, J=7.2Hz), 4.85(2H, s), 7.09(IH, d, J=7.5Hz), 7. 24-7.68(12H, m), 7.74-7.80(2H, m). 2-68 1.22(6H, t, J=7.2Hz), 2.26(3H, s), 2.84(3H, brs), 2.95(3H, brs), 3.48(2H, s), 4.10-4.61(4H, m), 4.88(2H, s), 6.99-7.73(14H, m), 8.43(1H, d, J=8.3Hz), 9.18(IH, brs). 2-69 1.21(6H, t, J=7.2Hz), 2.32(3H, s), 2.81(3H, brs), 2.93(3H, brs), 3.51(2H, s), 4.20(4H, q, J=7.2Hz), 4.81(2H, s), 7.01-7.74(14H, m), 8.36(1H, d, J=8.3Hz), 9.19(IH, br-s). 2-70 o O p 1.21(6H, t, J=7.2Hz), 2.33(3H, s), 2.82(3H, brs), 2.94(3H, brs), 3.51(2H, s), 4.20(4H, q, J=7.2Hz), 4.81(2H, s), 7.01-7.74(14H, m), 8.35(1H, d, J=8.3Hz), 9.19(IH, brs). 281 Table 32 Example Structure NMR (5,300MHz,CDCI3) 2-71 1.24(6H, t, J=7.2Hz), 2.84(3H, br-s), 2.95(3H, brs), 3.44(2H, s), 4.12-4.35(4H, ,m), 4.94(2H, s), 7.00(IH, d, 3=2.2Hz), 7.05-7.73(13H, m) , 8.31(IH, d, J=8.3Hz), 9.19(IH, brs) . 2-72 CH, mp 122.2-125.0 1.22(6H, t, 3=7.1Hz), 2.81(3H, brs), 2.94(3H, brs), 3.51(2H, s), 4.21(4H, q, J=7.1Hz), 4.80(2H, s), 7.03(IH, d, J=2.2Hz), 7.14-7.64(12H, m) , 7.70(IH, dd, J=1.6Hz, J=7.2Hz), 8.36(1H, d, J=8.6Hz), 9.19(IH, brs). 2-73 1.21(6H, t, J=7.2Hz), 2.80(3H, brs), 2.94(3H, brs), 3.50(2H, s), 4.20(4H, q, J=7.2Hz), 4.80(2H, s), 7.02(IH, d, J=2.3Hz), 7.18-7.71(13H, m) , 8.36(IH, d, J=8.3Hz), 9.18(1H, brs) .

CH, mp 132.0-134.4 2-74 1.16(3H, t, J=7.0Hz), 1.18(3H, t,J=7.2Hz), 2.82(3H, brs), 2.93(3H,brs), 3.04(1H, d, J=16.5Hz), 3.20(H, d, J=16.5Hz), 3.46(2H, s), 4.04-4.20(4H, m), 4.75(lH,d,J=11.4Hz), 4.82(lH,d,J=11.4Hz), 6.98(1H, d, 3=2.2Hz), 7 .11-7.72(14H, m), 8.34(IH, d, J=8.8Hz), 9.17(IH, brs). 2-75 1.22(6H, t, 3=7.1Hz), 2.84(3H, brs). 2.94(3H, brs), 3.44(2H, s), 3.74(3H, s), 4.22(4H, q, J=7.1Hz), 4.81(2H, s), 6.84-7.71(14H, m), 8.32(1H, d, J=8.7Hz), 9.18(1H, brs). 282 Table 33 Example Structure NMR (8, 300MHz,CDCI3) 2-76 1.21(6H, t, J=7.1Hz), 2.82(3H, brs), 2.94(3H, brs), 3.51(2H, s), 3.77(3H, s), 4.20(4H, q. J=7.1Hz), 4.81(2H, s). 6.83-6.91(3H, m), 7.04(1H, d, J=1.9Hz), 7.18-7.71(10H, m) , 8.35(IH, d, J=8.3Hz), 9.19(1H, brs) • OMe 2-77 1.21(6H, t, J=7.1Hz), 2.80(3H, brs), 2.93(3H, brs), 3.51(2H, s), 3.79(3H, s), 4.20(4H, q, J=7.1Hz), 4.80(2H, s) , 6.84(2H, dt, J=8.6Hz, J=3.4Hz), 7.03(IH, d, J=1.9Hz), 7.19-7.71(11H, m), 8.36(IH, d, J=8.7Hz), 9.18(1H, brs) . 2-78 1.21(6H, t, J=7.2Hz), 2.82(3H, brs), 2.94(3H, brs), 3.52(2H, s), 4.21(4H, q, J=7.2Hz), 4.83(2H, s), 7.05(IH, s). 7.19-7.30(6H, m), 7.61-7.84(7H, m), 8.34(1H, d. J=8.3Hz), 9.40(1H, brs) 2-79 1.20(6H, t, J=7.2Hz), 2.86(3H, brs), 3.06(3H, brs), 3.50(2H, s), 4.20(4H, q, J=7.2Hz), 4.82(2H, s), 7.06(IH, s), 7.15(IH, dd, J=2.1, 8.3Hz), 7.28-7.63(12H, m), 8.14(1H, d, J=8.3Hz), 9.25(IH, brs) m.p. 135-138 2-80 1.21(6H, t, J=7.0Hz), 2.83(3H, brs), 3.00(3H, brs). 3.51(2H, s), 4.21(4H, q, J=7.0Hz), 4.82(2H, s), 7.05(IH, d, J=2.2Hz), 7.19(IH, dd, 3=2.2, 8.4Hz), 7.25-7.65(12H, m), 8.27(IH, d, J=8.4Hz), 9.28(1H, brs) m.p. 128-130 283 Table 34 Example Structure NMR (8, 300MHz, CDC13) 2-81 XX xn A. jfWY ^ <k 1.24(6H, t. J=7.2Hz), 2.44(3H, s). 2.61(3H, t. J=7.1Hz). 2.86(3H, brs). 2.95(3H. brs), 3.46(2H, s), 4.07 (2H, t, J=7.1Hz), 4.23(4H, q, J=7.2Hz), 4.82(2H, s), 7.07-7.63(14H, m). 8 .37(IH, d, J=8.7Hz), 9.12(1H. brs) 2-82 T i rYT°NA°^(H fVVy 0 ^ 1.21 (6H, t. J=7.1Hz). 1.45(3H, t, J=7.2Hz), 2.81(3H, brs), 2.95(3H, brs). 3.50(2H, s). 4.11(2H, q. J=7.2Hz), 4.21(4H. q. J=7.1Hz), 4.82(2H, s), 6.86(IH, d. J=2.6Hz). 6.97(1H. dd, J=2.6, 8.7Hz), 7.03(1H, d, J=1.9Hz). 7.18(IH, dd, J=1.9, 8.7Hz). 7.28-7.30(5H, m), 7 .56-7.67(5H, m), 8.36(1H, d, J=8.7Hz), 9.17(IH, brs) 2-83 X X J^5sJ 0 oM r3 f 1 H i rw ^ Hc o^ cr>/^ CH 1.21(6H, t. J=7.2Hz), 1.28(6H, d. J=6.0Hz). 2.81(3H, brs). 2.95(3H, brs), 4.21(4H, q, J=7.2Hz), 4.64(IH, sept, J=6.0Hz), 4.82(2H, s). 6.85(1H, d. J=2.2Hz), 6.96(IH, dd, J=2.6, 8.7Hz), 7.03(IH, d. J=2.2Hz), 7.18(IH, dd, J=8.7, 1.9Hz), 7.28-7.30 ( 5H, m), 7.56-7.66(5H, m), 8.36(IH, d. J=8.3Hz), 9.16(IH, brs) 2-84 $ -AW ° ^ pyv </y»> F CH, 1.24(6H, t. J=7.2Hz), 2.61(2H. t. J=7.1Hz), 2.89(3H, brs), 2.94(3H, brs). 3.47(2H. s). 4.08(2H, t. J=7.1Hz), 4.24(4H. q, J=7.2Hz), 7.11-7.39(7H, m), 7.61-7.83(7H, m), 8.34(1H. d, J=8.7Hz), 9.36(IH. brs) 2-85 s rrroJ^>^ °YV^V 0 ^ 11 H X.CH, 0N 3 1 CH, m.p. 107-109 1.20(6H, t. J=7.2Hz), 2.81(3H. brs). 3.02(3H, brs), 3.49(2H, s), 3.78(3H, s), 4.20(4H, q, J=7.2Hz), 4.81(2H, s), 7.02(1H, d. J=1.9Hz), 7.07(IH, d, J=8.3Hz), 7.15(IH, dd, J=2.3, 8.7Hz). 7.24-7.30(6H, m). 7.41-7.60(5H, m), 8.22(1H. d, J=8.7Hz), 9.05(IH. brs) 284 Table 35 Example Structure NMR (8,300MHz,CDCI3) 2-86 m.p. 125-129 1.21(6H, t, 3=1.2Hz), 2.48(3H, s), 2.69(3H, brs), 2.91(3H, brs), 3.50(2H, s), 4.21(4H, q, 3=1.2Hz), 4.82(2H, s), 6.99(IH, d, J=2.2Hz), 7.20(1H, dd, J=l.5, 8.3Hz), 7.28-7.41(8H, m) , 7. 57-7.64(4H, m), 8.18(1H, d, J=8.6Hz), 8.81(IH, brs) 2-87 1.23(6H, t, J=7.2Hz), 3.00(3H, brs), 3.03(3H, brs), 3.58(2H, s), 4.22(4H, q, J=7.2Hz), 4.85(2H, s), 7.18(IH, d, J=1.9Hz), 7.28-7.33(6H, m), 7.79(IH, d, 3=1.9Hz), 7.92(1H, d. 3=1.9Hz), 7.99(IH, s), 8.35(IH, d, J=8.3Hz), 9.46(1H, s) 2-88 m.p. 129-131 1.21(6H, t, J=7.2Hz), 2.33(3H, s), 2.76(3H, brs), 2.93(3H, brs), 3.50(2H, s) , 4.21(4H, q, 3=1.2Hz), 4.82(2H, s), 6.99(IH, d, J=1.2Hz), 7.14-7.51(13H, m), 7.65(1H, d, 3=1.6Hz), 8.34(IH, d, J=8.6Hz), 8.78(IH, brs) 2-89 1.24(6H, t, J=7.2Hz), 1.29(3H, t, 3=1.6Hz), 2.92(2H, q, J=7.6Hz), 3.03(6H, brs), 3.57(2H, s), 4.23(4H, q, 3=1.2Hz), 4.85(2H, s), 7.18(IH, d, 3=2.3Hz), 7.27-7.33(6H, m), 7.51-7.60(3H, m), 8.40(IH, d, J=8.2Hz), 9.51(IH, brs) 2-90 1.21(6H, t, 3=1.1Hz), 1.22(3H, t, J=6.9Hz), 2.64(H, q, J=6.9Hz), 2.75(3H, brs), 2.93(3H, brs), 3.50(2H, s), 4.21(4H, q, 3=1.1Hz), 4.82(2H, s), 6.99(IH, d, J=1.8Hz), 7.17-7.66(14H, m), 8.30(1H, d, J=8.3Hz), 8.76(IH, brs) m.p. 110-112 285 .able 36 Example Structure NMR (5, 300MHz,CDCI3) ha^ch, 2-91 1.21(6H, t, J=7.1Hz), 2.13(3H, s), 2.71(3H, brs), 2.89(3H, brs), 3.49(2H, s). 4.20(4H, q. J=7.1Hz), 4.82(2H, s). 5.10(1H, s). 5.43(IH, s), 6.98(IH, d, J=2.2Hz), 7.19(IH, dd, J=1.9. 8.3Hz), 7.28-7.53(12H, m), 7.67(IH, d, J=7.6Hz), 8.39(1H, d, J=8.6Hz), 8.87(IH, brs) 2-92 m.p. 107-110 1.21(6H, t. J=7.1Hz), 1.21(6H, t, J=7.1Hz), 2.76(3H, brs), 2.89(IH, sept, J=7.1Hz), 2.94(3H, brs). 3.50(2H. s). 4.21(4H, q, J=7.1Hz), 4.82(2H, s). 7.01(IH, d. J=1.9Hz), 7.14-7.51(13H, m), 7.62(1H. d, J=6.4Hz), 8.21(1H, d, J=8.3Hz), 8.70(IH, brs) 2-93 1.23(6H, t. J=7.2Hz), 2.12(3H, s), 2.99(3H, brs), 3.04(3H, brs). 3.56(2H, s). 4.23(4H. q. J=7.2Hz), 4.85(2H. s). 5.15(1H. s), 5.23(IH, s), 7.15(IH, d, J=1.8Hz), 7.25-7.31(6H, m). 7.55(IH, s), 7.61(IH, d, J=7.9Hz), 7•73(IH, d, J=7.9Hz), 8.36(IH, d, J=8.3Hz), 9.35(1H, m) 2-94 1.24(6H, t, J=7.2Hz). 1.29(6H. t. J=6.8Hz). 3.03(6H, brs). 3.44(IH, sept, J=6.8Hz). 3.57(2H, s). 4.23(4H, q. J=7.2Hz), 4.85(2H, s), 7.18(1H, d, J=1.9Hz), 7 .26-7 . 33 (6H, in). 7.52(2H, s). 7.63(IH. s). 8.41(IH, d, J=8.3Hz), 9.44(1H, brs) 2-95 1.23(6H, t, J=7.1Hz), 3.01(3H, brs), 3.10(3H, brs). 3.57(2H. s). 4.23(4H, q, J=7.1Hz). 4.85(2H, s). 6.91-6.96(IH, m), 7•20-7.41(12H, m), 7.46(1H, s). 7.66(1H, d, J=7.7Hz), 8.29(1H. d, J=8.3Hz), 9.78(1H, s). 10.17(IH, brs) 286 fable 37 Example Structure NMR (6, 300MHz, CDCI3) 2-96 1.21(6H, t, 3=1.1Hz), 2.75(3H, brs), 3.02(3H, brs), 3.55(2H, s), 4.20(4H, q, J=7.1Hz), 4.84(2H, s),6.92(IH, d, J=8.3Hz), 7.15-7.68(14H, m), 8.07(IH, dd, 3=1.3, 7.7Hz) 2-97 1.22(6H, t, J=7.1Hz), 2.83(3H, brs), 2.86(3H, brs), 3.53(2H, s), 4.21(4H, q,, J=7.1Hz), 4.83(2H, s), 6.85(IH, d, J=7.7Hz), 7.07(IH, d, J=2.0Hz), 7.20-7.52(12H, m), 8.25(IH, dd, J=1.8, 7.9Hz), 8.41(IH, d, J=8.5Hz), 10.48(IH, brs) 2-98 0.65(6H, t, J=7.4Hz), 1.69(4H, q, J=7.4Hz), 2.81(3H, brs), 2.94(3H, brs), 3.50(2H, s), 4.30(2H, s), 7.02(IH, d, J=1.8Hz), 7.18-7.62(13H, m), 7.70 (IH, d, J=7.3Hz), 8.35(1H, d, J=8.5Hz), 9.15(IH, brs) 2-99 1.21(6H, t, J=7.1Hz), 2.87(6H, brs), 3.53(2H, s), 4.21(4H, q, J=7- 1Hz), 4.83(2H, s), 6.92(IH, d, J=7.6Hz), 7.08(1H, d, 3=2.1Hz), 7.20-7.48(10H, m), 7.63(2H, d, J=8.7Hz), 8.23(1H, dd, J=1•7, 7.9Hz), 8.35(IH, d, J=8.5Hz), 10.38(IH, brs) 2-100 0.85-0.93(4H, m), 2.78(3H, brs), 2.93(3H, brs), 3.52(2H, s), 4.16(2H, s), 7.04(IH, d, 3=2.1Hz), 7.17-7.61(13H, m), 7.70(IH, dd, J=1.5, 7.2Hz), 8.35(1H, d, J=9.0Hz), 9.15(1H, brs) 287 Table 38 Example Structure NMR (5, 300MHz ,CDC13) 2-101 JLA ° 'L^ " ^-CH.

CH, 2.79(3H, brs). 2.94(3H, brs). 3.45(2H, s), 4.31(IH, t, J=7•6Hz), 4.62(2H, d, J=7.6Hz), 6.96(IH, d, J=2.0Hz), 7.15-7.69(19H, m), 8.30(IH, d, J=8.5Hz), 9.15(1H, brs) 2-102 X 9 JOvCnHb 1 <*3 np. 103.0-109.0 1.62-1.76(4H, m), 1.82-1.99(4H, m), 2.78(3H, brs), 2.93(3H, brs), 3.44(2H, s), 4.08(2H, s), 6.97(IH, d, J=2.0Hz), 7.09-7.26(6H, m), 7.35-7.72(8H, m), 8.34(1H, d, J=8.5Hz), 9.15(IH, brs) 2-103 S X 0 °n AAkAJ O ^CH, O N 1 CH, 2.40(IH, t, J=5.7Hz), 2.42(1H, t, J=6.3Hz), 3.53(2H, s), 2.80(3H, brs), 2.93(3H, brs), 3.82(2H, dd, J=6.3, 11.4Hz), 3.96(2H, dd, J=5.7, 11.4Hz), 4.58(2H, s), 7.01(IH, d, J=1.8Hz), 7.14-7.71(14H, m), 8.29(IH, d, J=8.4Hz), 9.05(1H, brs) 2-104 Oi rrv^W AA^J 8 S <* U " 0^ 1 CH, 1.98(6H, s), 2.83(3H, brs), 2.93(3H, brs), 3.49(2H, s), 4.40(4H, S), 4.44(2H, s), 7.00(1H, d, J=2.2Hz), 7.15(1H, dd. J=2.2, 8.4Hz), 7•22-7.65(12H, m), 7.70(1H, dd, J-l.9, 7.0Hz), 8.32(IH, d, J=8.4Hz), 9.13(IH, brs) 2-105 F F. ,F o f] S~TX Vff rYY0s/ i JL^ o O^n ^CH ^ (Af** >, CH 3 mp. 98.8-103.3 1.23(6H, t, J=7.1Hz), 2.83(3H, brs), 2.94(3H, brs), 3.51(2H, s), 4.22(4H, q,, J-7.1Hz),4.82(2H, s), 6.94-7.04(3H, m), 7.16-7.71(10H, m), 8.34(1H, d, J=8.5Hz), 9.17(IH, brs) 288 fable 39 Example Structure NMR (s. 300MHz,CDCI3) 2-106 o o o O- -N-'""' CH3 013 mp. 116.1-121.6 1.22(6H, t, J=7.1Hz), 2.81(3H, brs), 2.93(3H, brs), 3.50(2H, s), 4.20(4H, q, J=7.1Hz), 4.79(2H, s), 7.01-7.04(2H, m), 7.25-7.71(11H, m) . 8.35(1H, d, J=8.5Hz), 9•17(IH, brs) 2-107 1.25(6H, t, J=7.1Hz), 2.75(3H, brs), 2.92(3H, brs), 3.78(2H, s), 4.22(4H, q, J=7.1Hz), 4.85(2H, s), 6.98(IH, s), 7.28-7.72(13H, m), 8.71(1H, S), 9.52(IH, brs) 2-108 1.22(6H, t, J=7.2Hz), 2.13(3H, s), 2.85(3H, brs), 2.93(3H, brs), 3.50(2H, s), 4.16-4.26(4H, m) , 4.80(2H. s), 6.78(IH, d, J=5.1Hz), 7.05(IH, d, J=2.2Hz), 7.15(IH, d, J=5.2Hz), 7.16-7.64(8H, m), 7.69(IH, dd, J=1.5, 7.3Hz), 8.33(IH, d, J=8.5Hz), 9.16(1H, brs) 2-109 np. 104.6-108.3 1.22(6H, t. J=7.2Hz), 2.44(3H, s), 2.84(3H, brs), 2.94(3H, brs), 3.52(2H, s). 4.20(4H. q, J=7.2Hz), 4.78(2H, s), 6.58(1H. dd. J=1.2, 3.5Hz). 6.76(IH, d. J=3.5Hz), 7.04{IH, d. J=2.0Hz). 7.20{IH, dd, J=2.1, 8.6Hz), 7.37-7.62(7H, m), 7.68(1H. dd. J=1.4, 7.6Hz), 8.33(IH, d, J=8.4Hz). 9.17(IH, brs) 2-110 mp.121.5-124.7 1.22(6H, t, J=7.1Hz), 2.85(3H, brs), 2.94(3H, brs). 3.46(2H, s), 4.23(4H, q, J=7.1Hz). 4.97(2H, s), 7.00(IH, d, J=2.2Hz), 7.13-7.16(IH, m), 7.36(IH, d, J=3.3Hz), 7.38-7.71(8H, m), 7.75(1H, d, J=3.3Hz), 8.31(IH, d. J-8.5Hz), 9.16(IH. brs) 289 Table 40 Example Structure NMR (6, 300MHz,CDCI3) H,C CH, \/ .0 2-111 CHs mp 96-98 0.97(6H, d, J=7.2Hz), 1.21(6H, t. J=7.2Hz), 2.45(IH, sep. 3-1.2Hz), 2.88(3H, brs), 2.94(2H, brs). 3.52(2H, s), 4.15(4H, q, J=7.2Hz), 4.50(2H, s), 7.09(1H, d, J=2.3Hz), 7.20-7.72(9H, m) , 8.34(1H. d. J=8.3Hz), 9.15(IH, brs). 2-112 CH, mp 100-104.5 0.90(3H, t. J=7.2Hz), 0.92(3H. t, J=6.5Hz), 0.95-1.10(1H, m), 1,21(3H, t. J=7.2Hz), 1.48-1.62(IH, m). 2.05-2.16(IH, m). 2.88(3H, brs), 2.94(3H, brs), 3.52(2H, s), 4.14{4H, q, J=7.2Hz). 4.51(2H, s). 7.09(1H, d, J=1.9Hz), 7.21-7.72(9H, m), 8.36(IH, d. J=8.3Hz), 9.16(1H, brs) . 2-113 CH, mp 106-109.5 0.83(6H, d. J=6.4Hz), 1.21(6H, t, 3=1.2Hz), 1.51-1.65(IH, m), 1.88(2H, d, J=6.4Hz), 2.88(3H. brs), 2.94(3H, brs), 3.53(2H, s), 4.15(4H, q, J=7.2Hz), 4.52(2H, s), 7.08(IH, d. J-2.3HZ), 7.22-7,71(9H, m). 8.37(1H, d, J=8.3Hz), 9.16(1H. brs). 2-114 0.88(3H, t. 1.09-1. 31 (2H, in).

J=7.2Hz), 1.21(6H, t, CH, mp 98-99.5 J=7.2Hz) 2.89(3H, 3.53(2H, J=7.2Hz) brs), 8.37(1H, d, brs). 1.79-1.93(2H, m), brs), 2.94(3H, brs), s), 4.15(4H, q, 4.49(2H, s), 7.09(IH, 7.21-7.74(9H. m), J=8.3Hz), 9.15(IH, 2-115 CH, mp 86.5-90.0 0.83(3H, t. J=7.5Hz), 1.21(6H, t. 3=1.2Hz), 1.96(2H, q, 3=1.5Hz), 2.88(3H, brs), 2.94(3H, brs). 3.53(2H, s), 4.16(4H, q. J=7.2Hz), 4.50(2H. s). 7.08(1H. d, J=1.9Hz), 7.21-7.74(9H, m), 8.36(1H, d, J=8.7Hz), 9.15(IH, brs). 290 Table 41 Example Structure NMR (8,300MHz,CDC13) 2-116 S? o o 0 ch, np 97.5-98.0 0.86(3H, t, J=7.2Hz), 1.06-1.36(4H, m). 1.21(6H, t, J=7.2Hz), 1.84-1.94(2H, m) , 2.88(3H, brs). 2.94(3H. brs), 3.53(2H, s). 4.15(4H, q, J=7.2Hz), 4.49(2H, s). 7.08(1H, d, J-2.3Hz), 7 . 21-7.71(9H, m) , 8.37(IH, d, J=8.6Hz), 9.16(1H, brs). 2-117 rap. 76. 9-82.0 1.21(6H, t. J=7.1Hz), 2.67{2H, d, J=7.4Hz), 2.87(3H, brs), 2.95(3H, brs), 3.54(2H. s), 4.10-4.20(4H, m). 4.47(2H, s), 5.00-5.10(2H, m), 5.56-5.67(IH, m). 7.09(1H, d, J=2.1Hz), 7.24(IH, d, J=2.0Hz), 7.38-7.68(7H, m), 7.70(1H, d, J=1.4Hz), 8.37(IH, d, J=8.4Hz), 9.14(IH, brs) 2-118 1.25(9H, t, J=7.2Hz), 2.89(3H, brs). 2.95(3H, brs), 3.56(2H, s). 4.23(6H, q, J=7.2Hz). 4.70(2H, s). 7.11(IH, d, J=1.8Hz), 7.24(IH; d. J=2.2Hz), 7.28-7.70(8H. m), 8.36(1H. d, J=8.8Hz), 9.16(IH, brs) 2-119 up.72.3-78.6 0.87(3H, t, J=7.2Hz), 0.92(3H, t. J=6.8Hz), 1.00-1.16(2H. m). 1.20(6H, t, J=7.1Hz), 1.38-1. 53(2H, m), 2.18-2.23(IH. m), 2.88(3H, brs). 2.95(3H, brs), 3.52(2H, s). 4.08-4.18(4H, m), 4.50(2H, d, J=2.1Hz). 7.08(IH, d, J=1.9Hz), 7.22-7.69(9H, m). 8.35(1H, d, J=8.6Hz), 9.15(IH, brs) 291 Example 3 2-(2-{3-Ethoxy-4-[(4'-trifluoromethylbiphenyl-2- carbonyl)amino]phenyl}acetoxymethyl)-2-phenylmalonic acid diethyl ester a) 3-Ethoxy-4-nitrobenzoic acid methyl ester To a suspension of sodium hydride (60% mineral oil: 1. 20g) in dimethylformamide (50 mL) was added 3-hydroxy-4-10 nitrobenzoic acid methyl ester (4.93 g) under ice-cooling, and the mixture was stirred at room temperature for 30 minutes. After addition of ethyl iodide (4.4 g), the solution was stirred at 60°C overnight, cooled down to room temperature, poured into saturated aqueous ammonium chloride, and extracted with ethyl 15 acetate-tetrahydrofuran. The organic layer was washed with saturated aqueous ammonium chloride and saturated brine, dried over sodium sulfate and concentrated to give a solid, which was washed with ethyl acetate-hexane to afford 3-ethoxy-4-nitrobenzoic acid methyl ester (3.30 g) as a pale 20 yellow solid. b) 3-Ethoxy-4-nitrobenzoic acid chloride 0 0 OH OEt 292 3-Ethoxy-4-nitrobenzoic acid chloride was obtained in a similar manner to Example 1 f) and Example 1 d) from the 3-ethoxy-4-nitrobenzoic acid methyl ester obtained in Example A solution of the 3-ethoxy-4-nitrobenzoic acid chloride (2.06 g) obtained in Example 3 b) in diethyl ether (30 mL) was added dropwise to a mixture of diazomethane in diethyl ether 10 (0.35M, 64 mL) and triethylamine (3.12 mL) under ice-cooling. The mixture was stirred for 2 hours under ice-cooling and the temperature was raised to room temperature, followed by stirring overnight. After addition of acetic acid (1 mL), the mixture was stirred at room temperature for one hour and 15 evaporated to remove the solvent. The residue was purified by column chromatography on silica gel with hexane:ethyl acetate=5:2 to give the title compound (1.80 g) as a yellow solid. d) 3-Ethoxy-4-nitrophenylacetic acid ethyl ester 3 a). c) 2'-Diazo-3-ethoxy-4-nitroacetophenone 0 0 OEt OEt 0 OEt OEt A solution of silver benzoate (270 mg) in triethylamine 293 (2.7 ml) was added dropwise in 10 divided doses to a solution of the 2'-diazo-3-ethoxy-4-nitroacetophenone (1.80 g) obtained in Example 3 c) in ethanol (25 mL) under reflux. The mixture was refluxed for 9 hours and the reaction solution was 5 filtered through a Celite pad. The filtrate was concentrated, and the concentrate was diluted with diethyl ether and washed with 10% aqueous sodium carbonate, water and saturated brine. The organic layer was dried over sodium sulfate and purified by column chromatography on silica gel with hexane:ethyl 10 acetate=4:l to give the title compound (1.27 g) as a yellow solid. e) 4-Amino-3-ethoxyphenylacetic acid ethyl ester obtained in Example 3 d) was subjected to reactions similar to those in Example 1-3 d) to give the title compound (1.12 g) as a brown oil. f) 2-(2-{3-Ethoxy-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetoxymethyl)-2-phenylmalonic acid 20 diethyl ester OEt OEt The 3-ethoxy-4-nitroacetic acid methyl ester (1.27 g) The 4-amino-3-ethoxyphenylacetic acid ethyl ester obtained in Example 3 e) and the 2-hydroxymethyl-2- 294 phenylmalonic acid diethyl ester obtained in Example 1-2 a) were subjected to reactions similar to those in Examples 1 e), If) and 1 g) to give the title compound (0.159 g) (see Table 42).

Example 3-2 {3-Hydroxy-4-[(4'-trifluoromethylbiphenyl-2- carbonyl)amino]phenyl}acetic acid 2,2-bisethylcarbamoyl-2- phenylethyl ester carbonyl)amino]phenylJacetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester (300 mg) obtained in a similar manner to Example 3, except that reduction of the nitro group was carried out with iron dust, was subjected to reactions in a similar 15 manner to Example 1-2 c) to give the title compound (244 mg) (See Table 42).

NHEt NHEt {3-Benzyloxy-4-[(4'-trifluoromethylbiphenyl-2- Examples 3-3 to 3-16 Compounds of Examples 3-3 to 3-16 were obtained in a 295 similar manner to Examples 3 to 3-2. The compounds thus obtained were shown in Tables 42 to 45. 296 Fable 42 Example Structure NMR (8,300MHz,CDC13) 1. 1. 3.

J= J= 6. 6. 7. dd 7. 7. dd d. 4. 4. 19(6H, t, 20(3H, t, 49(2H, s), 7.1Hz) 7.1Hz) 59(IH, d, 75(1H, dd, 25-7.33(5H J=1.5, 7 49-7.66(6H 70-7.76(IH J=1.5, 7.

J=8.0Hz) J=7.1Hz), J=7.1Hz), 3.77(2H, q, 18(4H, q, 83(2H, s), J=1.5Hz), J=1.5, 8.2Hz), , m), 7.44(IH, .2Hz), , m), , m), 7.80(IH, 2Hz), 8.35(IH, 3-2 1.05(6H, t, J=7.2Hz), 3.23(4H, dq, J=7.2, 7.2Hz), 3.48(2H, s), 4.83(2H, s), 6.48(IH, d, J=7.9Hz), 6.55(IH, dd, J=7.9,1.9Hz), 6.77(IH, d, J=1.5Hz), 7.17-7.86(15H, m) ,8.58(IH,s) 3-3 HH <*3 1.05(6H, t, J=7.2Hz), 3.23(4H, dq, J=7.2, 7.2Hz), 3.53(2H, s), 3.55(3H, s), 4.83(2H, s), 6.60(IH, s), 6.73(IH, d, J=7.9Hz), 7.10-7.66(15H, m), 7.85(IH, dd, J=7.5, 1.5Hz), 8.33(IH, d, J=7.9Hz) m.p. 112-114 3-4 1.19(6H, t, J=6.9Hz), 3.50(5H, s), 4.17(4H, q, J=6.9Hz), 4.83(2H, s), 6.58(IH, 6.75(IH, d, J=6.9Hz), 7.26-7.65(13H, m), 7.85(1H, d, J=7.3Hz), 8.31(1H, d, J=8.1Hz) s), 3-5 n-x^ch, 0.84(6H, t, J=7.2Hz), 1.43(4H, tq, 3=1.2, 7.2Hz), 3.16(4H, m), 3.52(2H, s), 3.55(3H, s), 4.83(2H, s), 6.60(IH, br.s), 6.72(IH, dd, J=8.3, 1.5Hz), 7.12-7.66(15H, m), 7.84(IH, dd, 3=1.9. 1.9Hz), 8.33(1H, d, 3=1.9Hz) 297 Table 43 Example Structure NMR (5, 300MHz,CDCI3) 3-6 1.13(6H, t, J=7.2Hz). 2.55(2H, t. J=8.0Hz), 3.30(4H, dq. J=7.2, 7.2Hz), 3.53(2H, s), 3.57(3H, s). 4.12(2H, t. J=8.0Hz), 6.67(IH, br.s). 6.82(1H. dd. J=8.3. 1.9Hz), 7.26-7.66(15H, m). 7.84(IH, dd, J=7.9. 1.9Hz), 8.33(IH, d. J=7.9Hz) 3-7 ^ 6 O^NH ^CHj 0^ CH, 1.05(6H, t. J=7.2Hz), 1.24(3H, t. J=7.1Hz), 3.17-3.29(4H, m), 3.52(2H, s), 3.83(2H. q, J=7.1Hz). 4.82(2H, s), 6.60(IH, d. J=1.5Hz). 6.69-6.76(IH, m), 7.04-7.14(2H. m), 7.15-7.22(2H, m), 7.25-7.34(3H, m). 7.41-7.47(IH. m). 7.49-7.66{6H, m), 7.73(1H. br-s), 7.77-7.83(IH, m). 8.37(1H, d. J=8.3Hz) 3-8 1.13(6H, t. J=7.2Hz), 1.24(3H, t. J=7.1Hz). 2.49-2.59(2H, m), 3.31(4H, dq, J=5.3, 7.2Hz), 3.52(2H. s). 3.87(2H, q. J=7.1Hz), 4.07-4.17(2H, m), 6.68(IH, d, J=1.5Hz), 6.78-6.84(1H, m). 7.23-7.37(5H, m), 7.41-7.47(IH, m), 7.48-7.66(8H, m). 7.73(1H, s), 7 .76-7 . 82( IH, in). 8.37(1H, d. J=8.3Hz) 3-9 1.10(6H, d. J=6.0Hz). 1.19(6H, t. J=7.2Hz), 3.48(2H. s). 4.19(4H, q, J=7.2Hz), 4.36(1H, sept. J=6.0Hz). 4.82(2H. s). 6.62(IH. d. J=1.5Hz). 6.70-6.77(IH. m), 7.27-7.32(5H, m), 7.41-7.46(IH, m), 7.49-7.67(6H, m), 7.72-7.82(2H, m), 8.39(IH, d. J=8.2Hz) 3-10 1.05(6H, t, J=7.2Hz), 1.13(6H, d, J=6.1Hz), 3.23(4H, dq. J=5.6, 7.2Hz). 3.52(2H, s). 4.40(1H. sept, J=6.1Hz), 4.82(2H, s), 6.62(IH, d. J=1.5Hz), 6.67-6.75(IH, m). 7.10(2H, br-t. J=5.6Hz), 7.16-7.23(2H, m), 7 .24-7.35(3H, m), 7.44(1H, dd, J=1.5, 7.6Hz), 7.50-7.70(6H, m). 7.71-7.82(2H. m), 8.40(IH, d. J=8.3Hz) 298 Table 44 Example Structure NMR (8,300MHz,CDCI3) 3-11 1.13(6H, t. 3=1.2Hz), 1.13(6H, d. J=6.1Hz), 2.48-2.60(2H, m), 3.31(4H, dq, J=5.7, 7.2Hz), 3.52 (2H, s). 4.07-4.17(2H, m). 4.43(1H, sept, J=6.1Hz). 6.69(IH, d, J=1.5Hz), 6.79(1H, dd, J=1.5, 8.3Hz). 7.23-7.37(5H, ra), 7.41-7.46(IH, m). 7.48-7.68(8H, m), 7.72-7.82(2H, m). 8.40(1H, d, J=8 . 3Hz ) _ 3-12 0.90(3H, t, J=7.4Hz),1.05(6H, t, J=7.3Hz), 1.53-1.69(2H, m) , 3.16-3.30(4H, m) , 3.53(2H. s) , 3.75(2H, t, J=6.7Hz), 4.82(2H, s), 6.58-6.74(2H, m), 7.02-7.78(16H, m), 8.36(1H# d, J=8.2Hz) 3-13 N \ H" CH, 1.04(6H, t, J=7.2Hz), 3.23(4H, dq, 3=1.2, 7.2Hz), 3.52(2H, s), 4.82-4.86(4H, m), 6.70-7.79(16H, m), 7.71(1H, br.s), 7.78(IH, dd, J=7.1, 1.9Hz), 8.40(IH, d, J=8.3Hz) 3-14 1.19(6H, t, 3=1.1Hz), 3.49(2H, s), 4.17(4H, q, 3=1.1Hz), 4.78(2H, S), 4.83(2H, s), 6.70(IH, d, J=1.9Hz), 6.78(IH, dd, J=8.3, 1.5Hz), 7.21-7.57(12H, m), 7.70(1H. br.s), 7.77(IH, dd, 3=1.2. 1.9Hz), 8.38(IH, d, J=8.3Hz) 3-15 1.20(6H, t, 3=1.2Hz), 3.47(2H, S), 4.19(4H, q, J=7.2Hz), 4.82(2H, S), 6.29(IH, d, J=7.9Hz), 6.57(IH, dd. J=7.9, 1.9Hz), 6.79(IH, d. J=1.9Hz), 7.18(IH, br.s), 7.28-7.74(11H, m), 7.86(1H, dd. 3=1.9, 1.5Hz), 8.39(IH, s) 299 Table 45 Example Structure NMR (8, 300MHz ,CDC13) 3-16 h3c- 1.17(6H, t, J=7.1Hz), 3.54(2H, s), 3.72(3H, s), 4.16(4H, q. J=7.1Hz), 4.83(2H, s), 6. 72-6.80(3H, m), 7.29-7.66(12H, m), 8.14(IH, dd, J=1.3, 7.7Hz) Example 4 2-{3-Dlmethylamlno-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenylJacetlc acid 2,2-bisethylcarbamoyl-2-phenylethyl ester a) 2-(3-Bromo-4-nitrophenyl)malonic acid tert-butyl ester methyl ester 02N COOtBu j^^COOMe Br Sodium hydride (60%, mineral oil; 0.985 g) was suspended in dimethylformamide (20 mL), and a solution of tert-butyl methyl malonate (4.29 g) in dimethylformamide (5 mL) was added dropwise thereto under ice-cooling. After foam generation is 15 stopped, a solution of 2-bromo-4-fluoro-1-nitrobenzene (2.71 g) in dimethylformamide (5 mL) was added dropwise thereto at the same temperature, and the mixture was further stirred at 300 60°C for 3 hours, and then concentrated. The residue was neutralized with IN hydrochloric acid and extracted with ethyl acetate. The extract was washed with saturated brine, dried over sodium sulfate and concentrated. The residue was purified 5 by column chromatography on silica gel with ethyl acetate:hexane=l: 4 to 1:5 to give the title compound (7.54 g) as an oil. b) (3-Bromo-4-nitrophenyl)acetic acid methyl ester COOMe The 2-(3-bromo-4-nitrophenyl)malonic acid tert-butyl ester methyl ester (1.18 g) obtained in Example 4 a) was dissolved in chloroform (10 mL), trifluoroacetic acid (10 g) was added thereto under ice-cooling, and the mixture was stirred at room temperature for 5 hours. The reaction mixture was 15 poured gradually into ice and saturated aqueous sodium bicarbonate, and extracted with ethyl acetate. The extract was washed with water and saturated brine, dried over sodium sulfate and concentrated to give the title compound (0.820 g) as a pale yellow oil. c) (3-Dimethylamino-4-nitrophenyl)acetic acid methyl ester The (3-bromo-4-nitrophenyl)acetic acid methyl ester (0.320 g) obtained in Example 4 b) was dissolved in 301 tetrahydrofuran (10 mL). To this solution were added triethylamine (0.237 g) and dimethylamine (2M tetrahydrofuran ; 0.58 mL), and stirred overnight while heating. The reaction mixture was concentrated and purified by column chromatography 5 on silica gel with ethyl acetate:hexane=l: 4 to give the title compound (0.145 g) as an orange oil. d) (4-Amino-3-dimethylaminophenyl)acetic acid methyl ester The (3-dimethylamino-4-nitrophenyl)acetic acid methyl 10 ester (0.245 g) obtained in Example 4 c) was subjected to reactions similar to those in Example 1-3 d) to give the title compound (0.188 g) as a red oil. 2-carbonyl)amino]phenyl}acetic acid 2,2-bisethylcarbamoyl-2-15 phenylethyl ester The (4-amino-3-dimethylaminophenyl)acetic acid methyl ester (0.188 g) obtained in Example 4 d) was subjected to 20 reactions similar to those in Example 1 e), 1 f) and 1 g) to give the title compound (0.058 g) (See Table 46). e) 2-{3-Dimethylamino-4-[(4'-trifluoromethylbiphenyl- H,N NHEt NHEt 302 Examples 4-2 to 4-8 Compounds of Examples 4-2 to 4-8 were obtained in a similar manner to Example 4. The compounds thus obtained were shown in Tables 46 to 47. 303 [■able 46 Example Structure NMR (6, 300MHz,CDCI3) 1.04(6H, t, J=7.2Hz), 2.26(6H, s), 3.23(4H, m), 3.51(2H, s), 4.83(2H, s), 6.86-7.80(15H, m), 8.40(IH, d, J=8.7Hz), 8.45(IH, brs).

H3C^ xch3 4-2 1.05(6H, t, J=7.3Hz), 1.49(6H, br.s), 2.48(4H, br.s), 3.24(4H, dq, 3=1.3. 7.3Hz), 3.53(2H, S), 4.84(2H, S), 6.93(2H, m), 7.20-7.70(15H, m), 8.40(IH, d, J=9.2Hz), 8.54(IH, br.s) 4-3 hK^CH, 1.04(6H, t, 3=1.3Hz), 1.76(4H, m), 2.59(4H, t, J=6.2Hz), 3.23(4H, dq, J=7.3, 7.3Hz), 3.51(2H, s), 4.83(2H, s), 4.82(2H, m), 7.12-7.63(14H, m), 7.74(IH, dd, J=7.3, 1.4Hz), 8.18(IH, br.s), 8.30(IH, d, J=8.1Hz) 4-4 1.20(6H, t, 3=1.1Hz), 1.48(6H, br.s), 2.47(4H, br.s), 3.49(2H, s), 4.19(4H, q, 3=1.1Hz), 4.83(2H, s), 6.92-7.72(15H, m), 8.39(IH, d, J=8.3Hz), 8.56(IH, br.s) 4-5 0-"\ CH, CHS 1.20(6H, t, 3=1.2Hz), 1.74(4H, m), 2.57(4H, m), 3.48(2H, s), 4.19(4H, q, 3=1.2Hz), 4.82(2H, s), 6.90(2H, m). 7.30-7.63(12H, m), 7.74(IH, dd, J=7.2, 1.5Hz), 8.20(IH, br.s), 8.29(IH, d, J=8.7Hz) 304 Table 47 Example Structure NMR (5,300MHz,CDC13) 4-6 1.20(6H, t, J=7.1Hz), 2.24(6H, S), 3.48(2H, s), 4.19(4H, q, J=7.1Hz), 4.82(2H, s), 6.88-6.98(2H, m) . 7.29(5H, brs),7.43( 1H, d, J=7.2Hz), 7.48-7.60(2H, ,m), 7.62(4H, s), 7.77(IH, d, J=7.5Hz), 8.39(IH, d, J=8.3Hz), 8.47(IH, brs). 4-7 1.21(6H, t, J=7.0Hz), 2.38-2.47(4H, m), 3.51(2H, s), 3.53-3.60(4H, m), 4.20(4H, q, J=7.0Hz), 4.84(2H, S), 6•93(1H, s), 7.00(1H, dd, J=1.5, 7.4Hz), 7.29-7.35(5H, m), 7.47-7.68(7H, m), 7 .73(IH, dd, J=1.8, 7.4Hz), 8.42-8.51(2H, m) 4-8 0.67(6H, t, J=7.0Hz), 1.21(6H, t, J=7.2Hz), 2.64(4H, q, J=7.0Hz), 3.49(2H, s), 4.21(4H, q, J=7.2Hz), 4.83(2H, s), 6.90-7.01(2H, m), 7.28-7.35(5H, m), 7.42-7.65(7H, m), 7.69(IH, dd, J=1.5, 7.2Hz), 8.41(IH, d, J=8.3Hz), 8.85(IH, br-s) 305 Example 5 2-[2-(2-{2-methyl-3-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetoxy)ethyl]-2-phenylmalonic acid diethyl ester a) 2'-Diazo-3-nitro-2-methylacetophenone CHN2 O 2-Methyl-3-nitrobenzoic acid (500 mg) was subjected to reactions similar to those in Example 3 b) and 3 c) to give the title compound (377 mg). b) 2-Methyl-3-nitrophenylacetic acid ethyl ester CHN2 O The 2'-diazo-3-nitro-2-methylacetophenone (377 mg) obtained in Example 5 a) was subjected to reactions similar to those in Example 3 d) to give the title compound (363 mg). c) 2-Methyl-3-nitrophenylacetic acid The 2-methyl-3-nitrophenylacetic acid ethyl ester (352 mg) obtained in Example 5 b) was subjected to reactions similar to those in Example 1 f) to give the title compound (307 mg). d) 2-(2-Benzyloxyethyl)-2-phenylmalonic acid diethyl ester 306 \/0 * BnO OEt OEt O O O Sodium hydride (406 mg) was dissolved in dimethylformamide (20 mL) and the solution was cooled to 0°C. To this solution was added phenylmalonic acid diethyl ester 5 (2.0 g), and the mixture was stirred at room temperature for 30 minutes. Bromoethyl benzyl ether (2.0 g) was further added thereto, stirred at 60°C for 4 hours, and water was added thereto. The reaction mixture was concentrated, diluted with ethyl acetate, washed with water, dried over sodium sulfate 10 and purified by column chromatography on silica gel with ethyl acetate:hexane=l:9 to give the title compound (1.2 g). e) 2-(2-Hydroxyethyl)-2-phenylmalonic acid diethyl ester ester (1.2 g, not purified) obtained in Example 5 d) was subjected to reactions similar to those in Example 1-2 c) to give the title compound (726 mg). f) 2-{2-[2-(2-Methyl-3-nitrophenyl)acetoxy]ethyl}-2-phenylmalonic acid diethyl ester The 2-(2-benzyloxyethyl)-2-phenylmalonic acid diethyl 307 0 OEt OEt The 2-methyl-3-nitrophenylacetic acid (307 mg) obtained in Example 5 c), 4-dimethylaminopyridine (217 mg) and the 2-(2-hydroxyethyl)-2-phenylmalonic acid diethyl ester (250 mg) obtained in Example 5 e) were subjected to reactions similar to those in Example 1-3 c) to give the title compound (366 mg). g) 2-[2-(2-{2-methyl-3-[(4'-trifluoromethylbiphenyl-2- carbonyl)amino]phenyl}acetoxy)ethyl]-2-phenylmalonic acid diethyl ester The 2-{2-[2-(2-methyl-3-nitrophenyl)acetoxy]ethyl}-2-phenylmalonic acid diethyl ester (345 mg) obtained in Example 5 f) was subjected to reactions similar to those in Example 1-3 d) and 1-3 e) to give the title compound (318 mg) (See Table 48).

Examples 5-2 to 5-18 Compounds of Examples 5-2 to 5-18 were obtained in a similar manner to Example 5. The compounds thus obtained were shown in Tables 48 to 51.

CF.

OEt OEt 308 Table 48 Example Structure NMR (5. 300MHz,CDCI3) 1.23(6H, t. J=7.0Hz), 1.70{3H, s), 2.61(2H, t, J=7.0Hz), 3.50(2H, s), 4.07(2H, t, J=7.OHz), 4.21(4H, q, J=7.OHz), 6.84(1H, br.s), 6.98(1H. d, J=7.7Hz), 7.13-7.71(15H, m), 7.80(IH, d. J=7.OHz) -2 1.17(6H, t, 3=1.1Hz), 3.50(2H, s), 4.14(4H, q, 3=1.1Hz), 4.83(2H, s), 6.83(IH, s), 6.91(IH, d, 3=1.5Hz), 6.99(IH, br.s), 7.16-7.81(15H, m) -3 XXX o-\ •a CH, 1.23(6H, t, 3=1.2Hz), 2.62(2H, t, 3=1.2Hz), 3.41(2H, S), 4.13(2H, t, 3=1.2Hz), 4.20(4H, q, J=7.2Hz), 7.05-7.79(18H, m) CH, m.p. 88-91 -4 \" <*> ^ 1.10(6H, t, J=7.2Hz), 2.53-2.61(2H, m), 3.28(4H, dq, J=5.3, 7.2Hz), 3.54(2H, S), 4.07-4.17(2H, m), 6.95-7.10(3H, m), 7.14-7.36(7H, m), 7.40-7.46(IH, m), 7.46-7.62(6H, m), 7.64-7.71(2H, m), 7.77(1H, dd, J=1.5, 7.5Hz) -5 CH, 0.85(6H, t. J=7.2Hz), 1.49(4H, tq, J=7.2, 7.2Hz), 2.54-2.63(2H, m), 3.16-3.25(4H, m), 3.53(2H, s), 4.08-4.17(2H. m), 6.96-7.01(lH, m). 7.03-7.10(2H, m). 7.15-7.36(7H, m), 7.40-7.46(1H, m). 7.47-7.62(6H, m), 7.65-7.71(2H, m), 7.77{1H, dd, J-l.5. 7.5Hz) 309 Table 49 Example Structure NMR (6, 300MHz ,CDC13) -6 1.24(6H, t, J=7.4Hz), 1.68(3H, s), 2.65(2H, t, J=7.3Hz), 3.50(2H, s). 4.09(2H, t, J=7.3Hz), 4.22(4H, q, J=7.4Hz), 6.81(IH, br.s), 6.92-7•83(16H, m) -7 1.23(6H, t, J=7.4Hz), 2.20(3H, s), 2.63(2H, J=7.OHz), 3.47(2H, s) 4.08(2H, t, J=7.OHz), 4.21(4H, q, J=7.4Hz), 6.94(IH, s). 7.07-7.81(16H, m) t. -8 H3C CH, 1.11(6H, d, J=6.4Hz), 1.13(6H, d, J=6.8Hz), 2.49-2.58(2H, m), 3.53(2H, s), 3.98-4.15(4H, m), 6.96-7.01(IH, m), 7.03-7.16(3H, m), 7.17-7.37(8H, m), 7.40-7.61(5H, m), 7.64-7.71(2H, m),7.77(lH, dd, J=1.5, 7.6Hz) -9 1.11(6H, t, J=7.OHz), 1.72(3H, S), 2.52(2H, t. J=7.9Hz), 3.29(4H, dq. J=7.0, 7.0Hz), 3.57(2H, s), 4.08(2H, t, J=7.9Hz), 6.85(IH, br.s), 6.99-7.81(18H, m) -10 0.98(6H, t, J=7.1Hz), 1.53(2H, m), 1.79(3H, s), 1.95(2H, m). 3.09(4H, dq, J=7.1, 7.1Hz), 3.64(2H, s), 4.06(2H, t, J=5.7Hz), 7.03-7.62(18H, m), 8.02(IH, br.s) 310 Table 50 Example Structure NMR (6,300MHz,CDCI3) -11 hh'^-ch, 0.86(6H, t, J=7.1Hz), 1.50(4H, tq, J=7.1, 7.1Hz), 2.53(2H, t, J=7.9Hz), 3.21(4H, m), 3.57(2H, s), 4.08(2H, t, J=7.9Hz), 6.85(IH, br.s), 7.00(1H, d, J=7.5Hz), 7.14-7.80(17H, m) -12 1.11(6H, t, J= 2.53(2H, t, J= 3.22(3H, d), 3 J=7.2, 7.2Hz), 4.09(2H, t, J= 6.95(IH, dd, J= 7.04-7.64(16H, 7. 74( IH, dd, J= 8.34(1H, dd, J 7.2Hz), 7.9Hz), .29(4H, dq, 3.55(2H, s), 7.9Hz), 7.5, 1.5Hz), m), 7.5, 1.5Hz), 8.3, 1.1Hz) -13 1.23(6H, t, J= 2.61(2H, t, J= 3.22(3H, s), 3 4.08(2H, t, J= 4.21(4H, q, J= 6.93(IH, dd, J= 7.28-7.75(14H, 7. 73(IH, dd, J= 8.33(IH, dd, J 7.1Hz), 7.2Hz), .49(2H s), 7.2Hz), 7.1Hz), 7.6, 1.5Hz), m), 7.6, 1.5Hz), =8.3, 1.5Hz) m.p. 78-81 -14 1.11(6H, t, J=7.4Hz), 1.15(3H, t, J=7.2Hz), 2.52(2H, t, J=7.5Hz), 3.29(6H, m), 3.54(2H, s), 4.09(2H, t, J=7.5Hz), 6.95(IH, dd, J=7.9, 1.1Hz), 7.10(IH, dd, J=7.9, 7.9Hz), 7.24-7.73(16H, m), 8.36(IH, d, J=8.3Hz) -15 O' \ CHj CH, 1.15(3H, t, J=7.2Hz), 1.23(6H, t, J»7.2Hz), 2.61(2H, t, J»7.2Hz), 3.29(2H, g, J-7.2Hz), 3.49(2H s), 4.07(2H, t, J=7.2Hz), 4.21(4H, g, J«7.2Hz), 6.94(IH, dd, J-7.5. 1.5Hz), 7.08(IH, dd. J-7.9, 7.9Hz), 7.30-7.73(14H, m). 8.34(1H. dd. J=7.9 > 1.5Hz) 311 Table 5] Example Structure NMR (6, 300MHz, CDC13) -16 p~F i ii n ° L# ffV^n t^^o-^V 0 vu Hi >~-o ^ U Y* 0 ^ ch3 1.05(6H, d, J=6.4Hz), 1.23(6H, t, J=7.2Hz), 2.62(2H, t, J=7.2Hz), 3.51(2H s), 3.85(1H, sep, J=6.4Hz), 4.10(2H, t, J=7.2Hz), 4.20(4H, q, J=7.2Hz), 6.95(1H, dd, J=7.9,1.5Hz), 7.07(IH, dd, J=7- 9, 7.9Hz), 7.30-7.61(12H, m), 7.68(IH, dd, 3=7.9, 1.5Hz), 7.75(IH, br.s), 8.28(1H, dd, J=7.9, 1.5Hz) -17 F F fiY^K °'^CK J 1 m <^0 ^ 0*S>^ 0 \ ch, 1.23(6H, t, 3—7.1Hz), 2.61(2H, t, 3=7.1Hz), 3.71(3H, s), 3.75(2H, s), 4.07(2H, t, J=7.1Hz), 4.22(4H, q, J=7.1Hz), 6.94(IH, d, J=7.6Hz), 7.29-7.62(13H, m), 7.72(IH, dd, J=1.4, 7.6Hz), 8.47(IH, d, J=8.3Hz), 10.25(IH, brs) -18 F^,F i ff rS °\ ff^T °^ca 1.13(3H, t, J=7.2Hz), 1.23(6H, t, 3=7.1Hz), 2.30(3H, s), 2.61(2H, t, 3=7.1Hz), 3.25(2H, q, J=7.2Hz), 3.44(2H, s), 4.07(2H, t, J=7.1Hz), 4.21(4H, q, J=7.1Hz), 6.75(IH, s), 7.30-7.69(14H, m), 8.19(IH, brs) 312 Example 6 4-[(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]benzoic acid 2-[9-(2,2,2-trifluoroethylcarbamoyl)-9H-fluoren- 9-yl]ethyl ester 5 a) 4-t(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]benzoic acid ethyl ester 4-Aminobenzoic acid ethyl ester (0.568 g) and triethylamine (0.570 g) were dissolved in methylene chloride 10 (20 mL), and to this solution was dropwise added a solution of 4'-trif luorome thylbiphenyl-2-carboxylic acid chloride, which is prepared from 4' -trif luorome thylbiphenyl-2-carboxylic acid (1.00 g) in a similar manner to Example 1 d), in methylene chloride under ice-cooling. The solution was stirred at room 15 temperature for 2 hours, followed by addition of methylene chloride (100 mL). The reaction mixture was washed with 2N hydrochloric acid and saturated brine, dried over sodium sulfate and concentrated to give the title compound (1.43 g). b) 4-[(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]benzoic 20 acid CF re 313 The 4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]benzoic acid ethyl ester (0.700 g) obtained in Example 6 a) was subjected to reactions similar to Example 1 f) to give the title compound (0.680 g) as a white solid. c) 9-[2-(Tert-butyldimethylsilanyloxy)ethyl]-9H-fluoren-9-carboxylic acid (2,2,2-trifluoroethyl)amide TBSO NH I NH CF3 ^ cf3 9H-Fluorene-9-carboxylic acid (2,2,2- trifluoroethyl)amide (3.00 g) was dissolved in tetrahydrofuran 10 (100 mL), and to this solution was added dropwise a 1. 5M solution (13.7 mL) of lithium diisopropylamide under ice-cooling. The mixture was stirred for one hour under ice-cooling, and to this was added a solution of tert-butyldimethylsilanyloxyethyl bromide (2.46 g) in tetrahydrofuran (5 mL). The temperature 15 was gradually raised from under ice-cooling to room temperature, and the mixture was stirred overnight. Saturated aqueous ammonium chloride was added to the reaction mixture under ice-cooling and then extracted with ethyl acetate (50 mL x 2). The extract was washed with saturated brine, dried over sodium 20 sulfate and purified by column chromatography on silica gel with ethyl acetate :hexane=l: 2.5 to give the title compound (6.00 g). d) 9-(2-Hydroxyethyl)-9H-fluoren-9-carboxylic acid (2,2,2-trifluoroethyl)amide 314 tbso nh NH I The 9-[2-(Tert-butyldimethylsilanyloxy)ethyl]-9H-fluoren-9-carboxylic acid (2,2,2-trifluoroethyl)amide (6.00 g) obtained in Example 6c) was dissolved in tetrahydrofuran 5 (13 mL) - acetic acid (39 mL) - water (13 mL). The solution was stirred at room temperature for 20 hours and concentrated in vacuo. The residue was purified by column chromatography on silica gel with ethyl acetate: hexane=1:1 to give the title compound (3.80 g) . e) 4-[(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]benzoic acid 2-[9-(2,2,2-trlfluoromethylcarbamoyl)-9H-fluoren-9-yl]ethyl ester 315 COOH The 4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]benzoic acid (0.345 g) obtained in Example 6 b) and the 9-(2-hydroxyethyl)-9H-fluoren-9-carboxylic acid (2,2,2-trifluoroethyl)amide (0.300 g) obtained in Example 6 d) were subjected to reactions similar to those in Example 1 g) to give the title compound (0.390 g) as a colorless solid (see Table 52).

Examples 6-2 to 6-22 Compounds of Examples 6-2 to 6-22 were obtained in a similar manner to Examples 6, 1-2 b), 1-2 c) and 1-2 d). The compounds thus obtained were shown in Tables 52 to 56. 316 Table 52 Example Structure NMR (8. 300MHz ,CDC13) 2.98(2H, t, J=6.8Hz), 3.63-3.71(2H, m), 3.81(2H, t, J=6.8Hz), 5.27(IH, br). 7.00(1H, brs), 7.12(2H, m), 7.30-7.84(18H, m). 6-2 2.45-2.58(2H# m), 4.10-4.18(IH, m), 4.21(2H, t, J=7.5Hz), 7.02(IH, brs), 7.14-7.88(20H, m). 6-3 3.01(2H, t, J=6.6Hz), 3.60-3.74(2H, m), 3.86(2H, t, J=6.6Hz), 5.27(18H, m), 7.20-7.61(18H, m), 7.75(2H, d, J=6.6Hz), 7.97(IH, brs), 8.52(IH, d, J=8.4Hz). 6-4 3.56(2H, t, J=5.2Hz), 4.06(2H, t, J=5.2Hz), 5.52(IH, br), 7.08(1H, brs), 7.15-7.98(21H, m). 6-5 3.42-3.54(2H, m), 3.55(2H, s), 4.26(2H, t, J=6.6Hz), 5.52(IH, br), 7.06(IH, brs), 7.18-7.88(21H, m). 317 Table 53 Example Structure NMR (5,300MHz, CDC13) 6-6 2.31-2,42(IH, m), 2.80-2.93(1H, m). 3.73-3.89(2H, m), 4.16-4.26(1H, m), 4.32-4.43(2H, m), 5.62(1H, br), 7.09((IH, brs), 7.26-8.01(19H, m). 6-7 2.15-2.29(2H, m), 3.34(2H, t. J=7.9Hz), 4.01-4.18(2H. m), 4.40(2H, t, J=6.2Hz), 6.15(1H, br), 7.08(IH, brs), 7.18-7.98(17H, m), 7.92(1H, d, J=8.4Hz). 6-8 2.88(2H, t. J=8.3Hz), 3.83-3.93(2H, m), 4.23(2H, t, J=8.3Hz), 5.90(IH, t, J=6.4Hz), 7.01(IH, brs), 7.16-7.86(22H, m). 6-9 2.12-2.29(IH, m), 2.56-2.68(IH, m), 3.70-3.80(3H, m), 4.09-4.29(2H, m), 5.41(1H, br), 7.05(1H, brs), 7.12-7.78(20H, m), 7.86(1H, d, J=7.5Hz). 6-10 2.16-2.30(2H, m), 2.62-2.72(2H, m), 3.61(1H, t, J=7.5Hz), 3.71-3.99(4H, m), 4.12-4.37(4H, m), 5.67(IH, br), 7.05(1H, brs). 7.15-7.91(17H, m). 318 Table 54 Example Structure NMR (6, 300MHz, CDCI3) 6-11 3.49(2H, t, J=6.9Hz), 4.09-4.29(2H, m). 4.56(2H, t, 3=6.9Hz), 6.34(IH, br). 7.08(1H, brs), 7.12-8.00(18H, m). 6-12 2.39-2.50(IH, m), 2.93-3.05(IH, m), 3.78-4.06(2H, m), 4.20-4.41(2H, m), 4.77(1H, d, J=6.4Hz, J=9.6Hz), 5.42(IH, IH, t, J=6.4Hz), 7.07(IH, brs), 7.19-7.88(15H, m). 6-13 2.19-2.30(IH, m), 2.62-2.73(IH, m), 3.79-3.82(2H, m), 4.20-4.40(3H, m), 5.80(1H, t, J=6.4Hz), 7.06(IH, brs). 7.16-7.92(16H, m). 6-14 1.22(6H, t, 3-1.1Hz), 2.77(2H, t, J=6.9Hz), 4.21(4H, q, J=7.1Hz), 4.30(2H, t, J=6.9Hz), 7.06(IH, brs), 7.19-7.88(17H, m) 6-15 1.23(6H, t, J=7.1Hz), 1.64(3H, s), 2.77(2H, t, J=6.9Hz), 4.21(4H, q, J=7.1Hz), 4.29(2H, t, J=6.9Hz), 6.93(IH, brs), 7.20-8.24(16H, m) 319 Table 55 Example Structure NMR (5, 300MHz,CDCI3) 6-16 1.22(3H, 1.23(3H, 2.76(2H, 4.20(2H, 4.21(2H, 4.29 (2H, J=7.1Hz), J=7.1Hz), J=6.9Hz), J=7.1Hz), J=7.1Hz), J=6.9Hz), 6.95-7.91(17H, m) 6-17 1.22(6H, t, 2.77(2H, t, 4.20(4H, q, 4.31(2H, t, 6.93(2H, d.

J=7.1Hz), J=6.9Hz), J=7.1Hz), J=6.9Hz), J=8.8Hz), 7.26-8.13(13H, m). 7.92(2H, d, J=8.8Hz) 6-18 1.22(6H, t. J=7.1Hz) 2.76(2H, t, J=6.9Hz) 4.20(4H, q, J=7.1Hz) 4.30(2H, t. J=6.9Hz) 6.85(2H, d, J=8.8Hz) 7.21-7.81(13H, m), 7 d, J=8.8Hz), 8.21(IH J=7.6, 1.3) .88(2H, . dd. 6-19 1.14(6H, t, J=7.2Hz). 2.63-2.71(2H, m), 3.31(4H, dq, J=5.6, 7.2Hz), 4.29-4.38(2H, m). 7.15-7.20(IH, m), 7.23-7.38(7H, m), 7.41-7.47(IH, m), 7.49-7.63(4H, m), 7.64-7.75(4H, m), 7.81(1H, dd, J=1.5, 7.5Hz), 7.86-7.93(2H, m) 6-20 1.14(6H, t, J=7.1Hz), 2.65-2.74(2H, m), 3.31(4H, dq, J=5.7, 7.1Hz), 4.33-4.43(2H, m), 7.08(1H, d, J=8.3Hz), 7.27-7.44(6H, m), 7.47-7.61(5H, m), 7.63-7.72(3H, m), 7.90(1H, dd, J=1.9, 8.6Hz), 8.07(IH, d, J=1.9Hz), 8.23(IH, dd, J=1.5, 7.9Hz) 320 Fable 56 Example Structure NMR (5. 300MHz,CDCI3) 6-21 1.14(6H, t, J=7.2Hz), 2.64-2.73(2H, m), 3.32(4H, dq, J=5.6, 7.2Hz), 4.31-4.41(2H, m), 6.91-6.98(2H, m). 7.26-7.36(5H, m), 7.41(IH, dd, J=l.l, 7.5Hz), 7.47-7.59(3H, m), 7.60-7.71(5H, m), 7.94-8.01(2H, m), 8.11(IH, dd, J=l.l, 7.5Hz) 6-22 1.13(6H, t, J=7.2Hz), 2.66-2.75(2H, m), 3.32(4H, dq, J=5.3, 7.2Hz), 4.36-4.45(2H, m), 7.27-7.46(8H, m), 7.48-7.54(2H, m), 7.55-7.73(4H, m), 7.99(2H, s), 8.32(IH, dd, J-l.l, 7.9Hz) 321 Example 7 Trans-4-[(4'-trifluoromethylbiphenyl-2- carbony1)amino]cyclohexanecarboxylic acid 2-[9-(2,2,2-trifluoroethylcarbamoyl)-9H-fluoren-9-yl]ethyl ester a) 4-[(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]cyclo-hexanecarboxylic acid CF, H„N ^V^COOH COOH 4-Amino-cyclohexanecarboxylic acid (0.538 g) was dissolved in 4N sodium hydroxide (0.933 mL), and to this 10 solution were dropwise added simultaneously a solution of the acid chloride which is obtained from 4 '-trif luorome thy lbiphenyl-2-carboxylic acid (1.0 g) in a similar manner to Example 1 d) in tetrahydrofuran (5 mL) and 4N aqueous sodium hydroxide (0.933 mL) under ice-cooling. The 15 mixture was stirred at room temperature for one hour, acidified with 2N hydrochloric acid and extracted with ethyl acetate. The extract was washed with saturated brine and dried over sodium sulfate to give the title compound (1.20 g) as a colorless powdery solid. 20 b) Trans-4-[(4'-trifluoromethylbiphenyl-2- carbonyl)amino]cyclohexanecarboxylic acid 2-[9-(2,2,2-trifluoroethylcarbamoyl)-9H-fluoren-9-yl]ethyl ester 322 cf, XX cooh The 4-[(4'-trifluoromethylbiphenyl-2- carbonyl)amino]cyclohexanecarboxylic acid (0.570 g) obtained in Example 7 a) and 9-(2-hydroxyethyl)-9H-fluoren-9-carboxylic acid (2,2,2-trifluoroethyl) amide (0.500 g) obtained in Example 6 d) were treated in a similar manner to Example 1 g) to give the title compound (0.534 g) as a colorless solid (see Table 57).

Examples 7-2 to 7-5 Compounds of Examples of 7-2 to 7-5 were obtained in a similar manner to Example 7. The compounds thus obtained were shown in Table 57. 323 fable 57 Example Structure NMR (5, 300MHz,CDCI3) uD * 1.08-1.20(4H, m), 1.28-1.42(4H, m), 1.87-1.94(IH, m). 2.80(2H. t, J=7.1Hz), 3.52(2H, t, J=7.1Hz), 3.65(1H, m), 3 . 89(IH, br), 5.18(IH, d, J=8.3Hz), 5.25(IH, t. J=6.4Hz), 7.29-7.79(16H, m) . m.p. 156.3-158.0 7-2 0 . 60-0.71(2H, m), 1.05-1.27{2H, m), 1.53-1.86(4H, m). 2.82(2H, t, 6.9Hz). 3.54(2H, t, J=6.9Hz), 3.56-3.73(2H, m). 4.96(1H, d. J=8.3Hz). 5.27(IH, t. J=7.7Hz), 7.30-7.80(16H, m). 7-3 1.33-1.73(8H, m). 2.00-2.13(IH, m), 2.22-2.37(IH, m), 2.45-2.60(IH, m), 3.52(1H. t, J=7.OHz), 3.66-4.11(4H, m). 5.30(IH, d. J=11.3Hz). 5.72(1H, t. J=8.2Hz), 7.20-7.33(13H, m). 7-4 1.09-1.20(2H, m), 1.24(6H, t, J=7.2Hz). 1.36-1.53(6H, m), 2.27-2.38(1H, m). 3.82-3.95(lH, m), 4.22(4H, q, J=7.2Hz), 4.80(2H, s). 5.21(1H, br-d. J=7.9Hz). 7.22-7.39(6H, m). 7.42-7.57(4H, m), 7.60-7.70(3H, m) 7-5 ■or cHj 1.12-2.27(9H, m), 1.24(6H, t, J=7.2Hz), 2.60(2H, t, J=7.2Hz), 3.59-3.7 8and3.90-4.15(lH, m), 4.02(2H, t, J=7.2Hz), 4.22(4H, q. J=7.2Hz), 4.98and5.30(IH, each d, J=8.4Hz), 7.18-7.22(13H, m) cis,trans mixture 324 Example 8 2-Phenyl-2-(2-{4-[(4'-trifluoromethylbiphenyl-2- carbonyl)amino]piperidin-l-yl}acetoxymethyl)malonic acid diethyl ester a) l-Benzyl-4-(4'-trifluoromethylbiphenyl-2-carbonylamino)piperidine 4 '-Trif luoromethyl-biphenyl-carboxylic acid (5.0 g) was dissolved in dimethylformamide (50 mL), and to this solution were added at room temperature 4-amino-l-benzylpiperidine (3.55 g), 1-hydroxybenzotriazole hydrate (3.0 g) and l-ethyl-3-(3*-dimethylaminopropyl)carbodiimide hydrochloride (3.58 g). The mixture was stirred at room temperature overnight, and the reaction solution was concentrated in vacuo to precipitate crystals. The crystals were washed successively with saturated aqueous sodium bicarbonate and water, and dried in vacuo to give the title compound (7.42 g). b) 4-(4'-Trifluoromethylbiphenyl-2-carbonylamino)piperidine re CF.

To a solution of the 1-benzyl-4-(4'- 325 trifluoromethylbiphenyl-2-carbonylamino)piperidine (1.47 g) obtained in Example 8 a) in tetrahydrofuran-methanol (1:1; 50 mL) was added palladium hydroxide (300 mg) in a stream of argon under ice-cooling. The mixture was stirred for one day at 5 normal pressure under hydrogen atmosphere, and further stirred for one day at normal pressure under hydrogen atmosphere after further addition of palladium hydroxide (300 mg). The reaction mixture was filtered through a Celite pad and washed with methanol. The filtrate and the washings were combined, 10 concentrated in vacuo and purified by column chromatography on silica gel with chloroform:methanol:aqueous ammonia=100:10:1 to give the title compound (1.03 g). c) [4-(4'-Trifluoromethylbiphenyl-2-carbonyl-amino)piperidin-l-yl]acetic acid ethyl ester To a solution of 4-(4'-trifluoromethylbiphenyl-2-carbonylamino)piperidine (1.03 g) obtained in Example 8 b) in dimethylformamide (5 mL) were added potassium carbonate (276 20 mg) and bromoacetic acid ethyl ester (223 (JiL). The mixture was stirred overnight at ambient temperature of 90°C, and then concentrated in vacuo. The residue was distributed with water and chlorofoirm, and the aqueous layer was further extracted with chloroform. The organic layers were combined, washed with CF.

CF, C0,Et 326 saturated brine, dried over sodium sulfate, concentrated in vacuo and purified by column chromatography on silica gel with chloroform:methanol=30:1 to give the title compound (598 mg). d) [4-(4'-Trifluoromethylbiphenyl-2-carbonyl-5 amino)piperidin-l-yl]acetic acid To a solution of [4-(4'-trifluoromethylbiphenyl-2-carbonylamino)piperidin-1-yl]acetic acid ethyl ester (595 10 mg) obtained in Example 8 c) in tetrahydrofuran-methanol (1:2; 10.2 mL) was added 1M aqueous lithium hydroxide (6.8 mL), and the mixture was stirred at room temperature for 6 hours. The reaction solution was concentrated in vacuo and 2N hydrochloric acid was added to the residue to adjust the pH to about 3, thereby 15 crystals were precipitated. The crystals were collected by filtration, washed with cold water and dried in vacuo to give the title compound (411 mg). e) 2-Phenyl-2-(2-{4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]piperidin-1-yl}acetoxymethyl)malonic acid 20 diethyl ester C02Et 327 o.

The [4-(4'-trifluoromethylbiphenyl-2-carbonyl-amino) piper idin-l-yl] ace tic acid obtained in Example 8 d) and the 2-hydroxymethyl-2-phenylmalonic acid diethyl ester 5 obtained in Example 1-2 a) were subjected to reactions similar to those in Example 1 g) to give the title compound (90 mg) (see Table 58).

Table 58 Example structure NMR(8,300MHz, CDC13) 8 H k ch3 1.07-1.19(2H, m). 1.25(6H, t, J=7.OHz), 1.54-1.68(2H, m). 2.10-2.22(2H, m), 2.52-2.62(2H, m). 3.08(2H, s), 3.70-3.85(IH, m), 4.24(4H, q. J=7.0Hz), 4.85(2H, s), 5.07-5.16(1H, m), 7.28-7.39(6H, m), 7.42-7.57(4H, m), 7.61-7.71(3H, m) Example 9 2-Phenyl-2-(2-{4-[(4'-trifluoromethylbiphenyl-2- carbonyl)amino]indol-l-yl}acetoxymethyl)malonic acid diethyl ester 328 a) (4-Nitroindol-l-yl)acetic acid ethyl ester BrCH,CO,Et OEt Sodium hydride (60% /mineral oil:81 mg) was dissolved in dimethylformamide (5 mL), and the solution was cooled to 0°C. After addition of 4-nitroindole (300 mg), the mixture was stirred for one hour, and bromoacetic acid ethyl ester (340 mg) was added thereto, followed by stirring at 0°C for 4 hours. Water was added thereto and the mixture was concentrated, diluted with ethyl acetate, washed with water, dried over sodium sulfate, then concentrated to give the title compound (367 mg). b) (4-Nitroindol-l-yl)acetic acid OEt The (4-nitroindol-l-yl)acetic acid ethyl ester obtained in Example 9 a) was subjected to reactions similar to those in Example 1 f) to give the title compound (243 mg). c) 2-[2-(3-Nitroindol-l-yl)acetoxymethyl]-2-phenylmalonic acid diethyl ester The (4-nitroindol-l-yl)acetic acid (229 mg) obtained in 20 Example 9 b), 4-dimethylaminopyridine (143 mg) and the 329 2-hydroxymethyl-2-phenylmalonic acid diethyl ester (240 mg) obtained in Example 1-2 a) were subjected to reactions similar to those in Example 1-3 c) to give the title compound (301 mg). d) 2-12-(4-Aminoindol-1-yl)acetoxymethyl]-2-phenylmalonic 5 acid diethyl ester phenylmalonic acid diethyl ester (100 mg) obtained in Example 9 c) was dissolved in tetrahydrofuran (2 mL), ethanol (4 mL) 10 and water (1 mL), and to the solution were added ammonium chloride (57 mg) and reduced iron (60 mg) . The mixture was stirred at 100°C for 2 hours, cooled, and filtered through a Celite pad. The filtrate was concentrated and diluted with ethyl acetate. The extract was washed successively with 15 saturated aqueous sodium bicarbonate, water and saturated brine, dried over sodium sulfate, and concentrated to give the title compound (93 mg). e) 2-Phenyl-2-(2-{4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]indol-l-yl}acetoxymethyl)malonic acid diethyl 20 ester The 2-[2-(3-Nitroindol-l-yl)acetoxymethyl]-2- CF, 9 OEt OEt The 2-[2-(4-aminoindol-1-y1)acetoxymethyl]-2- 330 phenylmalonic acid diethyl ester obtained in Example 9 d) was treated in a similar manner to Example 1 e) to give the title compound (119 mg)(see Table 59).

Example 9-2 2-(2-{2-methyl-4-[(4'-trifluoromethylbipheny1-2-carbonyl}amino]benzimidazol-1-yl}acetoxymethyl)-2-phenyl-malonic acid diethyl ester a) 2-Methyl-4-nitro-lH-benzimidazole 3-Nitrobenzene-1,2-diamine (1.0 g) was dissolved in ethanol (90 mL) and 5N hydrochloric acid (24 mL), and to this solution was added 2,4-pentanedione (1.3 g). The mixture was heated for 3 hours under reflux, cooled down to room temperature 15 and concentrated. To this concentrate was added ethyl acetate, and the mixture was washed successively with saturated aqueous sodium bicarbonate and water, and dried over sodium sulfate to give the title compound (1.1 g). b) (2-Methyl-4-nitrobenzimidazol-l-yl)acetic acid ethyl ester The 2-methyl-4-nitro-lH-benzimidazole (1.1 g) obtained in Example 9-2 a) was subjected to reactions similar to those in Example 9 a) to give the title compound (1.44 g). 331 c) 2-(2-{2-Methyl-4-[(4'-1rifluoromethylbiphenyl-2-carbonyl)amino]benz imidazol-1-yl}acetoxymethyl)-2-phenyl-malonic acid diethyl ester The (2-Methyl-4-nitrobenzimidazol-l-yl)acetic acid ethyl ester (500 mg) obtained in Example 9-2 b) was subjected to reactions similar to those in Examples 9 d), Id), 1 e), 1 f) and 1 g) to give the title compound (152 mg)(see Table 59).

Example 9-3 [2-Oxo-3-(4'-trifluoromethylbiphenyl-2-carbonyl)-2,3-dihydrobenzoxazol-6-yl]acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester 332 NHEt NHEt NHEt NHEt O The {3-Hydroxy-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester (195 mg) obtained in Example 3-2 was dissolved in chloroform (5 mL), and to this solution was added triethylamine (72 mg). The solution was cooled to 0°C and triphosgene (35 mg) was added thereto. After stirring for one hour, the reaction solution was washed with water, dried over sodium sulfate and purified by column chromatography on silica gel with hexane:ethyl acetate=l:l to give the title compound (173 mg)(see Table 59).

Example 9-4 2-(2-{3-Ethoxycarbonyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetoxymethyl)-2-phenylmalonic acid diethyl ester a) 5-Chloro-2-nitrobenzoic acid chloride -Chloro-2-nitrobenzoic acid was subjected to reactions similar to those in Example 1 d) to give the title compound, b) 5-Chloro-2-nitrobenzoic acid ethyl ester COOH COCI 333 COCI COOEt To a mixture of ethanol (1.23 mL), triethylamine (3.05 mL) and tetrahydrofuran (35 mL) was dropwise added a solution of 5-chloro-2-nitrobenzoic acid chloride (4.44 g) obtained in 5 Example 9-4 a) in tetrahydrofuran (10 mL) under ice-cooling. The mixture was stirred at room temperature overnight, and water was then added. The solution was diluted with ethyl acetate, and the organic layer was washed successively with saturated aqueous sodium bicarbonate and saturated brine, dried over 10 sodium sulfate and concentrated to give the title compound (4.43 g) as a pale brown solid. c) 3-Ethoxycarbonyl-4-nitrophenylmalonic acid dibenzyl ester COOBn CI + < C00Bn ^ COOBn C00Bn 0.N-V COOEt 2 COOEt The 5-chloro-2-nitrobenzoic acid ethyl ester (4.40 g) 15 obtained in Example 9-4 b) and malonic acid dibenzyl ester were subjected to reactions similar to those in Example 1-3 a) to give the title compound (4.61 g). d) 4-Amino-3-ethoxycarbonylphenylacetic acid COOBn COOBn M Q " COOEt COOEt The 3-ethoxycarbonyl-4-nitrophenylmalonic acid 334 dibenzyl ester (1.51 g) obtained in Example 9-4 c) was subjected to reactions similar to those in Example 1-3 d) to give the title compound (4.59 g). e) 3-Ethoxycarbonyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenylacetic acid CF, H2N r^^^COOH ^ ^ ^ 11 ^ 0 COOH COOEt The 4-amino-3-ethoxycarbonylphenylacetic acid (1.51 g) obtained in Example 9-4 d) and 4'-trifluoromethylbiphenyl-2-carboxylic acid chloride (1.99 10 g) were subjected to reactions similar to those in Example 7 a) with the proviso that sodium bicarbonate was used as a base, thereby the title compound (1.87 g) was given as a pale yellow amorphous powder. f) 2-(2-{3-Ethoxycarbonyl-4-[(4'-trifluoromethylbiphenyl-2-15 carbonyl)amino]phenyl}acetoxymethyl)-2-phenylmalonic acid diethyl ester 335 COOEt COOEt COOEt jQOf "OEt COOEt COOEt The 3-ethoxycarbonyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenylacetic acid (0.532 g) obtained in Example 9-4 e) and the 2-hydroxymethyl-2-phenylmalonic acid 5 diethyl ester (1.04 g) obtained in Example 1-2 a) were treated in a similar manner to Example 1 g) to give the title compound (0.524 g)(see Table 59).

Example 9-5 2-(3-{3-Dimethylcarbamoyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)-amino]-phenyl}-propionyloxymethyl)-2-phenyl-malonic acid diethyl ester a) 5-Methyl-2-nitrobenzoic acid chloride 5-Methyl-2-nitrobenzoic acid was treated in a similar manner to Example Id) to give the title compound, b) 5, N, N-Trimethyl-2-nitrobenzamide 336 O.N 0,N O N 0 CI The 5-methyl-2-n±trobenzoic acid chloride obtained in Example 9-5 a) was treated in a similar manner to Example 1 e) to give the title compound. 5 c) 5-Bromomethyl-N,N-dimethyl-2-nitrobenzamide The 5, N, N-Trimethyl-2-nitrobenzamide (4.16 g) obtained in Example 9-5 b), N-bromosuccinimide (3.56 g) and 2,2'-azobisisobutyronitrile (328 mg) were suspended in carbon 10 tetrachloride (80 mL). The suspension was stirred at 90°C for 2 hours, filtered through a Celite pad and purified by column chromatography on silica gel with hexane:ethyl acetate=5:4 to give the title compound (602 mg). d) 3-(3-Dimethylcarbamoyl-4-nitrophenyl)-2-methoxy-15 carbonylpropionic acid benzyl ester The 5-bromomethyl-N,N-dimethyl-2-nitrobenzamide (0.597 g) obtained in Example 9-5 c) and malonic acid benzyl ester methyl ester were subjected to reactions similar to those in 20 Example 9-4 c) to give the title compound (0.491 g). 337 e) 3-(4-Amino-3-dimethylcarbamoylphenyl)-2-methoxycarbony1-propionic acid COOMe COOMe 0;NIJ COOBn ^ COOH 0 0 I I The 3-(3-dimethylcarbamoyl-4-nitrophenyl)-2-methoxycarbonyl-propionic acid benzyl ester (0.490 g) obtained in Example 9-5 d) was subjected to reactions similar to those in Example 1-2 c) to give the title compound (0.353 g) . f) 3-(4-Amino-3-dimethylcarbamoylphenyl)propionic acid methyl ester COOMe /COOMe IT COOH O N^ 0 I The 3-(4- amino-3-dimethylcarbamoylphenyl)-2- methoxycarbonylpropionic acid (347 mg) obtained in Example 9-5 e) was stirred at 150°C for 40 minutes, cooled down to room temperature, and purified by column chromatography on silica 15 gel with hexane:ethyl acetate (1:1 to 0:1) to give the title compound (180 mg). g) 2-(3-{3-Dimethylcarbamoyl-4-[(4'-trifluoromethyl- biphenyl- 2 -carbonyl )amino]phenyl}propionyloxymethyl)-2-phenylmalonic acid diethyl ester 338 COOMe 0^ The 3-(4- amino-3-dimethylcarbamoylphenyl)propionic acid methyl ester (0.138 g) obtained in Example 9-5 f) was subjected to reactions similar to those in Examples 1 e). If) and 1 g) to give the title compound (0.158 g)(see Table 59).

Examples 9-6 to 9-29 Compounds of Examples 9-6 to 9-29 were obtained in a similar manner to Examples 9 to 9-5. The compounds thus 10 obtained were shown in Tables 59 to 64. 339 Table 59 Example Structure NMR (8,300MHz,CDCI3) LXt 1.18(6H, t. J=7.2Hz),4.15(4H, q, J=7.2Hz), 4.73(2H, s), 4.85(2H, s). 5.56(IH, d, J=3.OHz), 6.85(IH, d, J=3.4Hz), 6.91 (IH, d, J=8.3Hz), 7.16-7.78(16H, m), 7.92(1H, d, J=6.8Hz) 9-2 1.17(6H, t, J=7.1Hz), 2.38(3H, s), 4.13(4H, q, J=7.1Hz), 4.70(2H, s), 4.87(2H, s), 6.84(IH, d. J=7.9Hz), 7 .12-7.63(13H, m), 7.80(1H. dd, J=7.5, 1.5Hz). 8.18(IH, d. J=7.9Hz), 8.41(IH, s) 9-3 uN-^\ RH CH, 1.08(6H, t, J=7.2Hz), 3.27(4H, dq. J=7.2, 7.2Hz). 3.61(2H, s). 4.88(2H. s), 6.93(IH, d. J=1.1Hz), 7.04(IH, dd, J=8.3. 1.5Hz), 7.11-7.70(15H, m). 7.79(IH, d, J-8.3Hz) 9-4 1.21(6H, t. J=7.1Hz), 1.35(3H, t, J=7.1Hz), 3.55(2H, s), 4.15-4.30(6H,m) , 4.83(2H, s), 7.24-7.38(6H, m), 7.41-7.47(IH, m). 7.48-7.62(6H,m) , 7.76(1H. dd, J=1.5, 7.5Hz), 7.81(IH, d. J=1.9Hz), 8.68(IH, d. J=8.7Hz), 11.23(IH, br-s) 9-5 1.24(6H, t, 3=1.OHz), 2.53(2H, t, J=7.3Hz), 2.76-3.00(6H, br), 2.81(2H. t, J=7.3Hz), 4.24(4H, q, J=7.0Hz). 4.81(2H, s), 6.96(1H, d. J=2.3Hz), 7.17(IH, dd, J=1.2, 8.4Hz), 7.29-7.37(5H, m), 7 . 37-7.42(IH, m), 7 .44-7.57(2H, m). 7.60-7.64(4H, m), 7.68(1H, dd, J=1.5, 7.4Hz), 8.28(IH, d, J=8.4Hz), 9.05(1H, br-s) 340 Table 60 Example Structure NMR (5, 300MHz,CDCI3) 9-6 1.12(6H, t, 3=1.2Hz), 3.30(4H, dq. J=5.7, 7.2Hz), 4.39(2H, d, J=6.OHz), 5.08(2H, s). 5.59(IH, br-t. J=6.0Hz), 6.97-7.03(2H, m), 7.28-7.42(8H, m), 7.43-7.55(4H, m), 7.56-7. 61 (2H, m), 7.66-7.71(IH, m), 7.76-7.83(2H, m) 9-7 1.08(3H, t, J=7.2Hz), 2.64-2.82(2H, m), 2.86-2.97(2H, m). 3.13-3.36(2H, m), .87-5.98(IH, br). 6.03(1H. s), 7.00(1H, S), 7.04-7.15(4H, m), 7.30-7.40(5H, m), 7.43(1H, dd. J-l.l, 7.5Hz), 7.48-7.63(4H, m). 7.63-7.71(2H. m). 7.78(1H, dd. J=1.5. 7.5Hz) 9-8 1.04(6H, t. J=7.2Hz), 3.23(4H, dq, J=5.7, 7.2Hz), 3.55(2H, S), 4.85(2H, S). 5.23(2H, s), 7.08(2H, br-t, J=5.7Hz), 7.14-7.22(2H, m). 7.23-7.47(10H, m), 7.48-7.64(6H, m) , 7.76(1H, dd. 3=1.5, 7.1Hz), 7.81(1H, d, 3=2.2Hz), 8.69(1H, d, J=8.7Hz), 11.17(IH, br-s) 9-9 0 ^NH^CH, 1.05(6H, t. J=7.2Hz). 3.25(4H. dq, J=5.6. 7.2Hz), 3.58(2H, s), 4.86(2H, s), 7.11-7.63(15H, m), 7.72(1H. dd, J=1.5, 7.5Hz), 7.83(IH, d.

J=1.9Hz), 8.66(IH. d, J=8.6Hz), 11.10(1H, br-s) 9-10 1.07(6H, t, J=7.2Hz), 1.36(3H, t. J=7.2Hz), 3.26(4H, dq, J=5.4, 7.2Hz), 3.58(2H, s), 4.26(2H, q, J=7.2Hz), 4.86(2H, s), 7.10(2H, br-t, J=5.4Hz), 7.16-7.37(6H, m), 7.40-7.64(7H, m), 7.77(1H, dd. J=1.9. 7.1Hz), 7.80(IH, d, J=1.9Hz), 8.69(IH, d, J=8.7Hz), 11.22(IH, br-s) 341 Table 61 Example Structure NMR (8,300MHz,CDCI3) 9-11 1.19(6H, t, J=7.2Hz), 4.17(4H, q, J=7.2Hz), 4.79(2H, s), 4.90(2H, s), 6.94(IH, d, J=8.OHz), 7-15-7.63(13H, m). 7.82(1H, d. J=7.5Hz), 8.25(1H. d, J=8.OHz), 8.47(IH, br.s) 9-12 O NH ^ \iH, m.p 139.4-141.0 9-13 1.15(6H, t, J=7.2Hz), 2.64-2.73(2H, m), 3.32(4H, dq, J=5.3, 7.2Hz), 4.31-4.44(2H, m), 4.41(2H, d, J=6.0Hz), 5.62(IH, br-t, 3=6.OHz), 7.10-7.16(IH, m), 7.24-7.39(7H, m), 7.42-7.58(6H, m), 7.62-7.72(3H, m), 7.74-7.78(IH, m), 7.85-7.92(IH, m) 1.07(6H, t, J=7.1Hz), 3.26(4H, dq, J=5.7, 7.1Hz), 3.57(2H, s), 3.81(3H, s), 4.86(2H, s), 7.10(6H, br-t. J=5.7Hz), 7.16-7.23(2H, m), 7.25-7.37(4H, m), 7.41-7 .63(7H, m), 7.77(1H, dd, 3=1.5, 7.5Hz), 7.80(IH, d, 3=2.2Hz), 8.68(IH, d, J=8.3Hz), 11.15(IH, br-s) 9-14 1.19(6H, t, J=7.OHz), 3.52(2H, s). 4.19(4H, q, J=7.0Hz), 4.82(2H, s). 5.23(2H, s). 7.24-7.29(5H, m), 7.32-7.46(7H, m). 7.49-7.62(6H, m), 7.74-7.79(IH, m) , 7.82(1H, d, 3=2.2Hz), 8.67(IH, d, J=8.8Hz), 11.17(IH, br-s) 9-15 1.21(6H, t, J=7.1Hz), 3.56(2H, s). 4.21(4H, q, J=7.1Hz), 4.85(2H, s), 7.23-7.32(5H, m) , 7.36-7.63(8H, m), 7.77(1H, dd, J=1.5, 7.5Hz), 7.86(1H, d, 3=1.9Hz), 8.70(IH, br-d, J=8.3Hz), 10.89(IH, br-s) 342 Fable 62 Example Structure NMR (8,300MHz,CDCI3) 9-16 1.22(6H, t, J=7.1Hz), 3.57(2H, s), 4.23(4H. q. J=7.1Hz), 4.85(2H, s), 6.92(1H, s), 7.03(IH, d, J=8.3Hz), 7.30-7.69(13H, m), 7.77(1H, d, J=8.3Hz) 9-17 1.23(6H, t. J=7.1Hz) , 3.67(2H, s), 4.23(4H, q, J=7.1Hz), 4.85(2H, s), 7.23-7.34(6H, m), 7.42-7.49(3H, m). 7.52-7.67(5H, m), 7.95(1H, d, J=1.9Hz), 8.05(1H. dd, J=1.5, 7.5Hz) 9-18 1.21(6H. t, J=7.2Hz), 1.31(6H, d. J=6.4Hz), 3.55(2H, s), 4.21(4H, q, J=7.2Hz), 4.83(2H, s). 5.09(IH, sept. J=6.4Hz). 7.24-7.38(6H, m). 7.41-7.47(IH, m), 7.48-7.62(6H, m), 7.73-7•81(2H, m), 8.68(1H, d, J=8.6Hz), 11.33(IH, br-s) 9-19 I.21(6H, t, J=7.1Hz), 3.54(2H, s), 3.80(3H, s). 4.21(4H, q, J=7.1Hz), 4.83(2H, s), 7.24-7.38(6H, m), 7.44(1H, dd, J=1.6, 7.1Hz), 7.50-7.62(6H, m), 7.77(IH, dd, J=1.5, 7.1Hz), 7.81(1H, d, J=2.3Hz), 8.67(IH, d, J=8.7Hz), II.15(IH. br-s) 9-20 o-"\ o CH, 1.21(6H. t. J=7.1Hz), 1.85-2.03(2H, m), 2.05-2.27(2H, m). 2.50-2.67(IH, m), 2.81(3H, brs). 2.88(3H, brs). 3.02-3.16(IH. m). 3.51(2H, s). 3.71-3.86(1H. m). 4.20(4H. q. J=7.1Hz), 4.82(2H, s), 6.99(1H, d. J=9.OHz), 7.05(IH, d. J=1.8 Hz). 7.18(IH. dd. J=1.9Hz. J=8.3Hz), 7.22-7.37(5H. m). 7.56(IH. dd. J-1.8H. J=9.0Hz). 8.01(1H, brs), 8.08(IH. d, J=8.3Hz). 9.29(IH. brs). 343 Table 63 Example Structure NMR (8,300MHz,CDCl3) 9-21 °y'nh CH, 1.18(6H, t, J=7.1Hz), 2.03(3H, s), 3.53(2H, s), 4.14(4H, q, J=7.1Hz), 4.86(2H, s), 6.97-7.05(2H, m), 7.24-7.81(15H, m), 8.35(1H, brs). 9-22 y mp 146.4-148.6 OMe 1.20(6H, t, J=7.2Hz) , 3.52(2H, s), 3•72(3H, s), 4.18(4H, q, J=7.2Hz), 4.83(2H, s), 6.83(IH, brs), 4.95(1H, dd, J=1.8Hz, J=8.3Hz), 7.14(IH,d, J=8.3Hz), 7.18-7.80(15H, m). 9-23 11 rrY^r* rYW 0 ° ^ch.

S^'N CH, 1.20(6H, t, J=7.1Hz), 2.36(3H, S), 3.57(2H, s), 4.20(4H, q, J=7.1Hz), 4.85(2H, s). 6.85(IH, s), 7.18-7.59(14H, m), 8.67 (IH, d, J=8.6Hz), 12.71(1H, brs) 9-24 X1 ITY^^04 (^iV 0 0 v 1.19(6H, t, J=7.2Hz), 3.53(2H, s), 4.17(4H, q, J=7.2Hz), 4.82(2H, s), 6.89-6.96(3H, m), 7.17-7.55(17H, m), 7.67 (IH, dd, J=1.5, 7.5Hz), 8.45(1H, d, J=8.7Hz) 9-25 £ .&■ \ CH- 1.21(6H, t, J=7.1Hz), 3.59(2H, s), 4.21(4H, q, J=7.1Hz), 4.87(2H, s), 7.27-7.78(15H, m), 8.67(IH, d, J=8.3Hz), 9.61 (IH, brs), 11.K1H, brs) 344 Table 64 Example Structure NMR (5, 300MHz,CDCI3) 9-26 1.20(6H, t, J=7.OHz), 1.94(6H, S), 3.14(2H, s), 3.48(2H, s), 4.19(4H, q, J=7.OHz), 4.81(2H, s). 6.83(1H, d, J=2.OHz), 7.08(IH, dd, 3=2.0, 8.0Hz), 7.27-7.59(12H, m), 7.68(1H, dd, J=1.2, 7.6Hz), 8.22(IH, d, J=8.5Hz), 10.7(IH, brs) 9-27 1.21(6H, t, 3=7.1Hz), 3.20(3H, s), 3.36(3H, s), 3.52(2H, s), 4.21(4H, q, J=7.1Hz), 4.82(2H, s), 7.23-7.61(14H, m), 7.71(IH, d, J=7.3Hz), 8.31(IH, d, J=8.4Hz), 9.49(IH, brs) 9-28 1.06(6H, d, J=6.9Hz), 1.20(6H, t, J=7.2Hz), 3.42-3.51(IH, m) , 3.56(2H, s), 4.20(4H, q, J=7.2Hz), 4.85(2H, s), 7.28-7.77(15H, m), 8.72(1H, d, J=8.7Hz), 11.81{1H, brs) 9-29 0.49(3H, d, J=6.6Hz), 0.90(3H, d, J=6.6Hz), 1.14-1.25(6H, m), 1.40-1.58(IH, m), 2.41(1H, d, J=3.6Hz), 3.51(2H, d, J=3.6Hz), 3.81-3.88(IH, m), 4.02-4.18(4H, m) , 4.83(2H, s), 6.79(IH, S), 7.05-7.69(14H, m), 8.19(IH, d, J=8.1Hz), 9.01(IH, brs) 345 Table 65 Compound structure NMR(5, 300MHz, CDC13) 2 e) F1 (T X JTTo Jj H 1 2.86(3H, brs), 2.93(3H, brs), 3.56(2H, s), 7.09(IH, d, J=2.OHz), 7.23-7.71(9H, m), 8.29(IH, d, J=8.7Hz), 9.06(IH, brs). 2-17 e) /=\ 71 oxnr f h ^ ^ 1.75-1.99(4H, m), 3.32-3.52(4H, m),3.53(2H, s), 7.20-7.69(10H, m), 8.22(IH, d, J=4.4Hz), 9.74(IH, brs).

Formulation Hereinafter, the present invention will be illustrated 5 specifically by references of formulations.

Formulation 1 A film with a controlled thickness was prepared by use of a gelatin shell composition (a) in accordance with the 10 conventional method. Two sheets of the film were inserted into a rotating left-right symmetric metallic die rolls and molded into outer shells of soft capsules, while a filling solution (b) was injected into the outer shells of the soft capsules, and simultaneously the outer shells of the softcapsules were 346 melted and sealed by the rotation of the die rolls, then the capsules were cut from the film. The capsules were dried in a rotary dryer, and allowed to dry for 4 days to give soft capsules. Hereinafter, specific examples of formulations were 5 given.

Formulation 1-1 (a) film composition gelatin 100 parts sugar alcohol solution derived from corn starch 10 30 parts purified water 100 parts (b) filling solution (per capsule) propylene glycol fatty acid ester 295 mg ethanol 105 mg Formulation 1-2 (a) film composition gelatin 100 parts sugar alcohol solution derived from corn starch parts purified water 100 parts (b) filling solution (per capsule) compound of Example 2-5 5 mg propylene glycol fatty acid ester 291 mg ethanol 104 mg Formulation 1-3 (a) film composition gelatin 100 parts sugar alcohol solution derived from corn starch parts 347 purified water 100 parts (b) filling solution (per capsule) compound of Example 2-5 5 mg propylene glycol fatty acid ester 277 mg 5 ethanol 148 mg Formulation 2 The compound of Example 2-22, an excipient and a binder were mixed in a usual method to prepare granulated powder. The powder obtained was blended with a disintegrator and a lubricant 10 to prepare a powder for tablets in a usual method. The powder was compressed to give tablets in a usual method. Specific examples of formulations were hereinafter given.

Formulation 2-1 compound of Example 2-22 5 mg lactose 133.06 mg crystalline cellulose 18 mg hydroxypropyl methylcellulose 2910 5.4 mg crospovidone 18 mg magnesium stearate 0.54 mg Formulation 2-2 compound of Example 2-22 5 mg lactose 92.44 mg corn starch 15 mg hydroxypropyl methylcellulose 2910 3.6 mg carboxymethyl starch 3.6 mg magnesium stearate 0.36 mg Formulation 2-3 compound of Example 2-22 5 mg D-mannitol 158.4 mg 348 hydroxypropyl methylcellulose 2910 6 mg calcium silicate 20 mg crospovidone 10 mg magnesium stearate 0.6 mg Pharmacological test Test Example 1 Inhibition of interliposomal triglyceride (TG) transfer activity by MTP Microsomal triglyceride transfer protein (MTP) from bovine liver was partially purified in such a way described below. A buffer (50 mM Tris, 250 mM sucrose, 1 mM EDTA, 0.02% NaN3 (pH 7.4)) for making a homogenate preparation was added to bovine liver, and the mixture was homogenated under 15 ice-cooling, then centrifuged at 10,000 x g (4°C, 30 minutes). The supernatant was adjusted to pH 5.1 with hydrochloric acid, and stirred for 30 minutes. The solution was further centrifuged at 10,000 x g (4°C, 30 minutes), and 1 mM Tris buffer was added to the precipitated residue, and the mixture was 20 adjusted to pH 8.6 with sodium hydroxide. After addition of 2.7M ammonium sulfate solution, the mixture was stirred for 30 minutes, then centrifuged at 10,000 x g (4°C, 40 minutes). The resulting supernatant was served as a crude extraction fraction of MTP and stored at -80°C under freezing. In its practical 25 use, the crude extraction fraction of MTP was purified by column chromatography on diethylaminoethyl (DEAE) Sepharose using FPLC (Fast Performance Liquid Chromatography) system, and the purified MTP was used for the test.

Small unilamellar-vesicle (SUV) liposome (donor, 0.25 349 mol% triolein, 5 mol% cardiolipin) labeled with 14C-triolein and non-labeled SUV liposome (acceptor, 0.25 mol% triolein) were prepared. A fixed amount of donor and acceptor, and MTP were mixed with a sample dissolved in DMSO or with DMSO. The 5 mixture was incubated in a 15 mM Tris hydrochloride buffer (pH 7.4) containing 40 mM sodium chloride, 1 mM EDTA (ethylenediaminetetraacetic acid), 0.02% NaN3 and 0.5% bovine serum albumin at 37°C for one hour. After completion of the incubation, a suspension of DEAE cellulose (50% v/v) in 15 mM 10 Tris hydrochloride buffer (pH 7.4) was added to the above solution, and the mixture was centrifuged to separate the donor and the acceptor. The radioactivity in the acceptor was measured by liquid scintillation counter. The value obtained by subtracting the radioactivity in the blank from the amount 15 of radioactivity in the acceptor of a DMSO group was determined as MTP-mediated TG transfer activity, and it was compared with the value obtained by subtracting the radioactivity in the blank from the radioactivity in a sample group. The blank was prepared by adding 15 mM Tris-HCl buffer (pH 7.4) in place of 20 MTP. Inhibition rate (%) was calculated from the values obtained according to the following equation.

Inhibition rate (%) = 100 x (1 minus ((radioactivity of sample group minus radioactivity of blank group)/ (radioactivity of DMSO group minus radioactivity of blank 25 group))). 50% Inhibition rate (IC50) was determined on the basis of the above equation. The results were shown in Table 66 to 70. 350 Test Example 2 Inhibition of apolipoprotein B secretion from HepG2 cells HepG2 cells were suspended in Dulbecco' s Modified Eagle' s Medium (DMEM)(containing 10% fetal bovine serum, 100 units/mL 5 penicillin and 100 jig/mL streptomycin), and placed on a 96-well plate (4 x 104 cells/well), then incubated for 24 hours. After removal of the medium, DMEM was replaced by a medium containing a sample dissolved in DMSO or a medium containing DMSO (concentration of DMSO: 0.5%) and incubation was further 10 performed for 24 hours, after which the supernatant was recovered, and concentration of apo B in the supernatant was assayed by Enzyme-Linked Immunosorbent Assay (ELISA) ELISA was carried out as follows. Anti-human apo B monoclonal antibody (0.5 ng/well) diluted with a solution of 15 sodium carbonate in sodium bicarbonate buffer (50 mL, pH 9.6) was placed in a 96-well plate for ELISA, and allowed to stand at room temperature for 15 hours. After washing the plate, a blocking solution (250 |iL/well) was placed in the well, and allowed to stand at room temperature for 1.5 hours. After 20 washing the plate, a standard and a sample (100 iiL/well) were placed in the well and allowed to stand at room temperature for one hour. The standard was prepared by adjusting the concentration of the purified human apo B with the DMEM to 0 to lOOOng/mL. After washing the plate, an anti-human apo B 25 polyclonal antibody labeled with a horse radish peroxidase which was diluted in 1:1000 with DEME (100 (iL/well), and allowed to stand at room temperature for one hour. After washing the plate, 2,2-azinobis(3- ethylbenzothiazoline-6-sulfonic acid) solution (100 |xL/well) was placed in the well, and allowed to 351 stand at room temperature for one hour. The reaction was stopped by addition of 2% oxalic acid (100 nL/well), and absorbency at 405 nm was measured. Concentration of apo B in the sample was calculated on the basis of a standard curve of 5 the standard. Inhibition rate (%) was calculated from the assayed values in accordance with the following equation.

Inhibition rate (%) = 100 x (1 minus (concentration of apo B in sample group/concentration of apo B in DMSO group).

Based on the above equation, 50% inhibition concentration 10 (IC50) was determined.

The results were shown in Tables 66 to 70. 352 Table 66 Example Test Example 1 MTP inhibition ICso(nM) Test Example 2 Inhibition of apo B secretion ICs„(nM) Example Test Example 1 MTP inhibition IC50(nM) Test Example 2 Inhibition of apo 8 secretion ICso(nM) 1 0.6 .8 1-2 42 850 1-3 4.7 .75 1-4 3.4 190 1-5 0.66 0.65 1-6 1.2 .5 1-7 7.55 330 1-8 37.5 720 1-9 .95 3.2 1-11 32 22 1-12 7.6 63 1-13 .8 170 1-14 82 55 1-22 66.5 179.5 1-23 54 63 1-25 8.4 1-26 630 620 1-27 7 26 1-28 640 1-31 84.5 61 1-32 8.6 720 1-34 23 100 1-35 1.0 6.9 1-36 2.0 150 1-37 3.5 47 1-38 6.0 320 1-39 0.66 160 1-40 6.9 2.1 1-42 4.4 1-45 0.39 0.46 1-47 4.5 750 1-48 3.2 9.7 1-49 .3 1-51 0.96 530 1-52 690 1-53 0.43 860 1-62 .0 46 1-63 16 90 1-66 16 9.3 1-67 27 28 1-69 9.1 90 1-70 1.6 270 1-71 1.8 120 1-72 0.44 2.7 1-73 - 39 1-74 - 680 353 Table 67 Example Test Example 1 MTP inhibition ICso(nM) Test Example 2 Inhibition of apo B secretion ICso(nM) Example Test Example 1 MTP inhibition IC50(nM) Test Example 2 Inhibition of apo B secretion ICso(nM) 1-75 - 97 1-76 - 120 1-77 - 360 1-78 - 11 1-79 - 0.59 1-80 - 8.2 1-81 - 0.49 1-82 - 0.53 1-83 - 0.23 1-84 - 4.4 1-85 - 3.2 - - - 2 0.62 1.5 2-2 1.4 1.3 2-3 2.1 2.0 2-4 0.94 0.29 2-5 1.4 0.55 2-7 1.1 0.56 2-8 - 0.99 2-10 - 1.4 2-12 - 7.0 2-13 - 0.74 2-14 - 1.2 2-15 - 0.53 2-16 - 2.7 2-18 - 0.69 2-19 - 26 2-20 - 0.64 2-21 1.8 8.9 2-22 1.4 0.44 2-23 2.7 0.61 2-24 - 28 2-25 - 6.3 2-26 - 8.2 2-29 - 91 2-30 - 27 2-31 - 43 2-32 - 1.7 2-33 - 13 2-34 - 2.0 2-35 - 38 2-36 - 7.4 2-39 0.74 0.76 2-40 - 0.99 2-41 - 1.2 2-42 - 1.8 354 Table 68 Example Test Example 1 MTP inhibition ICso(nM) Test Example 2 Inhibition of apo B secretion ICsa(nM) Example Test Example 1 MTP inhibition IC50(nM) Test Example 2 Inhibition of apo B secretion IC5fl(nM) 2-43 - 9-0 2-44 - 33 2-45 - 39 2-46 - 2.9 2-47 - 1.2 2-48 - 0.36 2-49 - 49 2-50 - 21 2-51 - 47 2-53 - 4.6 2-54 - 8.5 2-55 - 4.2 2-56 - 0.93 2-57 - 0.56 2-58 - 1.9 2-59 - 0.99 2-60 - 1.3 2-61 - 0.38 2-62 - 0.37 2-66 - 57 2-67 - 43 2-68 - 2.25 2-69 - 0.91 2-70 - 2.34 2-71 - 0.54 2-72 - 0.95 2-73 - 2.93 2-74 - 0.84 2-75 - 12.54 2-76 - 0.85 2-77 - 2.74 2-78 - 0.14 2-79 - 1.3 2-80 - 0.79 2-81 - 0.96 2-82 - 4.41 2-83 - 8.87 2-84 - 2.01 2-85 - 0.49 2-86 - 0.42 2-88 - 1.92 2-90 - 1.74 2-91 - 0.54 2-92 - 1.47 2-93 - 45.8 2-95 - 18 355 Table 69 Example Test Example 1 MTP inhibition IC50(nM) Test Example 2 Inhibition of apo B secretion ICso(nM) Example Test Example 1 MTP inhibition IC50(nM) Test Example 2 Inhibition of apo B secretion ICsofnM) 2-96 - 81 2-97 - 22 2-98 - 0.97 2-99 - 19 2-102 - 14.63 2-103 - 42.6 2-104 - 3.58 2-105 - 0.2 2-106 - 0.44 2-107 - 50 2-108 - 0.82 2-109 - 0.93 2-110 - 0.65 2-114 - 3.1 2-115 - 44 2-117 - 38 2-118 - 1.9 3-2 - 4.2 3-3 0.40 1.0 3-4 2.1 13 3-5 - 2.2 3-6 .0 0.63 3-7 - 0.35 3-8 3.7 0.38 3-9 - 1.6 3-10 2.7 0.31 3-11 - 0.36 3-12 - 0.72 3-13 - 1.9 3-14 13 64 3-15 - 49.9 - - 0.33 4-2 - 16 4-3 - 7.9 4-5 - .2 4-6 - 7.5 4-7 - 4-8 - - - - 3.1 19 -2 66.5 875 -3 6.2 86.5 -4 2.4 57 356 Table 70 Example Test Example 1 MTP inhibition ICso(nM) Test Example 2 Inhibition of apo B secretion IC>io(nM) Example Test Example 1 MTP inhibition IC50{nM) Test Example 2 Inhibition of apo B secretion ICso(nM) -5 4.5 .0 -6 3.9 260 -8 14 340 -9 4.0 28 -10 6.2 300 -11 1.3 .1 1.3 2.4 0.34 6.4 3.0 .2 6 3.47 58.3 6-3 .2 510 6-8 50 630 6-10 22 870 6-14 6.3 87 6-15 2.0 57 6-16 2.9 170 6-17 2.3 420 6-19 3.2 6-21 9.8 920 7 4.97 60.0 7-2 2.46 26 7-5 16.2 237 - - - 8 33 595 - - - 9 11 260 9-2 4.2 450 9-3 - 59 9-4 - 9.9 9-5 - 3.1 9-6 - 59 9-8 - 6.9 9-10 - 2.3 9-11 210 9-13 - 0.53 9-14 - 41 9-17 - 23 9-21 - 9-22 - 0.96 9-23 - 8.77 9-24 - 7.86 9-27 - 0.82 - - - 357 Test Example 3 Olive oil-loading test Syrian hamsters (9-11 weeks of age) under non-fasted conditions were used in the test. Blood was collected 5 previously from orbital venous plexus, and a sample was suspended in 0.5% methyl cellulose (vehicle) and the suspension was forced to be administered orally to the hamsters at a dose of 0.3, 1, 3 or 10 mg/2 mL/kg. Only vehicle in the same volume was administered to the control group. Olive oil (2 mL/kg) was 10 forced to be administered orally 30 minutes after the administration of the sample, and blood was collected from orbital venous plexus 4 hours later. Plasma was recovered from the blood, and the amount of triglyceride (TG) in the plasma was determined by automatic analyzer (Hitachi Co.). The data 15 was expressed in terms of ATG(mg/dL)=the value at 4th hr minus the value before administration. Inhibition rate (%) was calculated from the data obtained on the basis of the following equation.

Inhibition rate (%) =100 x (1 minus ATG of sample group/ATG 20 of control group). The results were shown in Table 71. 358 Table 71 Example Test Example 3 Inhibition of fat absorption after olive oil-loading in Hamster (()mg/kg.p.o) Inhibition rate (%) Example Test Example 3 Inhibition of fat absorption after olive oil-loading in Hamster (()mg/kg.p.o) Inhibition rate (%) 1 57(100) 1-3 65(100) 1-5 59(3) 1-6 54(10) 1-35 59(100) 1-45 71(100) 1-66 52(100) 1-72 54(100) 2 95(10) 2-2 96(10) 2-3 68(3) 2-4 78(3) 2-5 70(3) 2-7 58(3) 2-8 89(3) 2-13 70(3) 2-14 80(3) 2-15 81(3) 2-18 58(3) 2-22 61(3) 2-25 55(3) 2-39 68(3) 2-48 87(3) - - 3-3 78(10) 3-5 80(10) 3-6 52(3) 3-7 74(3) 3-8 60(3) 3-10 85(3) 3-11 75(3) - - -9 78(100) -11 64(100) 9-10 54(3) 9-13 70(3) 359 Test Example 4 Liver TG release inhibition test Syrian hamsters (9 to 11 weeks of age) which were fasted for one day were used in the test.

Blood was collected previously from orbital venous plexus, and a sample was forced to be administered orally to the hamsters at a dose of 30, 100 or 300 mg/2 mL/kg, and the same amount of vehicle was administered to the control group. Triton WR 1339 (2 mL/kg) was intravenously administered to the hamsters 30 10 minutes after the above administration. Two hours later, blood was collected from orbital venous plexus, and plasma was separated from the blood. The amount of TG in the plasma was determined by automatic analyzer (Hitachi Co.). The data was expressed in terms of TG release velocity (mg/dL/min)=(value 15 at 2nd hour minus value before administration) /120. Inhibition rate (%) was calculated from the data obtained on the basis of the following equation.

Inhibition rate (%)= 100 x (1 minus TG release velocity of sample/TG release velocity of control group). The results were 20 shown in Table 72. 360 Table 72 Example No.

Test Example 4 Inhibition of liver TG release in Hamster (()mg/kg.p.o) Inhibition rate(%) Example No.

Test Example 4 Inhibition of liver TG release in Hamster (()mg/kg.p.o) Inhibition rate(%) 1 19(300) 1-6 0(100) 1-35 9(300) 2-5 0(100) 2-22 0(30) 2-39 6(100) 3-3 18(100) - - Test Example 5 Combination use test 5 Japanese white rabbits (male, 19 weeks of age, JW, purchased from Kitayama Labes Co., Ltd.) were fed previously in such a way that they were fed a high cholesterol diet (0.3 % cholesterol + 3 % peanut oil-added RC-4, Product of Oriental Yeast Co., Ltd.) of 70 g/day under limited feeding for one day. 10 The rabbits thus fed were used as a cholesterol-loaded rabbit model, and the grouping of such model was carried out in such a way that there might be no variation in the amount of plasma cholesterol among each group (five rabbits/group). After collection of blood from auricular artery, compounds of 15 Examples 2 to 5, simvastatin, and compounds of Examples 2 to 5 plus simvastatin were added to a high cholesterol diet in the dose as shown in Table below, and the rabbits were fed such diet. The rabbits were fed 70 g of each diet every morning. Blood 361 was collected from auricular artery 6 hours after the feeding on the 4th day of the administration, and cholesterol level in plasma was assayed. In the table, increased amount of plasma cholesterol during from the time of grouping to the 4th day was 5 shown.

Table 73 Increased amount of total cholesterol (mg/dl) Control 80.0 Simvastatin (1 mg/kg) 48.6 Example 2-5 (10 mg/kg) 8.6 Example 2-5 (10 mg/kg) + Simvastatin (1 mg/kg) 2.1 Test Example 6 Determination of the concentration in plasma 10 Syrian hamsters (9-15 weeks of age) under non-fasted conditions were used in the test. A sample was suspended in 0.5% methyl cellulose (vehicle), and the suspension was forced to be administered orally to the hamsters at a dose of 30 or 100 mg/2 mL/kg. After a fixed period of time, blood was partly 15 collected from orbital venous plexus, and the hamsters were subjected to laparotomy under ether anesthesia, and then blood was collected from portal vein. The blood was immediately cooled with ice to separate plasma. A portion of the plasma was extracted with an organic solvent and the supernatant was 20 recovered. Concentration of the sample (unchanged form) and 362 that of the metabolite in the supernatant were determined quantitatively by high performance liquid chromatography/mass spectrometry (LC/MS) comparing with chromatogram of synthetic standard.

Table 74 Compound Dose (mg/kg) Component Blood of portal vein (nM) Peripheral blood (MM) lh 2h 4h lh 2h 4h 1-2 Unaltered form <0.2 <0.2 <0.2 <0.2 <0.2 <0.2 Metabolite 1.6 2.2 6.7 0.9 1.3 2.9 1-12 Unaltered form <0.2 <0.2 <0.2 <0.2 <0.2 <0.2 Metabolite 11.8 18.2 24.4 7.3 12.1 .4 1-13 Unaltered form <0.2 <0.2 <0.2 <0.2 <0.2 <0.2 Metabolite 11.8 .6 27.3 .9 16.9 18.3 2-5 Unaltered form 0.01 0.03 0.01 <0.02 <0.02 <0.02 Metabolite 0.33 0.73 0.38 0.01 0.01 0.02 Test Example 7 Metabolic stability test in liver S9 and small intestine S9 Human and hamster liver S9 (final concentration: 2 mg 10 protein/mL), and human and hamster small intestine S9 (final concentration: 2 mg protein/mL) were each suspended in 100 mM potassium phosphate buffer (pH 7.4, containing |3-nicotinamide adenine dinucleotide phosphate: 1.3 mM, D-glucose-6-phosphate: 3.3 mM, magnesium chloride: 3.3 mM, 15 glucose-6-phosphate dehydrogenase:0.4 U/mL). The suspensions were mixed with a solution of a sample (Example 2-5) in DMSO. 363 The solutions were incubated at 37°C for 0, 10 and 60 minutes, and an organic solvent was added thereto. The solutions were centrifuged, and the concentration of the sample (unchanged form) in the supernatant was determined by high performance 5 liquid chromatography/mass spectrometry (LC/MS). Based on the data obtained, remaining rate (%) was calculated according to the following equation.

Remaining rate(%)=amount of sample 10 or 60 minutes after incubation/amount of sample at zero time after incubation x 100 10 Table 75 human hamster Remaining rate (%) after 10 min.

Remaining rate (%) after 60 min.

Remaining rate (%) after 10 min.

Remaining rate (%) after 60 min.

Small intestine S9 97.6 91.5 29.0 14.1 Liver S9 7.9 4.3 2.4 0 Test Example 8 Inhibitory activity on MTP and apo B secretion inhibition by 15 metabolites In a similar manner to Test Examples 1 and 2, the activity of metabolites was assayed. The results were shown in Table 364 below. Table 76 Compound Main metabolite MTP inhibition lC5o(nM) Inhibition of apo B secretion IC50 (nM) 1 p-F gjucnr >1000 >10000 9, <y NN \ ° \ CH3 ^CH3 >1000 >10000 1-35 p-F gxXnf >1000 >10000 n X o o X >1000 >10000 365 Table 77 Compound Main metabolite MTP inhibition IC50{ nM) Inhibition of apo B secretion IC50( nM) 2-5 l^F jCX I J H ^CH, O N 3 CH, >10000 >10000 H0Opo-x >-0 CH3 0 ^CH3 >1000 >10000 2-17 F^,F p^F Iw1" 0^NO - >10000 & ^Nn_\ 0 \ CH3 ^CH3 >1000 >10000 366 Table 78 MTP Inhibition of Compound Main metabolite inhibition apo B secretion ICso(nM) ICso(nM) p~F T ft nr™ >1000 >10000 3-4 ryS T H3C Cl ^0 CH3 ^CH3 >1000 >10000 Industrial Applicability It is apparent from the above Test Examples 1 to 3 that 5 novel compounds and their pharmaceutically acceptable salts of the present invention possess excellent MTP inhibition activity and also strongly inhibit absorption of triglyceride. In addition, as is apparent from Test Example 4, even when compounds of the present invention are administered at high 10 dose, inhibition rate of liver TG release is 18-19 % or lower, more effectively 9 % or lower, especially effectively 0 % or lower, and thus the compounds of the present invention inhibit little of liver TG release. Further, Test Example 6 reveals that active compounds after absorption in the small intestine 367 are present in portal vein in a very small amount, and since most (8-fold to 80-fold amount) of such active compounds are metabolites, they do not reach the liver. Furthermore, it is deduced from Test Example 7 that a small amount of active compound which has reached the liver is metabolized rapidly to a metabolite. In addition. Test Example 8 proves that ester moiety of these metabolites is cleaved by hydrolysis and thus they have little or no MTP inhibitory activity. Further, Test Example 5 reveals that combination use of the compounds of the present invention with other agents for treating hyperlipidemia (statin type agents) can remarkably inhibit the increase of cholesterol and exhibit extremely excellent synergistic effect. These facts elucidate that the compounds of the present invention can be used in combination with other agents, particularly other agents for treating hyperlipidemia, arteriosclerosis, coronary artery diseases, obesity, diabetes or hypertension.

From the fact as mentioned above, it is understood that novel compounds of the present invention and their pharmaceutically acceptable salts can inhibit lipid absorption in the small intestine and further do not inhibit TG release in the liver. This means that the compounds of this invention do not inhibit MTP in the liver, but selectively inhibit MTP in the small intestine.

Therefore, selective inhibition of MTP activity in the small intestine by the compounds of the present invention should lower lipid absorption, which makes it possible to control lipoproteins such as triglyceride, cholesterol and LDL, etc. in blood or to control lipid in cells. Further, since the 368 compounds of the present invention do not affect liver MTP, accumulation of triglyceride does not occur in the liver. Consequently, inhibition of fatty liver generation as an adverse effect might be expected. Therefore, the compounds of 5 the present invention can be said novel MTP inhibitors having no side effects such as a fatty liver, etc. or, in other words, they are novel agents for the treatment or prophylaxis of hyperlipidemia, arteriosclerosis, coronary artery diseases, obesity, diabetes or hypertension, and further for the 10 treatment or prophylaxis of pancreatitis, hypercholesterolemia, hypertriglyceridemia, etc., which rarely act on MTP in the liver and do substantially inhibit only MTP in the small intestine. 369

Claims (3)

WHAT WE CLAIM IS:

1. A biphenyl compound represented by the formula (100) 0 (100) (ch2), o— r50 wherein R1' is hydrogen, Ci-C6 alkyl, halogen, halo C1-C6 alkyl or C1-C6alkoxy; R2'" is hydrogen, Ci-C6 alkyl, halogen, halo Ci-C6 alkyl or C2-C6 alkenyl; R3" is -CON (Rlla) (R12a) wherein Rlla and R12a are each independently hydrogen, Ci-C6 alkyl, optionally substituted C6-Ci4aryl, optionally substituted C7-C16 aralkyl, Ci-C6alkoxy, or Rlla and R12a may be taken together with the nitrogen to which they are attached to form 15 20 f -n V (>)p (in which p is an integer of 0 to 2); R4'is hydrogen, halogen, C1-C6 alkyl or halo C1-C6 alkyl; R50 is hydrogen, methyl or optionally substituted C6-Ci4 aryl; and Intellectual ProDertv Office of N.Z. ^

2 5 JAN 2007 RECEIVFn 370 la is an integer of 1 to 3, or a prodrug thereof, or a pharmaceutically acceptable salt of either. 5 2. The biphenyl compound according to claim 1, wherein R1' is hydrogen, R2'" is halo C1-C6 alkyl, R3" is -CON (Rllb) (R12b) wherein Rllb and R12b are each independently hydrogen or Ci-C6 alkyl, or Rllb and R12b may be taken 10 together with the nitrogen to which they are attached to form R50 is hydrogen or methyl, 15 or a prodrug thereof, or a pharmaceutically acceptable salt of either.

3. A biphenyl compound represented by the formula (100) of claim 1 substantially as herein described with reference to the 20 Examples and excluding prior art and comparative examples. —N / [ V (in which p is an integer of 0 to 2) R4' is hydrogen, and JAPAN TOBACCO INC By their Attorneys BALDWINS 25 Intellectual Property Office ot ,xiZ. 2 5 JAN 2007 RECEIVED